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ABSTRACT
IN VIVO MEASUREMENT OF RAT SKELETAL MUSCLE OXYGEN CONSUMPTION
FOLLOWING BRIEF PERIODS OF ISCHEMIA WITH REPERFUSION AS ASSESSED
BY PHOSPHORESCENCE QUENCHING MICROSCOPY

By William H. Nugent
A thesis submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at the Medical College of Virginia Campus, Virginia Commonwealth University

Brief periods of skeletal muscle ischemia (ischemic pre-conditioning) alter cellular metabolism
in a way that confers protection over subsequent ischemic episodes. The mechanisms behind
this effect have been studied indirectly through assays for the byproducts of ATP synthesis and
in vitro studies of cellular signaling cascades and ROS generation. There have been no direct, in
vivo assessments of the changes in respiration during reperfusion. We employed
phosphorescence quenching microscopy in conjunction with a flow-arrest technique to assess the
influences of external, pressure-induced 1- to 10-min focal ischemia on interstitial oxygenation
(PISFO2) and the consumption of oxygen (VO2) in spinotrapezius muscles of Sprague-Dawley
rats. During reperfusion following an ischemic period VO2 was measured by the rate of PISFO2
decline during brief, serial flow-arrest compressions. Our tests of this intermittent compression
technique indicate that 5 s of flow-arrest followed by 15 s of flow restoration allow measurement
of VO2 without compromising baseline or reperfusion recovery of PISFO2. There was a steady
rise in VO2 during early reperfusion which was correlated with increasing ischemic durations.
Treatment with cyanide confirmed that at least some of this increase was due to an upregulation
of cytochrome c oxidase activity. Nitric oxide (NO) suppressed VO2 during rest and reperfusion,

xv

xvi
while L-NAME did not influence respiration under normoxic conditions. L-NAME produced a
significant rise in VO2 under hypoxic conditions following 10 minutes of ischemia, indicating a
greater role of NO in the regulation of respiration during low PISFO2 conditions. We conclude
that physiological levels of NO regulate mitochondrial respiration during hypoxia and confirm
that pharmacological elevation of [NO] reduces VO2 in a manner consistent with the ischemic
pre-conditioning effect.

xvi
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INTRODUCTION:
The Oxygen Supply
The microvasculature normally provides sufficient flow to meet the demands of perfused
tissues and it readily adapts to local changes. The arterioles constitute the major resistance
vessels to blood flow in the circulatory system. Their dilation and constriction maintain the O2
supply to and metabolite washout from tissues. Thus, they are excellent indicators of local
reactivity to both hypoxia and hyperoxia. Poiseuille’s law relates blood flow through a vessel to
the vessel’s dimensions and blood’s viscosity. It states that flow is proportional to the fourth
power of vessel radius. Thus, the microvascular response to hypoxia is usually dilation, the
opposite generally holding true for hyperoxia. This is achieved by relaxation or contraction of
vascular smooth muscle in the arteriolar wall, but the specific direct or indirect sensing
mechanism for this change in PO2 is under debate (Buehler and Alayash, 2004).
The processes of blood flow regulation that tend to maintain the balance between oxygen
supply and demand are typically grouped into three categories: the myogenic response, shearstress, and metabolic mediated mechanisms (Carleson, et al. 2008). In considering the relation
between regional changes in oxygen need and the corresponding flow-related response, this
discussion will primarily focus on the feed and terminal arterioles; they are the chief regulators
of functional capillary density in skeletal muscle (Segal, 2005).
The myogenic response is a vascular dilation or constriction following a decrease or
increase, respectively, in transmural pressure (Bayliss, 1902). The mechanism of action is not
fully understood, but it appears to maintain constant blood flow at some defined set point that
can be altered by various hormones and signaling molecules (Schubert and Mulvany, 1999).
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Sympathetic stimulation causes arteriolar constriction (Faber, 1988), resulting in a set-point that
is more restrictive of flow. But this is the opposite of what would seem to be needed during
exercise: increased flow to compensate for the increased metabolic activities of certain muscles.
It has been reported that competing regulatory mechanisms override the myogenic response
better as arteriolar diameter decreases (Folkow, et al. 1971). This permits better regional and
local matching of O2 supply to demand.
The shear-stress mediated mechanism allows the vasculature to react to and
accommodate changes in the velocity and turbulence of blood flow (Kuo, et al, 1990). Increased
or decreased levels of shear-stress are sensed by the vascular endothelium and it reacts by
increasing or decreasing the release of nitric oxide (NO) and prostacyclin respectively (Kuo,
1991; Kaley, et al. 1989). NO is a potent vasodilator that is released by endothelial cells. It acts
on vascular smooth muscle cell soluble guanylate cyclase receptors to initiate a cascade that
inhibits smooth muscle contraction (Furchgott and Zawadzki, 1980; Ignarro et al, 1987).
Although the specific role of this shear-dependent response is controversial (McGahren, et al.
1997), it is clear that it adds al layer of vascular regulation with its ability to override the
myogenic response on a region by region basis (Carlson, et al. 2008). But the need for better
precision in matching supply to tissue metabolic function involves another, more intimate
mechanism.
The first two levels of flow regulation are largely mechanosensitive and relevant at
regional and systemic levels. Thus, they are ill-equipped to precisely regulate capillary perfusion
in local instances of poor O2 supply-demand matching. The metabolic regulatory mechanisms
can meet these demands in concert with the larger-scale activities of the first two. This third
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mechanism of blood flow involves oxygen sensing and release of vasoactive metabolites (Segal
S, 2005).
Changes in the partial pressure of oxygen (PO2) can affect arteriolar diameter and,
therefore, capillary perfusion (Klitzman, et al. 1982). This suggests that an O2 sensor is a means
of vascular regulation. Indeed, there are two compelling theories that focus on the red blood
cells (RBC) as a vessel for O2 sensors because they facilitate PO2 dependent vascular relaxation
(McMahon, et al. 2002). The first involves the storage and eventual release of NO’s bioactivity
through the production of s-nitrosyl-hemoglobin (SNO-Hb) (Jia, et al. 1996). NO readily binds
to any of hemoglobin’s four heme groups, forming an iron nitrosyl heme complex; this is the
main reason RBCs are proposed to be NO scavengers. When hemoglobin is primarily in the Tstate (deoxygenated) NO is better able to bind because O2 does not have to be replaced
(Pawloski, et al. 2001). In the R-state (reoxygenated), hemoglobin’s Cys-93β becomes more
susceptible to reaction and thus the resident iron nitrosyl heme can S-nitrosylate it, forming
SNO-Hb (Jia, et al, 1996). SNO-Hb and other thionitrites are considered to be the most potent
vasorelaxive compounds known with effectiveness much higher than that of NO (Singel and
Stamler, 2005). This, coupled with the fact that they are more abundant in the blood and blood
vessel walls than NO is, suggests a mechanism for hypoxic, vasodilatory mediation in vivo
(Singel and Stamler, 2005). But it is unclear how SNO-Hb’s vasodilatory signal is transduced
through the RBC membrane to affect vascular dynamics. A second theory, which has gained
substantial ground over the past decade, involves RBC adenosine triphosphate (ATP) release
upon exposure to hypoxic conditions (Ellsworth, 1995). This is hypothesized to be mediated by
deoxyhemoglobin’s interaction with the N-terminal, cytoplasmic fragment of band 3 (a protein
bound within the RBC membrane). Upon binding with deoxyhemoglobin under low PO2
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conditions, key regulatory glycolytic enzymes are displaced, resulting in glycolytic stimulation
and an accumulation of ATP along the membrane that then triggers its release (reviewed by
Jensen, 2009). Thus, as the RBC enters the hypoxic venules of respiring tissue, it releases ATP
which then activates purinergic receptors on venular endothelial cells. This transduces a
vasodilatory signal (NO) to nearby arterioles (Ellsworth, 2004). Which of these two mechanisms
for RBC regulation of blood flow serves a greater role is unclear, but they most likely
complement or augment each other under various conditions.
The preceding mechanisms are mostly reactive in nature, and the release of vasoactive
metabolites by tissues could be considered a more proactive mechanism to match supply and
demand during rapid changes in respiration. During periods of hypoxia, as seen in exercise and
ischemia, skeletal muscle cells supplement oxidative phosphorylation with glycolytic ATP
generation. A byproduct of this is lactate, which then diffuses to the local vasculature and acts as
a vasodilator (Garhofer, et al. 2003). During active muscle contraction, the resulting potassium
efflux induces vasodilation in skeletal muscles with mixed fiber-types (Hudlicka, 1985). As
there is a rapid rise in interstitial potassium levels during skeletal muscle contraction (De Clerck,
et al, 2003), this mechanism may function independently of hypoxia, allowing timelier perfusion
matching to demand. Although these, in addition to other products of both resting and
contracting skeletal muscle tissues, provide more precise control of the vasculature they cannot
wholly account for vasodilation (Green, et al, 1996). For example, larger increases in flow are
primarily dependent on the dilation of feed arterioles which are upstream from where the
metabolite release occurs (Green, et al, 1996). The three major levels of regulation work in
conjunction to provide rapid, precise and sustainable adjustments to blood flow, resulting in
periods of hypoxia that are transient and less severe.
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The Oxygen Demand
During exercise, the amount of oxygen needed varies proportionately with activity level.
As energy needs rise, the mitochondria respond by increasing the generation of high energy
phosphates through a proton gradient that is established by donating negative charges to oxygen.
This activity is readily apparent in contracting skeletal muscle, and mitochondrial function can
be translated directly to oxygen consumption. But what about resting muscle? Does high energy
phosphate production account for all observed oxygen consumption (VO2)? Certainly, at rest
there is a need to maintain a consistent supply of cellular fuel that accounts for a great deal of
oxygen utilization, but contributions from reactive oxygen species generation, extramitochondrial enzymatic processes, and variations in myoglobin PO2 may account for a
significant fraction.
Myocyte function depends on the availability of adenosine triphosphate (ATP), which is
produced by both anaerobic and aerobic pathways. Anaerobic respiration occurs in the form of
glycolysis and basically nets 2 molecules each of ATP and pyruvate from one molecule of
glucose. Aerobic uses oxidative phosphorylation within the mitochondria to further reduce the 2
pyruvates from glycolysis to 30-32 molecules of ATP. Anaerobic respiration has the advantage
of being able to generate ATP in an oxygen-free environment, but its low efficiency and waste
products are limiting. Aerobic respiration is much more efficient and its byproducts are readily
carried in the vasculature to the lungs, thus making it ideal for long-term energy production that
is limited only by the diffusivity of oxygen (Wagner, 2000).
Oxygen is the terminal electron acceptor in the mitochondrial electron transport chain
(see Figure 1), binding to the cytochrome c oxidase complex (complex IV), absorbing the
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negative charge and leaving as H2O. The rate of oxygen uptake is directly related to the
maintenance of the cellular ATP/ADP ratio. During resting conditions, as ATP is converted to
ADP, the mitochondria convert carbohydrates, fats, and proteins to NADH via oxidative
phosphorylation. NADH is then oxidized and its electrons are passed into the mitochondrial
matrix. These electrons are then carried along a series of complexes via intermediaries (see
Figure 1) to power the transport of 10 protons per pair into the matrix. This leads to the
development of the proton motive force necessary for the regeneration of ADP to ATP. Oxygen
provides the driving force for the electrons and is easily removed as H2O (Lodish, 2004). Under
normal conditions, this system in skeletal muscle is capable of increasing ATP output by 100
fold during strenuous exercise limited only by the rate of oxygen diffusion to the mitochondria
(Ortenblad, et al, 2009). Energy production is responsible for a majority of mitochondrial
oxygen consumption. But since no system can be 100% efficient, there are other diversions of
O2.
In addition to energy production (released as ATP and heat), mitochondrial oxidative
phosphorylation produces small quantities of reactive oxygen species (ROS). Complexes I
(NADH coenzyme Q reductase) and III (ubiquinol cytochrome reductase) are two points that
contribute to a loss of between 0.2 and 2% of the total O2 consumed by mitochondria to the
generation of ROS in myocytes under physiological conditions (Misra et al, 2009; Tahara, et al,
2009). Mitochondrial ROS generation occurs when O2 is converted to superoxide (O2•-) by
single electron transfer during interaction with either of these two inner membrane complexes.
Free radicals are generally considered to be harmful in their interactions with DNA, lipds,
enzymes etc. and are usually kept in check by various enzymatic (catalases) and non-enzymatic
(nitric oxide) processes. While ROS production accounts for only a small fraction of total
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Figure 1: Diagram of mitochondrial electron transport chain. Electrons are passed through a
series of complexes via electron carriers to facilitate proton (H+) loading of the intermembrane
space. This H+ gradient is then used to convert ADP + Pi to ATP. Oxygen is the final electron
acceptor as it receives the negative charges from cytochrome c oxidase (complex IV). Complex
IV is also the site of respiratory inhibition for both cyanide and nitric oxide.

Figure adopted from:
Cuperus R, Leen R, Tytgat GAM, Caron HN, and Van Kuilenburg ABP. Fenretinide induces
mitochondrial ROS and inhibits the mitochondrial respiratory chain in neuroblastoma.
Cell Mol Life Sci. 67(5): 807–816, 2010.
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oxygen consumption, periods of oxidative stress do arise during altered mitochondrial function.
When the ETC becomes highly reduced, for example, during a glut of NADH generated, in the
mitochondrial matrix, from oxidative phosphorylation there is an increased likelihood that
electrons will pass directly to O2 from complexes I & III and form superoxide (Wallace and Fan,
2009). Though somewhat controversial (see Figure 2; Clanton TL, 2005), this situation has been
observed during hypoxia, when low oxygen tensions inhibit aerobic respiration, causing the ETC
to become reduced and mitochondrial ROS production to increase (Sato et al, 2005; Vanden
Hoek, 1998). Mild hypoxia can deplete cellular ATP reserves. Oxidative phosphorylation’s
regulation is then shifted to cytochrome c, resulting in a PO2-dependence on ETC activity (Lynn,
et al, 2007), creating the reducing conditions for enhanced mitochondrial ROS production.
Although ROS production has been reported to be proportional to mitochondrial oxygenation
(Boveris, 1977), moderate hypoxia appears to provide enough oxygen to supply the newly
converted ROS-producing ETC complexes I and III (Clanton, 2007). As one study has reported,
ROS production had risen approximately 3 fold with total VO2 suppressed from the normoxic
state following the development of moderate hypoxia in isolated mitochondria from rabbit hearts
(Korge, et al, 2008). This study also confirmed that ROS production was not elevated during
periods of anoxia.
More severe disruptions in mitochondrial function, such as lengthy ischemia followed by
reperfusion, can further disrupt the proton motive force across the mitochondrial inner membrane
and thus divert an even greater percentage of oxygen utilization to ROS production (Chen et al,
2003; Thaveau et al, 2007). With severe perturbations to the mitochondria, ROS generation
contributes to the eventual decline of cellular function. An ROS burst during early reperfusion
can expand the existing size of the ischemia-derived infarct (Solaini and Harris, 2005; Yang, et
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Figure 2: Model of the production of ROS and electron transport chain functionality over the
physiological range of intracellular PO2s. As oxidative phosphorylation becomes O2-limted at
~8 mmHg, NADH levels begin to rise. Around 3 mmHg, ROS production becomes elevated and
is slowed only when it becomes oxygen limited around 1 mmHg, long past the point where
oxidative phosphorylation had become insufficient to reduce NADH to NAD+. This profile
would likely be similar but shifted to the right for measurements of interstitial PO2 (PISFO2).

Figure adopted from:
Clanton TL. Hypoxia-induced reactive oxygen species formation in skeletal muscle. J Appl
Physiol 102: 2379-2007, 2007
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al., 2004). The time course of ischemia differentiating enhanced ROS production from the burst
associated with reperfusion injury is difficult to determine, but one study has reported that
superoxide production rose by 35% after 1 minute of ischemia and then by 95% following 20
minutes of ischemia in isolated guinea pig hearts (Kevin, et al, 2003). As this indicates a
progressive rise in ROS production, it makes sense that measurements of oxygen consumption
for the purposes of determining ETC function would be subject to greater error over time during
hypoxia and become complicated by the confounding effects of reperfusion-associated
mitochondrial dysfunction.
Accurately accounting for the ROS induced error when calculating tissue VO2 is difficult
because of numerous differences between the data derived from the in vitro and in vivo settings.
Extra-mitochondrial sources of ROS, such as the metabolism of arachidonic acid by the
lipoxygenase pathway and phospholipase A2, exist under resting conditions, while NADPH
oxidase and xanthine oxidase can contribute appreciably during muscle contraction (Mishra,
2009; Clanton, 2007). Extracellularly, when the cofactor tetrahydrobiopterin (H4B) is absent or
otherwise unavailable, nitric oxide synthase (prevalent in the endothelial cells of the intact
vasculature) can uncouple and become an ROS generator (Moens and Kass, 2006). These
additional sources may not be present in preparations of isolated mitochondria and ex vivo
perfused tissues, nor might all forms of their counterparts—ROS scavengers. Antioxidants can
be both enzymatic (catalase, super oxide dismutase etc) and non-enzymatic (NO, vitamin E, etc)
and their availability may be compromised outside of the in vivo setting. Their presence may
confound measuring ROS by consuming it. The in vivo setting is challenging as well because
systematically inhibiting ROS production in living tissue to determine its share of oxygen
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consumption would disrupt other cellular processes, thereby compromising the physiological
situation.
Reactive oxygen species production can clearly be confounding when attempting to
translate the measurement of oxygen consumption to mitochondrial energy production in states
of long term ischemia followed by reperfusion. But, for situations where tissue oxygenation is
either normal or moderately hypoxic, the contribution of ROS to VO2 does not appear greater
than 5%. Thus, VO2 measurements probably do not have an appreciable error over the
physiological range of PO2, where hypoxia has not induced sufficient oxidative stress.

Measurements of VO2:
In mammalian circulatory systems oxygenated blood flows into an organ and
deoxygenated blood flows out, reoxygenation occurring at the interface with the atmosphere—
the pulmonary system. As arteries and veins are separated by capillary beds, the O2 extraction of
an organ (VO2) follows Fick’s principle:

VO2= Q(CaO2-CvO2)

Equation 1

where Q indicates blood flow and CaO2-CvO2 indicates the difference in oxygen concentration
between arterial inflow and venous outflow from the organ or tissue. During conditions of rest
and exercise, VO2 and energy production are proportional. Thus, VO2 calculated from
arterial/arteriolar oxygenation and venous/venular oxygenation is a metric of tissue/organ
respiration. Using this approach, reported mean values for VO2 in mammalian resting skeletal
muscles range from 0.054 to 0.92 mlO2/100g*min (Edmunds, et al, 2001; Hoy, et al, 2009). One
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of the earliest reports assessing VO2 in the resting human forearm gave a range of 0.09 to 0.52
mlO2/100g*min, roughly consistent with subsequent findings (Mottram, 1955). Although it will
determine the amount of O2 consumed by a particular capillary bed, Fick’s principle does not
reveal the rate at which specific tissues are consuming oxygen or what the spatial relations are
between VO2 and the gradients of oxygen supply. Additionally, it has poor temporal resolution
because the interstitium can act as a buffer between cellular respiration and changes in vascular
oxygen levels.
Another approach to determining the rate of oxygen extraction in a particular region of
tissue is to arrest blood flow and track the changes in local PO2. A minimally invasive technique
for region-specific sampling of vascular PO2 is Near-Infrared Spectroscopy (NIRS). First
developed for the simultaneous measurement of hemoglobin oxygenation and cytochrome c
oxidase’s redox state in the rat brain in 1987 (Masahide, et al, 1987), this method has been
adapted to a number of tissues and extended to measurements of oxygen consumption
(Schumacker and Samsel, 1990). Illuminating the target tissue with a pair of 700-805 and 830805 nm wavelengths to assess hemoglobin oxygenation, blood volume dynamics (relative
measurements of absorption at ~805 nm over time) and the mitochondrial cytochrome aa3
oxygenation to simultaneously measure both vascular oxygen supply and tissue metabolic rate.
During blood flow arrest, the rate of oxyhemoglobin conversion to deoxyhemoglobin gives the
change in PO2 over time and thus provides information on VO2 kinetics. Values for resting VO2
in human calf muscles have been reported to be ~0.20 mlO2/100g*min using this technique
(Cheatle, et al, 1991; De Blasi, et al, 2009). These values correspond to those found using the
Fick principle, but have greater spatial and temporal resolution as well as an assessment of
mitochondrial respiration by which to compare the measured oxygen disappearance rate. But a
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significant temporal delay in oxygen uptake kinetics may exist because of the skeletal muscle
interstitial space’s buffering action.

Nitric Oxide
As reviewed by Lane and Gross (2002), nitric oxide (NO) is a gaseous free radical
biomessenger with a diverse repertoire of in vivo functions including but not limited to: gastric
emptying, long term potentiation in memory, neurotransmitter release, immunological defense,
blood pressure regulation, etc. The observations that NO can alter both the supply and demand
for oxygen differentially over a range of physiological and patho-physiological conditions that
may persist in skeletal muscle seems relevant to discussions of VO2. This molecule’s ubiquity
and near-universal involvement in biological functions is a result of two important properties—
reactivity and hydrophobicity (Lane and Gross, 2002).
NO, as a free radical, possesses an unpaired valence electron that enables it to react with
a number of biological components and constituents such as: itself, O2, ROS, protein thiols, iron
heme groups, and other free radicals. This reactivity is somewhat dampened compared to other
free radicals, resulting in concentration-dependent regulation of both beneficial and harmful
effects (Lane and Gross, 2002). The regulatory influences of NO on biochemical processes are
typically associated with low concentrations (in the nM- μM range) with cytotoxicity coming
into play at higher concentrations (in the higher μM range) (Chi, et al, 2006). Additionally,
although many intercellular signaling molecules transduce their signals through the plasma
membrane because of their inability to penetrate the lipid bilayer (Lodish et al, 2000), NO is
lipid-soluble and mostly unaffected by this level of regulation. The current belief is that it is able
to freely transverse these barriers—quite similar to O2 (Lane and Gross, 2002). Therefore, NO’s
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involvement in various reactions is regulated both spatially and temporally by its sites of
production or release in the tissues (Lane and Gross, 2002).
The vast majority of nitric oxide is enzymatically produced by nitric oxide synthases
(NOS) expressed throughout the mammalian organism. At least three distinct isoforms of NOS
have been identified with the designations neuronal (nNOS), inducible (iNOS), and endothelial
(eNOS) by location of discovery, or, more recently, NOS1, NOS2, and NOS3 respectively by
order of isolation (Michel ed, and Feron, 1997). The classical nomenclature has been deemed
misleading as these NO producing enzymes are widely distributed. NOS1 has been detected in
neuronal tissue, skeletal muscle (Michel ed, and Feron, 1997), mast cells and the vasculature
(Kasiwagi, et al, 2002). NOS2, originally identified in immunoactivated macrophages, has been
localized to cardiac myocytes, glial cells, and vascular smooth muscle (Michel ed, and Feron,
1997). Finally, NOS3, originally and still mostly identified with the endothelial cells of blood
vessels has been detected in cardiac myocytes, blood platelets, extra-vascular regions of the brain
(Michel ed and Feron, 1997), and red blood cells (Kleinbongard, et al, 2006).
NOS, in its functional dimeric state, catalyses a two-step reaction that converts L-arginine
to the intermediate Nω-hydroxy-L-arginine and finally to NO and L-citrulline (Li and Poulos,
2005). This process requires O2 to bind to NOS’s ferrous heme and nicotinamide adenine
dinucleotide phosphate (NADPH) to act as an electron donor linked to the heme by a flavin
mononucleotide/flavin adenine dinucleotide reductase (Li and Poulos, 2005). Additionally, there
is a strict requirement for the cofactor tetrahydrobiopterin (H4B), which serves as an electron
donor to the heme-oxygen complex (Li and Poulos, 2005). Calmodulin (CAM), whose
influence/binding is typically controlled by intracellular calcium (Cai2+) levels, then regulates the
NOS catalyzed oxidation of L-arginine to NO at the level of electron transfer between the
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reductase and the heme domains (Li and Poulos, 2005). This reaction profile is essentially
conserved amongst the three NOS isoforms, although kinetics and regulatory mechanisms are
not.
Despite a >50% sequence homology between the three most verifiable NOS isoforms,
with the active site being highly conserved, significant differentiation occurs in terms of their
activities and expression (Li and Poulos, 2005). Both NOS1 and NOS3 are constitutively
expressed enzymes whose activities are influenced by changes in Cai2+ (Li and Poulos, 2005).
NOS2’s expression, on the other hand, is transcriptionally regulated via cytokine signaling and is
Cai2+ independent (Lopez- Figueroa MO, et al, 2000). The Cai2+ requirement arises from CAM.
The constitutively expressed NOS’s require Ca2+ to promote the CAM binding that enables the
production of NO, while inducible NOS has a permanently bound CAM and is independent of
Cai2+ levels (Li and Poulos, 2005). As a consequence, coupled with its high level of expression
during transcriptional stimulation, NOS2 is capable of a high NO production rate for an extended
period of time (4-24 h) compared to NOS’s 1 & 3 whose rates are low and have durations on the
order of seconds to minutes (Lopez-Figueroa, et al, 2000). Indeed, differences also exist
between the two constitutive forms in terms of kinetics. Chen and Popel (2007) developed a
computational mathematical model of vascular and perivascular NO release, (based on reported
kinetic values of the biochemical pathways involved in NO synthesis) and determined that NOS1
has a steady state production rate (0.39-1.16 μM/s) much higher than that of NOS3 (~.017 μM/s).
Additionally, their findings support indications of NOS1’s high dependence of NO production on
local [O2]; as NOS1 production decreases with hypoxia, whereas NOS3 was much less sensitive
(Chen and Popel, 2007; Li and Poulos, 2005). So, under normal physiological conditions, it is
apparent that the distribution of NOS types 1 and 3 will determine which tissues/regions have the
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greatest potential for regulation by NO, while actual concentrations are influenced by
consumption.
Nitric oxide’s longevity depends on the proximity of its production to its reactants
(scavengers); unlike classical signaling molecules, there is no storage of its free radical form
(Thippeswamy and Morris, 2001). Intravascular NO’s half-life—endothelium derived—was
measured, using microelectrodes, to be ~2 ms, which is less than what might be predicted
(Thomas, et al, 2001). This is probably due to the presence of red blood cells, which contain high
amounts of hemoglobin with a high binding affinity to NO. Extravascular measurements
indicate a half-life of .09 to >2 s, as the interstitial space contains fewer NO scavengers (Thomas,
et al, 2001). While the NO concentration gradients of skeletal and cardiac muscle have been
found to extend over that of the vascular spaces (Rassaf, et al, 2007), consumers of NO such as
intracellular myoglobin maintain a presence amongst the myocytes. Moreover, the changing
conditions in vivo (i.e. hypoxia) may significantly affect the presence of scavengers.
ROS contributes to the disappearance of NO in vivo, as demonstrated by the ability of
superoxide dismutase (SOD), an ROS scavenger, to induce aortic dilation by preventing NO
consumption (Pohl and Busse, 1989). NO also undergoes auto-oxidation at a rate dependent on
local [O2] indicating a decrease in scavenging at low PO2 (Liu, et al, 1998). Some workers,
however, do not consider this reaction to be important to overall scavenging due to its slow rate
under physiological concentrations of NO (Chen, et al, 2006). Others give it a much more
significant role; it was found that within cellular membranes the reaction has a 300-fold
acceleration (Liu, et al, 1998). This could be important due to the presence of membrane-bound
NOS3 (Bachetti, et al, 2004), and may add validity to the idea of the membrane as an NO
diffusion barrier under normoxic conditions (Lui, et al, 1998; Herrera, et al, 2006). It would
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follow that a certain degree of hypoxia would result in a decrease in NO scavenging and a
concomitant increase in regional [NO]. But the magnitude of influence events at the sarcolemma
would have on the local mitochondrial NO concentration and ultimately respiratory kinetics is
unclear.
NO and some of its derivatives have been implicated in facilitating a decrease in the
proximal demand for oxygen (VO2) via NO’s direct and reversible competition with O2 on
mitochondrial cytochrome c oxidase (Brown, et al, 1994). For comparison, carbon monoxide,
another diatomic, is a competitive inhibitor of O2 in mitochondrial respiration and NO has been
reported to be 1,000 to 2,000 times more effective (Mason, et al, 2006). Binding occurs on
cytochrome c oxidase’s reduced heme (referred to as heme a3) site of action for the terminal
electron acceptor (O2) in the electron transport chain. As [NO] rises, there is a decrease in the
ability of cytochrome oxidase c to utilize oxygen and thus a reduction in VO2 (Schweizer and
Richter, 1994). It should be noted that at rest under normoxic conditions the cytochrome oxidase
c reserve capacity is large. It has been reported that endogenous mitochondrial respiration must
be inhibited by over 50% before there is a noticeable difference in tissue oxygenation (Thomas,
et al, 2005). This is most attributable to the fact that cytochrome c oxidase, collectively, does not
typically operate at maximal capacity, so normoxic levels of NO do not interfere with VO2
(Palacios-Callender, et al, 2007).
As NO is rather insidious, it is not surprising that a small percentage of interaction with
mitochondrial respiration has been reported to involve alternative pathways. The competitive
inhibition was first described as a single site model, in which binding of NO to the a3 heme was
completely reversible in both active and quiescent conditions of cytochrome c oxidase activities
(Brookes, et al, 2003). This paradigm was supported by data indicating that VO2 had a roughly
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proportionate inverse relationship to [NO]. Brown, et al (1994) reported half inhibitions of
cytochrome c oxidase at 250 nM NO when O2 was 130 µM and 60 nM NO when O2 was 30
µM—an indication that the percentages approximate closely. But Brookes et al, (2003) also
reported that the single site model does not account for all of the data. They indicated a
differential degree of NO inhibition between cytochrome c oxidase’s active and quiescent states
with greater potency during high enzymatic turnover. This prompted the development of a
second model that involves the copper portion of cytochrome c oxidase’s binuclear center
(Mason, et al, 2006). Their data not only mimicked the original finding of greater inhibition
during high enzymatic turnover, but also indicated that as activity decreased, the hill coefficient
increased to above 1—an indication of a secondary binding of NO. Given NO’s affinity for
metallic centers, they focused on potential interactions with the local copper. It was found that
during high enzymatic turnover, a3 heme binding occurred as reported by the single site model,
but NO began engage in lower affinity non-competitive interactions with the oxidized copper in
an irreversible fashion as respiration dropped (Mason, et al, 2006). Presumably, NO’s inhibitory
effects during the quiescent state are reduced because a portion is oxidized to nitrite by reaction
with the copper while this does not occur during high activity. This new, two site model was
able to fit all of the data presented in the two studies described here for mitochondrial inhibition
by NO (Buerk, 2007). Additionally, NO or its derivatives stimulate the production of both ROS
and reactive nitrogen species (RNS) from the mitochondria (Brown and Borutaite, 2001), which
then are capable of inhibiting the electron transport chain at multiple sites in addition to that of
NO (Han, et al, 2007). These reactions tend to be more destructive and associated with a longterm elevation in [NO] that results in irreversible inhibition of mitochondrial respiration
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(reviewed by Brown, 2001). The end result is that NO appears to have differential effects at
various conditions of mitochondrial respiration and hence VO2.
As hypoxia drives the regulation of VO2 to the oxygen binding domain of cytochrome
oxidase c, NO may be an important physiological regulator of VO2 during this time. NO
becomes more effective with diminished PO2, supporting the potential relevance of this
mechanism (Schweizer and Richter, 1994). This has been attributed to the similar conditions of
high enzymatic turnover where PO2 is the limiting reagent in both cases, which leads to the
greater effective interaction of NO with the a3 heme to facilitate competitive inhibition (Mason,
et al, 2006). Thus, the same amount of NO has a much greater influence during times of
hypoxia. The implication is that this mechanism results in a higher tissue PO2 during low
oxygen conditions than would occur if respiration was unaffected by NO (Chen, et al, 2006).
It is somewhat counterintuitive that NO might become more effective at regulating VO2
during hypoxia because O2 is one of the critical components to its production. As previously
discussed, the kinetics of NOS production reveal that although NOS1&2’s production has a
strong dependence on O2 over the physiological range, NOS3 is relatively insensitive to hypoxia
(Chen and Popel, 2007; Li and Poulos, 2005). One consequence of this might be that
endothelial-derived NO gradients would have a greater inhibitory effect on local myocyte
mitochondria, but whether the continued production of NOS3 would be sufficient to compensate
for the production drop-off from NOS1 is unclear.
Another mechanism may actually facilitate increased NO-bioavailability around the
mitochondria of some skeletal muscle fiber-types during hypoxia. Myoglobin, an intracellular
oxygen binding hemeprotein typically associated with temporary O2 storage, possesses
mechanisms similar to hemoglobin in the preservation and release of NO bioactivity via nitrite
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reduction (Cosby, et al, 2003). This may be of critical importance to the overall scheme of O2
regulation during muscle contraction since certain fiber types usually associated greater O2 needs
possess a larger mitochondrial population than others (Weibel, 1984). Similar to hemoglobin,
myoglobin converts NO to nitrate under normoxic conditions and releases NO during hypoxia in
cardiac muscle cells (Rassaf, et al, 2007). Additionally, as NO is released by deoxymyoglobin, it
can escape immediate rescavenging because the reaction leaves behind the ferric form of
myoglobin (met-myoglobin), which does not interact with NO (Rassaf, et al, 2007). This may
facilitate a more substantial reduction in VO2 than the limiting presence of O2 alone but to what
extent remains unknown as quantification of NO has yet to be conducted reliably in vivo.
The literature is rife with examples of increased [NO] leading to an elevation in tissue
PO2 (Chen, et al, 2005). Part of this may be explained by increased oxygen supply by NOinduced vasodilation, but the inhibitory effect on demand cannot be ignored. Studies have
shown that supplementation with dietary nitrite, which is then converted to NO during raised
metabolic demands, causes a decrease in VO2 and an increase in gross skeletal muscle efficiency
(Larsen, et al, 2007). NOS3 knockout mice have greater tissue oxygen consumption and a 40%
decrease in their longitudinal oxygen gradients within microvessels (Cabrales, et al, 2005). It is
clear that there is a physiological mechanism of VO2 regulation and that it is important in
pharmacological effects on hypoxic tissues.

Ischemia and Reperfusion:
Interruption of blood flow to the heart or brain, even for a few minutes can cause
irreparable damage and may result in death. During a myocardial infarct, the damage done
during a short period of ischemia may appear to be limited, but reperfusion with oxygen can
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reveal irreversible effects. In fact, reoxygenation of an ischemic region can alter the ways
mitochondria handle oxygen, adding to the damage. But ischemia/reperfusion injury is not a
linear progression of effects; protective mechanisms involving the manipulation of VO2 kinetics
can provide some endurance to ischemia. Ironically, this mechanism of protection was identified
by preconditioning the tissue with brief episodes of ischemia; this led to the search for its
pharmacological reproduction to improve the clinical outcomes of heart attack and stroke. While
much of the focus has been on the long-term influences of various protocols of preconditioning
(with and without drug intervention) on infarct size and tissue survival, a description of VO2
kinetics during brief ischemic preconditioning episodes may provide advance the understanding
of these protective mechanisms. Overall despite the numerous regulatory mechanisms, no
known chemical or mechanical intervention can protect the mitochondria (hence the tissue) from
prolonged anoxia.

Ischemia:
For the purposes of this discussion, the state of ischemia in mammalian muscle tissue can
be defined as dramatic reduction in blood flow due to occlusion of supply vessels that results in
insufficient oxygen delivery to meet demand. The hypoxia or anoxia that occur in the ischemic
tissue can then lead to damage. The time course of ischemic injury varies between tissues of
different metabolic rates. Cardiac muscle tissue degrades rapidly, as exemplified by isolated
neonatal rat cardiomyocytes showing morphological changes after ~30 minutes of anoxia
(Musters, et al, 1991); human and mouse skeletal muscle tissue appears to remain viable for 2 to
2.5 hours (Eberlin, et al, 2008; Martou, et al, 2006). The principle mechanism of damage is
suspected to be ischemia-induced alterations in mitochondrial structure and function (Veitch, et
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al, 1992). As hypoxia is associated with increased ROS production by the electron transport
chain, the oxidative stress of accumulating free radicals damages the respiratory chain
complexes. Complexes I then III are affected first (Narabayashi, et al, 1982) and, being the
primary mitochondrial generators of ROS during hypoxia, their dysfunction compounds the
problem by further elevating ROS production (Chen, et al, 2003). While the precise length of
time necessary to cause this is uncertain, there is one report that ischemic cardiac muscle ROS
production is slightly elevated but stable for 25 minutes followed by a much higher rate of
production (Kevin, et al, 2003). This self-feeding burst of ROS appears to be responsible for the
poor outcomes associated with prolonged ischemia in skeletal and cardiac muscle tissues
(Laskowski, et al, 2000).
Enhanced ROS production during prolonged ischemia in skeletal muscle is not solely due
to functional changes in the mitochondrial ETC, but appears to come from other enzymatic
sources as well. During ischemia, ATP is catabolized to hypoxanthine (ATP-ADP-AMPadenosine-inosine-hypoxanthine-xanthine) with a rise in Cai2+ (McCord, 1987). Xanthine
dehydrogenase is then converted to xanthine oxidase by a cytosolic protease whose activation is
Cai2+ dependent (Korthuis, 1986). Xanthine oxidase a major source of ROS in both rat and
human skeletal muscle (Smith, et al, 1989; Hellsten, et al. 1997), generates superoxide with any
available O2 during ischemia; more so if reoxygenation occurs (Singal, 1989).

Reperfusion:
Reoxygenation of ischemic tissues is necessary for their survival, but an unfortunate
consequence of prolonged hypoxia and or anoxia is that normoxic oxygen levels become toxic
and can cause further damage from mitochondrial dysfunction and necrosis (reviewed by
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Halestrap et al, 2007). The stage for reperfusion injury is set during ischemia. As intracellular
PO2 falls below the critical point of VO2 dependence on oxygen, oxidative phosphorylation
slows down. The continued demand for ATP becomes reliant on anaerobic respiration, which is
insufficient; the result is net conversion of ATP to ADP with a drop in intracellular pH due to the
accumulation of lactic acid. The cell compensates for the increased acidity with the membranebound Na+/H+ antiporter. Because of the ATP deficiency, the extra sodium cannot be removed
by Na+/K+ ATPase, and the Na+/Ca+ pump is activated. This results in intracellular calcium
(Cai2+) loading. The low pHi exacerbates ROS production by the mitochondrial respiratory
complexes, which then acts in combination with the elevated Cai2+ to break down the
mitochondrial electrochemical gradient and hence, the ability to produce ATP upon reperfusion
and the return to normal pHi (Halestrap, et al, 2007; Griffiths and Halestrap, 1995; Kim, et al,
2006).
Reperfusion injury has been proposed to be mediated through the following two
destructive events: 1) reoxygenation of mitochondria causes a burst in ROS production (Kevin
et al, 2003); and 2) the high [Cai2+] coupled with a return to normal intracellular pH increases the
open-state probability of the mitochondrial permeability transition pore (MPTP) (Kerr, et al,
1999). While ROS is inherently destructive, and a burst of ROS even more so, one explanation
of reperfusion injury may be that the opening of this MPTP that causes depolarization of the
mitochondrial inner membrane, thus destroying the capacity for ATP synthesis, and eventual
apoptosis (Halestrap, 2006). The MPTP has been described as a hole in the mitochondrial inner
membrane that is permeable to anything <1.5 kDa. This causes obvious problems with
maintaining the proton gradient needed to drive ATP synthesis and can reverse the protontranslocating ATPase so that it hydrolyses of any remaining ATP (Halestrap, 2007). While a
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single MPTP opening will not doom an entire mitochondrion, the depolarization increases the
chance of additional MPTPs opening (Scorrano, et al., 1997). ROS is not excluded from this
model although it is also suspected to cause an increase in MPTP opening probability, thus
contributing to both oxidative damage and energy starvation of the cell. The result of these
reperfusion-induced mitochondrial dysfunctions is apoptosis and local inflammation, which can
cause further degradation of surrounding tissues leading to increased infarct size (Schoen, 2006).
It is reasonable to conclude that the usage and conditions of usage of oxygen by the mitochondria
are tied to cellular fate. Thus, it should be no surprise that modulating the supply of oxygen to
alter demand led to a key mechanism of protection against ischemic damage.

Preconditioning:
First described by Murry et al, in 1986, brief episodes of ischemia in dog myocardium
prior to a typically destructive duration of ischemia and reperfusion, now referred to as ischemic
preconditioning (IPC), reduces the infarct size (Murry, et al, 1986). The authors of this study
theorized that the mechanism of protection was related to a reduction in the rate of ATP
depletion conferred by IPC. This would improve endurance to a subsequently longer ischemic
event. The IPC effect has been observed in human to rat cardiac and skeletal muscle (as
discussed by Pang, et al, 1993; Veitch, et al, 1992), but despite the reproducible nature of the IPC
response amongst various tissue types, the mechanism or mechanisms of action to confer this
ischemic protection are not resolved.
A profile of 5 to 10 minutes of ischemia followed by 5 to 10 minutes of reperfusion for 1
to 3 cycles confers protection against prolonged ischemia in both cardiac and skeletal muscle
(Martou, et al, 2006; Addison, et al, 2003). This time course for the induction of IPC protection
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in skeletal muscle has been repeatedly confirmed over the past 20 years and is attributed to
changes in mitochondrial potential that depress the rate of ATP depletion (Pang, et al, 1993;
Pasupathy and Homer-Vanniasinkam, 2005). Although the exact mechanism of action remains
controversial (as reviewed by Halestrap, 2007), there is a rise in ROS production upon
reoxygenation following 5 to 10 minutes of severe hypoxia. Thus, brief episodes of ischemia
induce this small ROS burst, which activates mitochondrial KATP channels, resulting in a reduced
rate of ATP hydrolysis (Vurionen, et al, 1995; Vander Heide, et al, 1996; Santos, et al, 2002).
This ROS burst upon reoxygenation has been consistently implicated as necessary for the
protection conferred by the IPC protocol (Dost, et al, 2008), and there is considerable evidence
that the subsequent opening of KATP channels leads to a reduction in both ATP hydrolysis and
the probability of MPTP opening during a subsequent ischemic event with reperfusion (Moses
MA, et al, 2005). An alternative mechanism in skeletal muscle is the necessary activation of
protein kinase c (PKC) by ROS to elicit the effects of IPC (Ytrehus, et al, 1994; Pain, et al,
2000). Whether the two mechanisms are mutually exclusive or integrate to induce IPC
protection is unclear, but they are downstream from the changes in mitochondrial function that
have been identified as a burst in ROS, which is necessary for induction of IPC (Dost, et al,
2008).
The evidence indicates that the damaging and protective qualities of various durations of
ischemia and reperfusion reflect changes in mitochondrial function during hypoxia and
subsequent reoxygenation. As the O2 consumption is tightly correlated to mitochondrial
function, VO2 may be a powerful indicator of changes in cellular respiration during the brief
episodes of ischemia that are associated with preconditioning. The oxidative capacity of rat
skeletal muscle following 5 hours of ischemia indicates a reduction of Vmax by 43% (Brandao, et

25

26
al, 2003; Thaveau, et al, 2007), which is improved in groups exposed to IPC for the same time
course and severity of ischemia (Thaveau, et al, 2007). This is consistent with the notion of
progressive damage to mitochondria during severe ischemia. It is currently believed that IPC
reduces the rates of ATP hydrolysis and oxidative phosphorylation. Therefore, a description of
the VO2 profile following these IPC regimens during this time is important as an assessment of
mitochondrial function. Additionally, pharmacological modification of this profile may help
resolve whether there is an earlier step to the ROS burst in mitochondrial adaptation to oxygen
deprivation.

Pharmacological IPC:
Nitric oxide mimics IPC protection in heart, which is abolished by NO scavenging
(Cohen, et al, 2006; Costa, et al, 2005; Jones and Bolli, 2006). This effect has also been noted in
skeletal muscle sugesting that both tissues are protected by the same or similar mechanisms
(Ozaki, et al, 2002). If preconditioning’s primary mechanism of protection is to preserve
mitochondrial function by a slowing down the kinetics of the ETC, then NO may function
similarly to IPC in reducing the mitochondrial inner membrane potential and thus the probability
of MPTP opening because it inhibits cytochrome oxidase c (Hausenloy, et al, 2004). Whether
NO only functions during the IPC phase (Qui, et al, 1997), or continues to provide benefits
during the subsequent phase of damaging ischemia and reperfusion is unclear, but following
ischemia, a positive effect of “post-conditioning” is reduced by the NOS inhibitor L-NAME
(Yang, et al, 2004). As post-conditioning involves brief periods of reperfusion following a
damaging ischemic event (thus limiting the exposure of O2 to dysfunctional mitochondria), NO
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may act similarly to alter VO2 kinetics and limit the destructive effect of full-scale
reoxygenation.

Summary of Study:
A novel technique for multiple and continuous measurements of VO2 dynamics in thin
tissues is presented here, using the rat spinotrapezius muscle. The VO2 sampling technique was
adapted from a method that utilized externally transduced pressure to rapidly arrest flow while
the resultant drop in interstitial oxygen tension (PISFO2) was observed through phosphorescence
quenching microscopy (PQM) (Golub, et al, in revision). The VO2 sampling technique makes
use of an automatic dual pressure system to toggle the pressurization of an objective-mounted air
bag between high and low at regular intervals. With brief, periodic compressions, the initial
component of the oxygen disappearance curve during complete blood flow arrest is reported by
phosphorescence quenching microscopy and then translated into VO2 without observable impact
on subsequent measurements. The utility and sampling resolution of 3 per minute was extended
to reperfusion following 1 minute durations of flow arrest (ischemia) via a sustained air bag
pressurization. There was a slight indication of hyperemia for recovery profiles exposed to the
VO2 sampling technique, but the impact on VO2 kinetics was presumed minimal when
categorized to 3 different ranges of PISFO2 immediately preceding compression. High
compression pressure was also found to be optimal from 120-140 mmHg with minimal
perturbation of the tissue for the 5x15 compression/recovery cycle.
Translation of the linear fall in PISFO2 has 3 components: tissue VO2, consumption by
PQM (K), and refill (R). Using an in vitro analysis, K and R values were determined and a
correction factor was developed to directly relate the initial part of the ODC to VO2 with
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minimal noise. This correction was universally applicable to measurements made with the R2
probe and under the conditions of topical application described in Methods and Materials.
Resting skeletal muscle VO2 was assessed and plotted against PISFO2 to determine the
point at which cytochrome c oxidase became a limiting factor for respiration as measured by
PQM’s assessment of PISFO2. VO2 data was then divided into three categories: hypoxic,
intermediate, and normoxic by the PISFO2 immediately prior to compression (P0), allowing those
groups to be compared. Data from the Normoxic and Intermediate groups were statistically
similar and slightly higher than other reported VO2 measurements in skeletal muscle tissue. The
resting state VO2 of the rat spinotrapezius muscle was then pharmacologically altered with
cyanide, nitroglycerin, and L-NAME and compared to control values.
The VO2 profiles for 5 through 85 seconds of reperfusion following ischemic durations of
1, 5, and 10 minutes were assessed with the VO2 sampling technique and compared in the
categories of hypoxia, intermediate, and normoxia. Ischemia clearly produced a rise in VO2 over
baseline proportional to the duration. This effect was attenuated, but not abolished, by cyanide,
attributing at least some of the effect to cytochrome c oxidase activity. Treatment with the nitric
oxide donor nitroglycerin produced a similar reduction in VO2 and a corresponding enhancement
in PISFO2. L-NAME, an inhibitor of nitric oxide synthase, reduced tissue PO2 through a
reduction in vascular delivery by constriction of arterioles, but did not appear to stimulate
respiration in the normoxic PISFO2 range. It produced a significant rise in VO2 during hypoxia,
which indicates that NO has a greater influence during hypoxia. Since NO is protective during
ischemia/reperfusion injury and a down-regulation in ATP production is consistent with the
induction of this protection during preconditioning, the data in this study support the hypothesis
that that treatment with NO prior to the induction of ischemia results in a reduction in VO2
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consistent with the mitochondrial inhibition needed to confer protection during
ischemia/reperfusion.
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MATERIALS AND METHODS
Animals
The following non-aseptic, non-survival animal protocols were approved by the Virginia
Commonwealth University Institutional Animal Care and Use Committee and are consistent with
both the National Institutes of Health guidelines for the humane treatment of laboratory animals
as well as the American Physiological Society’s Guiding Principles in the Care and Use of
Animals. By following these standards of humane animal research, both animal duress and the
appearance of confounding data from the effects of undo surgical and experimental stress on the
physiological situation were minimized.
Seventy-four male Sprague-Dawley rats (Harlan, Indianapolis, IN), chosen due to their
ease of handling, calm disposition, and wide usage throughout medical research, were used.
Males with an average weight of 286.30 grams (SE: 4.60) were used exclusively in order to
reduce the influence of hormonal cycling on systemic parameters that might have complicated
analysis of the microcirculation. These animals, segregated by pairs, were housed in plastic
isolation containers in the facilities maintained by the Virginia Commonwealth University
Division of Animal Resources. The animal housing provided continual ventilation in a climatecontrolled room kept at 20-23 oC on a 12 hr: 12 hr light-dark cycle. Laboratory chow and water
were provided ad libitum along with sanitation under the supervision of a certified animal care
technician.
In accordance with standard non-aseptic, non-survival surgery protocols, all animals were
euthanized under anesthesia via intravascular injection of 0.1 ml Euthasol (Pentobarbital 390
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mg/ml and Phenytoin 50 mg/ml Delmora Laboratories, Inc., Midlothian, VA) following the
conclusion of experimentation.

Surgical Practices
Pre-op
The animals were weighed on a triple-beam balance and given an intraperitoneal
injection of Ketastet/Acepromazine (75 mg/kg and 2.5 mg/kg respectively) as an initial
anesthetic in the lower left quadrant of the abdomen. Ketastet (Ketamine HCI, Fort Dodge
Animal Health, Fort Dodge, IA) is commonly used to provide a sufficient depth of anesthesia for
major surgical procedures before venular access is available for the use of a continually infused
anesthetic. Acepromazine Maleate (Boehringer Ingelheim Vetmedica Inc., St. Joseph, MO) was
used to reduce anxiety and stress and mitigate some of the sympathetic stimulation caused by the
use of Ketastet.
Once an animal was verified to have entered a sufficiently deep anesthetic plane by
inspection of reflexes such as toe and heel “pinch”, it was transported to a mat, thermallystabilized at ~37 oC via circulating, heated water, and made ready for “shave and prep.” Three
areas were cleared by use of electric clippers and a depilatory (Nair, Church and Dwight Co.
Inc., Princeton, NJ): (1) the left, dorsal region that extended from the shoulder blades to the
lower lumbar area for exteriorization of the spinotrapezius; (2) the skin above the ventral clavicle
for the tracheotomy and any necessary jugular vein and carotid artery canulations; and (3) the
ventral, inner right thigh for access to the femoral vein and artery.
With all surgical areas cleared and wiped clean with isopropyl alcohol swabs (Curad,
Medline Industries Inc., Mundelein, IL), the animal was moved to the pre-heated,
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homoeothermic surgical mat for immediate femoral vein cannulation and tracheotomy to ensure
the continued maintenance of the anesthetic plane and health.

Femoral Vein Cannulation:
The right hind leg was taped to the bench top and a 1 cm incision was made into the
integument along the limb/abdomen boarder. Next, the blunt dissection scissors were used to
tease apart the skin from the deeper fascia, revealing the cleft between the leg and abdominal
muscles. Probing the cleft and teasing away the deeper layers of fascia exposed the femoral
vein, artery, and nerve bundle. At this point, the region was placed under a stereomicroscope
(Nikon SMZ660, Melville, NY) and the bundle was dissected from the surrounding tissue with
micro-dissecting forceps.
The isolated femoral vein was lifted superficially onto a thin, hand carved metal platform
(sometimes referred to as the “lift”) for cannulation. Taking care to maintain vessel moisture
with the application of phosphate buffered saline (PBS), a tie (Ethicon surgical silk size: 00, San
Angello, TX) was placed approximately 0.5 cm distal of the intended cannulation site to arrest
flow and a second tie (not tightened) was positioned approximately 0.5 cm proximal to the
intended cannulation site. Micro-dissecting (3mm straight) scissors, with careful direction
beneath the stereomicroscope, were then used to cut an incision just large enough to
accommodate the cannula (Polyethylene Tubing (PE)-50, Clay Adams, Parsippany, NJ) into the
femoral vein. The cannula, having been checked to ensure that it was free of air bubbles, was
then fed into the vein ~2 cm deep and then the proximal tie was tightened to secure it in place.
The integument was then closed with superglue (Loctite® Super Glue Gel, Henkel Consumer
Adhesives Inc., Avon, OH).
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Gaining prompt access to the femoral vein allowed for a seamless transition in terms of
anesthetic depth between the initial use of Ketastet and the onset of the continuously infused
Alphaxan (Vetoquinol Uk Limited, Buckingham, MK18 1PA). In the rare occasion of
indications of animal arousal prior to femoral vein access, an additional injection of 0.1-0.2 ml
Ketastet was given as described above and surgery was delayed until the animal returned to the
appropriate plane of anesthesia. Alphaxan was administered continuously at an average rate of
0.38 ml/h (SE: 0.01) using an electronic infusion pump (Sp120P Syringe Pump, WPI, Sarasota,
FL) with adjustments to the flow rate by diligent monitoring of the animal via toe and heel pinch
in addition to other appropriate metrics of anesthetic depth.

Tracheotomy:
Taking into consideration animal well-being and sensitivity of systemic oxygen levels on
proper ventilation, the maintenance of a patent airway was essential. The ability to rapidly clear
aspirating fluids that might otherwise confound measurement or bring about animal death was
achieved via the insertion of a flexible tube (PE-240) into the trachea immediately following
femoral vein cannulation.
To start, a 1 cm lateral incision was made into the skin perpendicular to the body axis
(across the throat), approximately 1.5 cm below the mouth and separated from the underlying
connective tissue revealing a thick tissue layer bracketed by two mandibular glands. The fascia
between the glands was then teased apart to expose the underlying sternohyoid muscle. Next,
using the microdissection forceps, the natural separation running down the center of the muscle
was spread apart revealing the deeper tracheal tube. The trachea was then carefully freed from
its surroundings and elevated by the passage of one of the curved micro-dissecting forceps
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beneath it. Ensuring that the airway was not constricted by this action, any bleeding that might
have occurred during tracheal exposure was then staunched using a low temperature cautery
(Gemini RS-300, Roboz Surgical Instrument Co., Rockville MD).
A piece of 3-0 non-sterile, braided silk suture (Ethicon, San Antonio, TX) was threaded
under the trachea and positioned caudal to the intended site of tracheal insertion. Then, using the
microdissecting scissors, a cut just large enough to accommodate the PE-240 tube was made
between the bands of cartilage lining the trachea and the tracheal tube was inserted. Once
positioned to a sufficient depth to prevent expulsion, but not deep enough to obstruct the
branching bronchioles, the suture was tied to fix the tube in place and the integument was closed
around it with super glue. Subsequent observances of fluid in the trach-tube were dealt with by
suction from an inserted PE-90 tube attached to a 10 ml syringe.

Spinotrapezius Preparation:
The protocol for the exteriorization of the rat spinotrapezius muscle for intravital
microscopy was first described by Gray (1973) and has since been adapted to suit our needs for
continuous sampling of tissue VO2 on our thermostatic animal platform (Golub and Pittman
2003; see Figure 3).
To begin, a region of hair approximately 8 x 5 cm starting at the shoulder blades on the
rat’s dorsal side and proceeding caudally to the rat’s lower lumbar area was trimmed with hair
clippers and subjected to a depilatory (Nair, Church and Dwight Co. Inc.) to allow access to the
skin. Next, having completed all canulations, tracheotomy, and assured the continued
maintenance of a proper plane of anesthesia, a dorsal midline incision was made in the lower
lumbar region of the hairless patch to expose the underlying fascia. Care was taken to cut only
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the thick layer of skin and not penetrate the fascia as this can cause damage to the deeper
spinotrapezius muscle. Using the curved blunt dissecting scissors (pointed up and away from the
spinotrapezius), the skin was carefully teased apart from the underlying fascia proceeding
rostrally towards the shoulder blades. As the skin was freed, the incision was continued along
the midline until reaching the shoulder blades. Excess bleeding from the cut dermal layer was
staunched with the low temperature cautery and a few drops of PBS were occasionally applied to
the exposed, deeper tissues to prevent desiccation.
Using the same technique of teasing, cutting, and cauterizing, the incision was continued
at both endpoints turning 90 degrees left and proceeding laterally for approximately 3 cm (longer
for larger rats). This produced a flap of skin that was pulled away, exposing the underlying
fascia covering the left spinotrapezius muscle. Some additional teasing and cauterization was
occasionally required to fully separate the skin flap from the deeper layers.
Grasping the superficial layer of fascia around the lumbar region with the microdissecting forceps, a pinched section was lifted away from the underlying tissue. Next, a hole
was made in the pinched fascia and the curved blunt dissecting scissors, faced upwards, were
inserted to begin teasing the fascia apart from the deeper layer. As some of the deeper layer was
the actual spinotrapezius muscle, care was taken to prevent damage. The fascia pulled away
along its lateral boarder, allowing it to be folded up and over the dorsal midline. In the event that
it did not pull free, use of the cautery to cut the remaining connections was appropriate. Teasing
was then continued rostrally until the left, lateral feed vessels to the spinotrapezius were revealed
and then progressed medially along the entire flap of fascia until reaching the midline. This
exposed the entire exteriorizable portion of the spinotrapezius along with its attached “strap”
muscle along the lateral boarder. Continued dripping of PBS prevented drying.
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With the superficial fascia cleared, the thin “strap” muscle (lateral to the spinotrapezius)
was gripped and cut away from the connective tissue along its lateral boarder. This separation
was coupled with the careful teasing apart of both the strap and attached spinotrapezius from
deeper muscle layers. This technique required the insertion of closed, curved blunt dissecting
scissors beneath the spinotrapezius followed by their slow opening and withdrawal. It was
important to keep the curved end pointed away from the spinotrapezius (downward in this case)
at all times to minimize tissue damage. Separation of the spinotrapezius began at the lateral
grouping of feed vessels and proceeded distally to the “tip.” Upon reaching the tip, a low
temperature cautery was occasionally necessary to prevent bleeding from cut distal feed vessels.
At this point, two equidistant sutures (Surgik 4-0, Broken Arrow, OK) were placed along the
strap muscle at the lateral boarder of the spinotrapezius with a third being fixed to the muscle’s
tip. This allowed the spinotrapezius muscle to adopt a more natural form when it was placed on
the pedestal. Separation then continued proximally along the medial boarder with careful use of
the cautery to staunch bleeding until such a point was reached where the medial and lateral
separations were of equal length. At this time, two final sutures were placed along the medial
boarder mirroring the work on the lateral boarder.
Note: Surgik 4-0 monofilament nylon suture was ideal for use in this situation as it
minimizes tissue damage and stretching. The needles came pre-attached to the suture, which
allowed for a smooth transition from the metal to line. This prevented damage from trying to
yank knots through the tissue. Additionally, the needles were disposable after a few experiments
and thus never reached the point of dulling under normal use.
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Figure 3: Thermostatic animal platform adapted for use with the PQM setup. A: The
transparent, heated pedestal that allows for isolation and measurement of the exteriorized
spinotrapezius preparation. B: A thermal plate that maintains the animal’s core body
temperature during anesthesia. C: An adjustable spacer that can accommodate animals of
varying body size. D: This is the thermo regulator that controls platform heating.
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Animal Mounting on Thermostatic Platform:
To meet the demands of microscopy and animal well-being during experimentation, the
rat was placed on a platform that was specially adapted for use with PQM. Prior to animal
mounting, the stage was prepared by covering the spinotrapezius observation pedestal with a
single layer of oxygen impermeable Krehalon (Krehalon CB-100) and then securing it in place
with a neoprene pedestal ring. This prevented the R2 probe from contaminating the pedestal
surface as well as allowing for easy cleanup. Additionally, the stage was preheated to minimize
the amount of time both the rat and tissue might spend below normal body temperature.
To mount, the rat was first laid down on the stage’s core heating platform and the
spinotrapezius was placed flat on the pedestal so that the deeper side was faced upwards. The
sutures were then gently pulled and anchored to the neoprene pedestal ring with hot glue so that
the spinotrapezius was held flat against the platform, yet still retained a close approximation to
its natural size and shape. Some mild stretching of the tissue was necessary to prevent it from
bunching up during experimentation (see Figure 4). An ideal mounting of the muscle showed a
clear image under trans-illumination and had no discernable shift (movement/compression
artifact) in PO2 when switching between high and low compression. Additionally, when shifting
locations under trans-illumination and low pressure, the tissue remained in focus.
Note: in general, proper exteriorization has not been found to significantly alter blood
flow in the rat spinotrapezius muscle (Bailey, et al 2000). Thus, inconsistent and improper
technique was the greatest enemy to consistency. Along with gentle handing of the muscle
during exteriorization, it was important to maintain muscle hydration at all times or else the
microcirculation would reflect that of an undesirable dehydrated state. A few drops of PBS
whenever the surface of the muscle seemed to have lost the sheen of wetness took care of this
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Figure 4: An exteriorized spinotrapezius preparation. The muscle has been secured to the
observation pedestal and covered temporarily with a sheet of saran to prevent drying. This
image was taken immediately prior to the application of the R2 probe.
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problem and allowed for consistently strong flow along with proper phosphorescent probe
loading and reporting.

R2 Probe Application:
The R2 phosphorescence probe was necessary for measurements of ISFPO2 using PQM. It
was bound to 5% human serum albumin (HSA), as described later, to maximize the uniformity
of signal and allow for efficient loading into the interstitium To apply, approximately 100 to 150
μl of R2 probe was first dripped on to the surface of the muscle—already properly hydrated and
mounted on the observation pedestal—until completely covered. Next, a few drops of PBS were
placed around the pedestal’s perimeter, but not in contact with the tissue, and a single sheet
(~10x8 cm) of Krehalon was laid gently atop the prep. Where air bubbles remained along the
boarder of the tissue, they were pushed out with a cotton swab taking care not to disturb the layer
of probe that sat atop the tissue. Once bubble-free contact had been made with the Krehalon
flush against the pedestal, pushpins were used to anchor the Krehalon to the neoprene ring.

R2 Loading:
The platform, complete with animal, was relocated to its relevant PQM setup (see Figure
5) and the onboard heating was reengaged immediately. Anesthesia tends to disable
hypothalamic control over thermoregulation, causing a rapid decline in body temperature
(McKay and Clement, 1977) and thus the platform’s thermal plates were needed to supplement
heat for both the animal’s core and the exteriorized spinotrapezius on the pedestal. Although
normal core temperature was maintained during surgery via the heating pad, the spinotrapezius
probably underwent some cooling during exteriorization and mounting. Thus, in addition to
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satisfying the need for a sufficient probe loading time, a 30 minute period before beginning the
measurements allowed the microvasculature to stabilize and return to its best approximation of
the physiological condition. No pressure or other experimental intervention was made during
this period in order to prevent regional variations in final probe concentration.
Upon completion of the rest/incubation phase, a cotton swab was used to apply a thin
layer of silicone lubricant (Touch Massage: KY Brand) to the surface of the Krehalon, which
reduced the friction at the bag interface. The gentle brushing action also served to ensure that the
Krehalon was in good, solid contact with the tissue. Finally, the objective was lowered into
place so that the Krehalon compression bag (Figure 10), pressurized at 5 mmHg, was in contact
with the Krehalon above the tissue. The low pressure minimized the fluid layer above the tissue
and therefore allowed the majority of the phosphorescent signal to originate from the dyesaturated tissue interstitium.

Intravital Microscopy:
Observation and measurement of exteriorized spinotrapezius preparations—mounted on
the thermostatic animal platform—were conducted via an intravital microscope (Axioimager2m,
Carl Zeiss, Germany; see Figure 5) configured for both epi and trans-illumination through a
20X/0.8 objective (Plan-APOCHROMATE, Zeiss, Germany). To ensure exclusive measurement
of the tissue and for purposes of blood flow interruption, the objective was affixed with a
transparent saran bag that maintained physical contact at low (5 mmHg) and high (120-140
mmHg) pressures with the Krehalon-covered preparation throughout experimentation. Friction
between the two layers of Krehalon was minimized with a layer of KY lubricant.
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Figure 5: Intravital Microscopy Setup. A: The optical components and base of the
Axioimager2m light microscope. B: The photomultiplier tube which provided signal
enhancement of the phosphorescence emissions. C: The xenon flash lamp delivered uniform
pulses of light to the 300 μm diameter octagonal excitation region to induce phosphorescence.
D: This device controlled pulse frequency. E: The oscilloscope provided a visual representation
of the phosphorescence lifetime during experimentation. This enabled real-time feed back for
tissue oxygenation under various conditions. F: Images could be viewed during
transillumination on this LCD monitor. The TV’s high resolution was essential for site selection,
flow assessment and measurements of arteriolar diameter.
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Epi-illumination:
Excitation of the R2 phosphorescent probe, distributed in the interstitium of the
spinotrapezius preparation, was achieved via a xenon flash lamp (Model FX249, EG&G Electrooptics Co., Salem, MA ) epi-illumination, which delivered 0.5 J/Flash for a duration of 4 μs (full
width at one third maximum pulse height) to an octagonal region of tissue 300 μm in diameter at
a frequency of 10 Hz. Light from the flashtube was directed through a filter cube into the
objective lens and delivered to the desired point of focus within the tissue’s microvasculature.
The filter cube consisted of a narrow-band filter (INTOR 525/70/75%, Intor Inc. Socorro, NM),
specifically designed to excite the probe at the 525 nm wavelength of light (the Q-band), a
dichroic mirror (Chroma 565 DCLP, Chroma Technology Corp. Bellows Falls, VT) and a wideband filter (Oriel Cut-on >650nm, Newport Corp, Stratford, CT) for selective collection of
phosphorescence emissions. The subsequent phosphorescence emission was collected through
the 20X objective and detected by a photomultiplier tube (PMT). The signal from the PMT then
traveled to a modified amplifier (OP37EP, Analog Devices, Norwood, MA) which functioned as
a current-to-voltage converter outfitted with a precision analog switch (ADG419BN, Norwood,
MA) allowing for a gating time of 12μs. The 12 μs delay between pulse initiation and data
collection covered the 5 μs propagation delay from the plasma arc to the flash, the 4 μs light
pulse, and 4-5 μs of any residual thermal tail from the flash lamp and lingering fluorescence
signal from tissue or probe. Thus, the data collected were optimized to contain the highest
contribution from phosphorescence with the time resolution to acquire the earliest components of
the lifetime for reliable measurements of high PO2. These signals were visually monitored in
real-time with an oscilloscope (72-3060, Tenma, Springboro, OH) before they were passed to a
12-bit analog-to-digital converter (PC-MIO-16E-4, National Instruments, Austin, TX), and saved
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digitally on a Dell Optiplex PC (Round Rock, TX). See Figures 5 and 6 for pictorial and
diagrammatical views of this setup.

Data Acquisition and Analysis:
Data acquisition was controlled by the “ASGARD” program, written by Dr. Aleksander
Golub using the software LabVIEW (National Instruments, TX) for this specific application.
This allowed sampling at 500 kHz with 500 data points per curve. Curve collection number per
measurement varied from 600 to 3000 depending on the time course. “RECTSINHFixFOff,”
another program written in LabVIEW by Dr. Golub, was used to automatically calculate the
phosphorescence decay curves and translate them into measurements of PO2 (see Figure 8),
while Origin 6.1 and Origin 7.0 (OriginLab, Northampton, MA) were used to further analyze
measurements of oxygen disappearance, interstitial PO2 averages. An Origin 6.1 non-linear fit
program (CONS&REFILL, written by Dr. Golub) was used to additionally calculate the rate of
oxygen consumption occurring as a result of phosphorescence quenching.

Transillumination:
The tissue’s microvasculature was visualized under transillumination with white light
from a light emitting diode (Luxeon V Star white, Quadica Developments Inc., Brantford,
Ontario) that was fed up through the microscope’s condenser (Model LN19A450C1D, Samsung,
Seoul, Korea. The image, under 20X magnification, was captured in real-time by a color CCD
camera (KP-D20BU, Hitachi, Tokyo, Japan) and displayed on a flat-screen color TV (Model
LN19A450C1D, Samsung, Japan). Transillumination was used during the measurement site
selection process, establishment of the appropriate focal plane and verification of flow
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Figure 6: Schematic of the intravital microscope and data acquisition equipment as adapted for
phosphorescence quenching microscopy.
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conditions. For phosphorescence excitation and measurement, it was blocked along with other
sources of stray light in order to minimize their influence.

Phosphorescence Quenching Microscopy
Partial pressures of oxygen were measured using phosphorescence quenching microscopy
(PQM), a non-invasive method with high selectivity and spatial and temporal resolution.
Phosphorescence occurs when molecules absorb an appropriate wavelength of light and
transition from the ground to the singlet state. While many quickly return to ground state via
fluorescent emission, some undergo intersystem crossing into the triplet state before returning to
ground state with a phosphorescence emission. The conversion to the triplet state separates the
rapid burst of fluorescence from the lingering phosphorescence, which decays with lifetimes
from microseconds to milliseconds (Wilson, et al. 1987). In addition to emitting a photon
(phosphorescence) to return to the ground state, molecules in the triplet state can transfer their
energy to other molecules, a process known as quenching. Quenching has the effect of reducing
phosphorescence lifetimes in inverse proportion to the concentration of the quencher. As O2 is
the principle quenching agent in biological tissues and is only limited by diffusion, a relationship
between phosphorescence lifetime and tissue PO2 can be readily established. The oxygen
dependence of the phosphorescence decay is described by the Stern-Volmer equation:

1/τ=1/τ0+kqPO2

(Equation 2)

where τ is the lifetime at the measured PO2, τ0 is the phosphorescence lifetime in the absence of
oxygen, and kq is the quenching coefficient. While this simple equation is sufficient for samples
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with homogenous PO2, the interstitium of skeletal muscle exists as a dynamic gradient between
vascular supply and tissue respiration—most noticeably during changes in metabolic demand.
This heterogeneity can cause underestimates of PO2 when calculations are made with a monoexponential function. In response, Golub et al (1999) proposed a rectangular distribution model
that minimizes the systematic error by accounting for regional variability in PO2 levels within the
measurement area (see Figure 8). All interstitial PO2 values were therefore calculated using the
following equation:

y1 = a*exp[-(k0+kqM)τ]*sinh(kqδτ+y0

(Equation 3)

where a is the phosphorescence signal amplitude in volts, k0 is the phosphorescence lifetime in
the absence of oxygen, kq is the coefficient of quenching, M is the mean PO2, δ is the half-width
of the PO2 distribution, and y0 is the baseline offset. The values for constants k0 and kq, 1.53*10-3
μs-1 and 0.43*10-3 μs-1mmHg-1 respectively, were determined by systematically accounting for
conditions of temperature and pH in living tissue (Dunphy I, et al. 2002), and confirmed with
micro slides containing various known PO2s.

Description of Phosphorescence Probe:

Pd-meso-tetra-(4-carboxyphenyl)porphyrin (Oxyphor R2) was solubilized in phosphate
buffered saline and bound to human serum albumin as described later. The R2/Albumin-bound
probe was topically applied to the spinotrapezius muscle at a concentration of 10 mg/ml and,
following 30 minutes of incubation, reached a level within the interstitium that allowed for a
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strong phosphorescence signal that did not appreciably diminish over 3-4 hours of
experimentation and followup post mortem analysis. The average interstitial probe concentration
was 19.5μg/ml (SE: 2.3) and this value was used as an in vitro reference for quantifying the
oxygen consumption by the method. Additionally, the skeletal muscle tissues were not uniform
in terms of structure and density, which resulted in some minor heterogeneity in the distribution
of the probe. These differences were not noticeable or were excluded from measurement. It has
also been established that the probe concentration does not affect the phosphorescence lifetime,
thus, all measured sites could be accurately converted to measurements of PO2 regardless of
minor variations in signal amplitude (Vanderkooi, et al. 1987).
R2 has two absorption peaks (415 and 524 nm, the soret and Q bands respectively) and
an emission peak of 690 (see Figure 7; Dunphy et al, 2002). A filter cube set the excitation
wavelength at 525 nm in order to take advantage of the deeper tissue penetrance of a longer
wavelength of light with maximum and specific excitation at the Q-band. The resulting
emissions signal, collected through the 20x objective, was passed through a >650 nm cut-on
filter that allowed for the exclusive collection of the wide R2 phosphorescence 690 nm emission
peak before reaching the photomultiplier tube. This, in conjunction with signal gating, helped
ensure the best possible collection of a pure phosphorescence signal. Additionally, all
measurements were performed under dark conditions with the microscope shielded from stray
light. When necessary, an amber light source that did not alter the R2 probe’s disposition was
used to illuminate the setup for adjustments and maintenance of rat health.
The binding of the phosphorescence probe Pd-MTCPP to albumin not only penetrates the
entire depth of the spinotrapezius muscle during topical application, but occupies only the
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Figure 7: Diagram of the R2 phosphorescent probe’s absorption and emission peaks. This
study made use of the “Q-band” at 524 nm for excitation.

Figure adopted from:
Dunphy I, Vinogradov SA, and Wilson DF. Oxyphor R2 and G2: phosphors for measuring
oxygen by oxygen-dependent quenching of phosphorescence. Anal Biochem 310: 191198, 2002.
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Figure 8: Mathematical fitting of an R2 phosphorescence decay curve. The fitting (pink line) of
raw decay curve (yellow line) was done using the RECTSINHFixOFF software developed by Dr.
Golub based on equation [2], this calculation gave a PO2 value of 75.4.
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interstitial space (Tevald, 2006). R2 was similarly bound to albumin, and therefore had a similar
diffusivity to Pd-MTCPP. Any proliferation into the vascular lumen would have resulted in
immediate clearance and the sarcolemma were impermeable to albumin. Thus, all measurements
are from probe that is exclusively within the interstitium of the spinotrapezius muscle.

Energy Density
The excitation energy impacting the tissue was measured using a commercially available
sensor (Lasercheck, Coherent, Auburn, CA). Using a flash rate of 20 Hz, the energy per flash
was measured to be 5.366 (SE: 0.0078) μW. With an octagonal excitation area of 74,600 μm2,
the energy density per flash was 3.59*10-12 J*μm-2.

Oxygen Consumption by the Method
Excitation and intersystem crossing of a phosphorescent molecule produces a triplet state
that is capable of interacting with O2 to yield singlet oxygen and superoxide (Vanderkooi, et al.,
1987). Although reactive oxygen species generation does not appear to cause damage during
lengthy excitation of phosphorescence probes (Vanderkooi, et al., 1987), their production
consumes oxygen. This could lead to measurement error with repeated measurement of a
stationary volume of tissue. Prior PQM measurements have taken advantage of a relatively low
level of oxygen consumption per flash compared to the large and continual influx of oxygen in
well perfused tissues, so the method did not significantly alter interstitial PO2 (Tevald, 2006).
Since the most recent setup was designed to make use of 140 mmHg air bag compression to
completely arrest blood flow, and thus the primary source of oxygen influx, consumption by the
method became an important component when accounting for the PO2 disappearance rate.
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Determination of Probe Concentration in Tissue:
After the experiment, the spinotrapezius muscle was cut at its proximal connection and
pressed to a thickness of 500 μm between two glass microscope slides. The assembly was then
placed on the heated pedestal of the thermostatic animal platform and allowed to equilibrate to
~38 o C for 10 minutes. Simultaneously, three 100 μm thick micro capillary tubes (Vitrotubes
0.1X1.0 mm I.D. Fiber Optic Center Inc., New Bedford, MA) were loaded with 25, 50, and 100
μg/ml solutions of R2 probe bound to 5% albumin in PBS. This range of probe concentrations
were chosen based on the projected level in the interstitium upon topical loading with 10mg/ml
R2 bound to 5% albumin in PBS. The tubes were sealed with Critoseal (Krackeler Scientific
Inc., Albany, NY) to prevent contamination by atmospheric O2 and placed on the heated pedestal
alongside the muscle prep for equilibration to 38 o C.
The amplitude of the phosphorescence signal was a function of both probe and oxygen
concentrations. Thus, for a given PO2, the concentration of R2 in a particular measurement area
could be expressed in terms of the signal voltage. It was determined that measurement of the
signal amplitude was most accurate when conducted at the lowest PO2 possible. This then
allowed a reliable comparison between the tissue sample and known concentrations. A high
intensity green LED was shone on both the tissue preparation and the micro capillary tubes
following the 10 minute equilibration period to stimulate photoconsumption and reduce the PO2
to the practical zero. The tissue was then measured with PQM at multiple sites in order to obtain
the average signal amplitude, with a gating time of 50 μs. Without altering the signal gain, the
tissue was removed and replaced with the known samples. The average amplitudes from each
sample were compared to that of the tissue average and known concentration with the same

52

53
signal strength as that of the tissue was divided by 5, accounting for the 5 fold difference in
thickness between the micro capillary tube and the muscle preparation, to achieve an
approximate value for the concentration of R2 probe bound to albumin in the interstitial fluid of
skeletal muscle.

In Vitro Consumption Microcapillary Tubes:
A solution of R2 bound to 5% albumin in PBS at a concentration of 19.5 μg/ml (based on
previous measurements of tissue concentration) was oxygenated by simple agitation during
atmospheric exposure under dark conditions. The probe concentration was not scaled to account
for the difference in excitation volume since the consumption rate at a particular probe
concentration should be independent of volume. It was then loaded into micro capillary tubes,
sealed with Critoseal to prevent further contamination by atmospheric oxygen, and placed on the
heated pedestal of the thermostatic animal platform for 10 minutes to equilibrate to 38 o C. Next,
using a short series of 1 hz pulses, the solution PO2 was approximated. A green LED was then
shone on the micro capillary tubes for brief periods until the PO2 had decreased to ~100 mmHg.
Our reasoning was that the analysis would be complicated in both consumption and refill by
having unrealistically high PO2s inside and outside the excitation region. Finally, various sites
were exposed to 3000 flashes at 1, 10, and 100 hz excitation to obtain both the rate of PQM
consumption and the refill from passive diffusion at the periphery of the measurement site.

In Vitro Consumption by Alginate Gel
Three 2% alginate gels were prepared and loaded with the R2 probe for assessment of
PQM oxygen consumption. First, a 2% alginate solution was prepared by producing a 5 ml
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solution of 5% HSA in deionized H2O, and R2 probe at 19.5 μg/ml and combining it with 100
mg sodium alginate (Sigma Aldrich, St. Louis, MO) under vigorous stirring. The solution was
then allowed to sit undisturbed for 30 minutes to eliminate any bubbles. Next under dark
conditions, 600 μl of the solution was pipetted into plastic molds 39 cm in diameter to give an
eventual thickness of 0.5 mm. Finally, a solution of 0.2 M calcium chloride was misted onto the
molds and the alginate was covered and left alone for 1 hour to gel.
Once hardened, the alginate gels were carefully removed from their molds and placed on
glass microscope slides. A sheet of Krehalon was then laid on top of the gel, in the same fashion
as done with the spinotrapezius muscle preparation, to act as a barrier against atmospheric
oxygen. Two 0.5 mm spacers were then placed alongside the gel and a second glass microscope
slide was used to press the gel to the 0.5 mm thickness. Clips were attached to ensure stability
and the assembly was then placed on the heated animal platform pedestal for a 10 minute
equilibration period to achieve ~38 oC temperature. Sites nearest to the center of each gel were
then selected and exposed to 10 Hz excitation for 3000 curves (5 minutes). The volume of gel
was sufficient so that reoxygenation was not necessary between measurements. Data were
truncated to begin at 100 mmHg since the PQM setup was optimized to function over the PO2
range of 100 to ~0 mmHg.

VO2 Sampling Technique
Interstitial fluid PO2 is a function of oxygen supply and demand. Under resting
conditions in skeletal muscle, supply and demand are sufficiently balanced by regulatory
mechanisms so that the value of PISFO2 lies between the PO2 at the nearest vascular source of
oxygen to the lower value at the neighboring respiring cells. For the most part, these PO2
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gradients can be averaged over a 300 μm diameter region of measurement without apparent
heterogeneities in the phosphorescence lifetime due to dramatic differences in PISFO2. As this
average is a balance between vascular inflow of oxygen and tissue respiration, alterations in one
or the other will result in a shift to a new average PISFO2. Thus, when temporarily eliminating
the vascular supply of oxygen by both flow-arrest and the extrusion of red blood cells in the
localized region of interest, the rate of decline in PISFO2 becomes a function of tissue respiration
and consumption of oxygen by the method. Measuring the rate of PISFO2 decline immediately
following cessation of the vascular supply, with correction for PQM oxygen consumption yields
the rate of tissue oxygen consumption by the tissue (VO2).

Air-Bag Design and Assembly
Flow-arrest and blood extrusion for the purpose of VO2 measurements in the rat
spinotrapezius muscle were facilitated by a focused compression of the PQM excitation region
using a transparent air-bag mounted to the objective lens. The use of a compressive force to alter
vascular dynamics for purposes of microscopic observation was first described by Roy and
Brown in 1880, and recently adapted towards the goal of VO2 measurements in a variety of thin
tissues (Golub et al, 2007). What follows is a further modification of this approach to
accommodate serial VO2 measurements as part of a local ischemia/reperfusion protocol (see
Figures 9 and 10).
First, the interior a rubber grommet (The Hillman Group, Cincinnati, OH) was bored out
until a snug fit was obtained to the 20X objective of the Axioimager2m microscope. The
grommet was then punctured with a syringe tip to provide a means of airflow into the air-bag
that would be placed over the objective lens. Next, a 10 cm x 10 cm sheet of transparent
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Krehalon was cut and placed flat on a clean surface. Since the objective used is wider than
previous models, an additional piece of restraint plastic was needed to focus the force of the
bag’s pressure on the site of measurement. Thus, a piece of thicker plastic was cut and folded so
that a ~3 cm diameter hole could be precisely cut in the center. It was then placed atop the
Krehalon. Both sheets together were then flipped over and placed over the mouth of an open
cylinder—sized with a gauge slightly wider than the 20X objective—centered on the opening in
the restraint-plastic. While maintaining the alignment of the opening in the restraint-plastic
within the mouth of the cylinder, the Krehalon+restraint-plastic sheet was depressed ~1cm and
then overlaid with the objective so that the grommet made contact with the edges of the mouth
and the optics now fitting within the sheet’s 1 cm depression. Next, the objective, sheet, and
tube were carefully flipped and an O-ring (Danco #30 O-ring: Irving, TX) was slipped
downwards and snapped over the grommet so that the Krehalon+restraint-plastic sheet was now
affixed to the objective, thereby encasing the optics in an air-tight bag. A brief inflation was
then conducted to test the bag’s form. It was determined that a pressure of 5 mmHg should
inflate the bag so that its lower border was between 1 and 2 mm from the objective lens. If the
lower border of the air-bag were any closer to the objective lens, the bag would not make
sufficient contact with the preparation to extrude the fluid layer and furthermore would cause
insufficient flow-arrest during high pressure. Finally, all excess plastic was trimmed around the
edges and the bag was sealed with tight wrappings of black electrical tape. Once tested for form
and integrity at extreme pressure (200 mmHg), the air bag was assessed for its ability to stop
flow in tissue before operational use.
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Figure 9: Materials involved in mounting air-bag to the 20X objective. A: A 20X objective
provided a mount for the air-bag as well as optics for both intravital microscopy and PQM. B:
This sheet of plastic is heavier than Krehalon and was used as an elastic restraint to control the
size of the air-bag’s compression area. C: The Krehalon sheet provided the substance of the airbag and was the only component to make physical contact with the Krehalon-covered
spinotrapezius muscle preparation. D: When forming the air-bag around the objective’s tip, this
open-ended cylinder was used for correct positioning. E: An O-ring was used to secure the
Krehalon air-bag to the grommet forming an air-tight seal. F: The grommet was fit snugly to the
objective to provide a mounting for the air-bag. G: This needle acted as the pressure input into
the air-bag. It was threaded through the grommet and secured in place by hot glue.
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Figure 10: Air-bag mounted to 20X objective. A: The objective as it appears with the mounted
air-bag. Black electrical tape helps to seal any minor air-leaks. B: The 20X objective with
mounted air-bag as it appears during operation. The pressure is set to 5 mmHg.
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Flow Arrest
Assessment of VO2 in the intact, perfused rat spinotrapezius muscle preparation with
PQM required an immediate and complete cessation of flow and extrusion of blood from the
measurement area. To achieve this, an objective-mounted air-bag (see Figures 7 and 8) was
inflated to topically deliver a focal compression that accomplished both aims of flow-arrest and
blood extrusion.
Initially, the air-bag was pressurized to 5 mmHg to make soft contact with the
preparation while providing sufficient force to press the Krehalon layer against the tissue. This
functioned to extrude any surface accumulation of fluid that might report erroneous
phosphorescent lifetimes. By observing the microvasculature in the focal plane during low
pressure contact, it was determined that 5 mmHg did not visably alter blood flow. Typically,
exclusion of the surface fluid layer via 5 mmHg pressurization of the air-bag was necessary for
accurate PO2 measurements even when flow-arrest was excluded from the protocol. Next, the
bag was pressurized to 120-140 mmHg (depending on the tissue thickness), which immediately
(<1s) stopped flow. Flow-arrest and red blood cell extrusion was visualized via transillumination
for quality assurance. Additionally, transillumination was used during tissue compression to
observe whether compression caused any shifting of the measurement area within the horizontal
plane. Unintended tissue movement could typically be corrected by relocating to a different site,
or in the most extreme cases, preparing a new air-bag. Following sufficient compression
duration, the pressure in the air-bag was released back to 5 mmHg and flow was restored. Flow
restoration was best assessed using PO2 measurement by PQM, as visual inspection through
transillumination was in some cases subjective.
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Quasi-Continuous VO2 Sampling
It was systematically determined, as described later, that a 5 second blood flow arrest
brought on by pressurizing the air-bag at 120-140 mmHg followed by 15 seconds at 5 mmHg
allowed for a sufficient temporal resolution of VO2 without compromising either VO2 or the
recovery back to baseline PO2. This rate of measurement provided a VO2 sampling resolution of
3 per minute for as long as necessary. To precisely deliver the compressions of the appropriate
duration and pressure, an automatic dual stage pressure cycling device was designed and
constructed by Dr. Golub (Figure 9). Its function allowed for appropriately timed oscillation
between two pressure levels, high and low, accommodating the 5 seconds of compression and 15
seconds of recovery in the measurement sequence. A digital display reported the current
pressure inside the air-bag and a toggle switch allowed for the selection of manual pressure
delivery for longer durations of both high and low pressure.
VO2 sampling in vivo was conducted in the following manner: First the low (~5 mmHg)
and high (~120-140 mmHg) pressures were selected and the device was set to manual control.
This pressurized the air-bag to 5 mmHg for soft contact with the spinotrapezius muscle
preparation—necessary for extrusion of any accumulated fluid layer that might interfere with the
measurement. Next, PQM was used to record a baseline PO2 at the typical 10 Hz excitation
frequency. Finally, the device was switched to automatic mode for the prescribed duration and
switched back to manual until the next measurement (see Figure 10 for typical VO2 sampling
profile).
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Figure 11: Automatic Dual Stage Pressure Cycler. This device allowed for both manual
toggling of low/high pressure and an automatic cycling of 5 seconds high pressure followed by
15 seconds of low pressure. High and low pressures could be adjusted to fit the individual needs
of each measurement.
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Arteriolar Diameter

Measurements of vessel diameter in the spinotrapezius preparation were made by visual
inspection under transillumination at either 10X or 20X objective magnifications. The
microscope was focused in the microvascular plane and the image projected to a TV screen.
Vessel widths were then measured in millimeters as they appeared on the screen and then
converted to actual values using the following equation:

d = (x*0.9)

Equation 4

where x is the value measured from the image in millimeters and d is the actual arteriolar
diameter in μm. This conversion appropriately adjusts the image size to the actual size.

Chemical Preparation
R2 Probe
For the purposes of measuring the interstitial PO2 of the rat spinotrapezius muscle, the
phosphorescent probe Oxyphor R2 (a palladium porphyrin dendrimer) was bound to human
serum albumin (HSA) as follows:
First, 100 μl of 25% HSA by wt. (ZLB Behring AG, Berne, Switzerland) was removed
from the stock container via a sterile syringe wiped with alcohol swabs before and after insertion.
It was then mixed via gentle pipette action with 400 μl PBS in a 1 ml microcentrifuge tube to
yield 500 μl of 5% HSA by wt. in PBS. Next, 5 mg of dry R2 grains were placed into a weigh
boat and measured on a Sartorius CP64 digital scale (Balance People Inc., Newport News, VA).
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Then, the solution of 5 % HSA was poured into the weigh boat and swirled until the R2 grains
were completely dissolved. Finally, the R2 probe solution was poured back into the
microcentrifuge tube, encased in photoprotective aluminum foil, and refrigerated until needed.
Prior to each use, the probe solution was checked for signs of bacterial contamination and each
preparation was discarded at the end of its 3-5 day shelf-life.

Phosphate Buffered Saline
In addition to the requisite maintenance of ionic balance during fluid intervention, many
of the chemicals used in these studies were pH-sensitive and, thus all solutions were buffered to
the physiological pH of 7.4 with isotonic Phosphate Buffered Saline (PBS). This solution was
prepared by mixing 1 packet of powdered PBS (Sigma Aldrich, St. Louis, MO) with 1000 ml of
deionized H2O to obtain a concentration of 0.01 M.

Cyanide
Cyanide (NaCN) has a molecular weight of 49.01 and is water-soluble. It was used as an
inhibitor of mitochondrial respiration in the rat spinotrapezius muscle preparation. 49.01 mg of
powdered NaCN (Sigma Aldrich, St. Louis, MO) was added to 100 ml of room temperature PBS
to produce a 10 mM stock solution. A dilution of 1:10 was then conducted by taking 100 μl of
stock and adding to 900 μl PBS to obtain 1 mM NaCN. Further dilutions followed the same
procedure with the exception that the 100 μl of NaCN were taken from the newly diluted
concentration rather than the stock solution.

L-NAME
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Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME) was used as a non-specific
inhibitor of the enzymatic production of nitric oxide (through nitric oxide synthase, NOS) in the
rat spinotrapezius muscle. A 1.48 mM stock solution was made by adding 100 mg of powdered
L-NAME (Sigma Aldrich, St. Louis, MO) to 250 ml PBS. This volume was refrigerated when
not in use and serially diluted for application by factors of 10 to obtain the additional
concentrations of 0.148, 0.0148, and 0.00148 mM in PBS.

Nitroglycerin
Nitroglycerin (NTG) was used as a nitric oxide donor that was topically applied to the rat
spinotrapezius muscle preparation. To prepare as a solution, 1 tablet consisting of 0.4 mg NTG
was allowed to dissolve in 1 ml PBS for 5 minutes. This mixture was then shaken vigorously
until homogenized and then passed through a syringe filter (size: 0.45 μm type: HA, Millipore
Corp, Bedford, MA) to remove any undissolved particulate matter. The resulting 1.76 mM NTG
stock solution was then wrapped in aluminum foil to protect against photo-damage and serially
diluted by factors of 10 in PBS as needed.

Specific Protocols
Determination of Stop-Flow Pressure
Microvascular flow-arrest was induced by the downward projection of force onto the rat
spinotrapezius muscle via a pressurized airbag. Since these protocols required multiple
compressions of both short and long durations at a single site, it was necessary not only to stop
flow completely, but to allow for rapid and total reperfusion. This meant providing enough
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pressure to overcome intravascular pressure, but not so much as to cause damage and prevent
return of normal flow.
The baseline mean arterial pressures (95.2 ± 2.5 mmHg) of 13 Sprague Dawley (SD) rats
under anesthesia for our non-survival surgery protocol were determined and used as an indicator
of the pressure needed for the collection of preliminary data. Further investigation revealed that
in normotensive SD rats, feed arterioles with diameters of ~60 μm had an average intravascular
pressure of ~60 mmHg (Boegehold, 1991). As these vessels were at least 4-fold greater in
diameter than what was generally included in the area of compression, a lower pressure was
sought for use. With decreasing pressure, complete flow-arrest became more difficult to obtain
and it was decided that a systematic approach was needed to determine an ideal pressure range.
The spinotrapezius muscle was prepared and mounted as previously described.
Following a 30-minute adaptation period, a site was selected that contained well perfused vessels
with diameters < 15 μm. Based on preliminary and concurrent measurements, a compression
recovery profile of 5 seconds high pressure and 15 seconds low pressure was selected to assess
the influence of increasing pressure on both –dPO2/dt and the PO2 recovery time course back to
baseline. After a brief baseline measurement using PQM at low pressure (~5 mmHg) the
sequence of high and low pressures was initiated. The first compression was set to 40 mmHg
and each one was subsequently increased by 10 mmHg to a maximum of 180 mmHg. Upon
completion of a single round, another site was selected and the process repeated.

Determination of VO2 Sampling Resolution
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Optimization of the quasi-continuous VO2 sampling technique was necessary to
maximize the number of measurements per unit time, while minimizing method-induced
alterations to the microvasculature.
A 5-second compression at 120-140 mmHg was determined to provide an adequate
rendition of -dPO2/dt upon inspection of the oxygen disappearance curve and measurements at
various stop-flow pressures. At the 10 Hz excitation rate, this meant 50 points could be collected
during the entire time course of compression. The first second of the resulting curve was ignored
during data analysis to reduce any noise arising from a compression artifact. The remaining 4
seconds yielded 40 points and a robust fit of the linear decline in PISFO2.
With the compression duration fixed at 5 s, the next step was to assess the appropriate
recovery time needed to restore PO2 to baseline. The rat spinotrapezius muscle was prepared and
mounted as previously described and allowed to accommodate for 30 minutes prior to
experimentation. The microvasculature was visualized though a transilluminated 10X objective
to locate measurement sites within 200 μm of 70-100 μm arterioles with robust capillary
perfusion. Next, the site was observed through the airbag-mounted 20X objective pressurized at
5 mmHg and the totality of flow-arrest was assessed during a quick compression (<2 s) for
purposes of quality control. After a subsequent 5-minute rest period, quasi-continuous VO2
sampling was conducted over multiple sites with 5-, 10-, 15-, 20- and 30-second recovery
durations. Each measurement lasted 100 s and was preceded by a 10 s baseline recording by
which to compare the PISFO2 during each recovery period. To reduce the influence of any sort of
sequence artifact, multiple recordings at the same site were performed in random order. The data
obtained following high pressure compression were then compared in terms of recovery to
baseline PO2 and any systematic changes in VO2.
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Determination of Stop-Flow Influence for the 1-Minute I/R Protocol
To assess the potential sensitivity of the reperfusion period following various ischemic
durations, 8 animals were exposed to ischemia and reperfusion protocols with and without quasicontinuous VO2 sampling where applicable.
Following site selection, a 20-second baseline at low (~5 mmHg) bag pressure was
obtained and then blood flow was arrested via high (120-140 mmHg) bag pressure for a duration
of one minute. Next, the bag was switched to low pressure and flow was restored. The PISFO2
was measured during this period of reperfusion for 100 seconds with and without the 5 s x 15 s
high/low pressure cycle described above. Measurements were conducted in a random order at
the same site and different sites and compared in terms of the PISFO2 time course.

Determination of PO2-Dependence of VO2
VO2 measurements were made in the spinotrapezius muscle preparation as described
above over the entire physiological range of PISFO2. This was accomplished by selectively
targeting regions proximal to venules for lower PISFO2 and arterioles for higher PISFO2. Poorly
perfused regions also contributed information for the analysis in VO2 for hypoxic regions. The
data were then plotted as VO2 versus PISFO2 to define the point where VO2 became dependent on
PISFO2.

Quasi-Continuous VO2 Sampling to Determine VO2 of Resting Muscle
The spinotrapezius muscle was prepared and mounted as described above. Following a
30 minute stabilization period, sites proximal to arterioles 40-100 μm in diameter that were well-

67

68
perfused were selected and visualized under 20X magnification with air-bag contact at low
pressure. A brief compression (<2 seconds) was observed under transillumination to confirm
that the selected pressure was sufficient to cause immediate and complete flow arrest. Then,
upon determination that the site was acceptable, quasi-continuous VO2 sampling of varying
duration (1-10 minutes) was performed using the 5 s x 15 s high/low pressure cycle with a
preceding 20-second baseline at low pressure. All measurements were made at 10 Hz excitation
frequency.

I/R Protocols
Ischemic durations of 1, 5, and 10 minutes were assessed in terms of PO2 recovery and
changes in VO2 during early reperfusion. To begin, the spinotrapezius muscle preparation was
mounted, as previously described, and allowed to stabilize for 30 minutes. Next, well-perfused
sites within approximately 200 μm of large arterioles (40-100 μm in diameter) were located
using the 10X objective under transillumination. The sites were then assessed at 20X objective
magnification with low pressure contact from the air-bag both in terms of vessel perfusion and
relative PISFO2 via a rapid sequence of 1 Hz PQM pulses. Sites having relatively low PO2 (as
assessed by the phosphorescence decay tracing on the oscilloscope) and/or poor perfusion were
rejected.
The protocols for ischemia/reperfusion (see Figure 13) were separated into 1-, 5- and 10minute durations. The period of ischemia was defined as the moment of high pressure tissue
compression onset until the moment reperfusion began with low pressure in the air-bag. For the
1-minute ischemia protocol, a 20-second baseline measurement of PISFO2 at low air-bag pressure
preceded the high pressure induction of flow arrest. After 1 minute, the air-bag was switched
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back to low pressure to permit reperfusion and the automatic regulation of quasi-continuous VO2
sampling was engaged via the Automatic Dual Pressure Cycler. VO2 measurements were taken
at 5, 25, 45, 65 and 85 seconds after reperfusion onset. The same protocol was observed for the
5- and 10-minute durations of ischemia except a 10-second baseline preceded ischemia and
PISFO2 was only recorded for the first 50 seconds following bag compression and 10 seconds
prior to reperfusion to establish the totality of ischemia and reduce the excessive time that would
have been required to process these redundant low PISFO2 values. Since the 1-minute ischemic
period was relatively short, PQM measurements at 10 Hz were continuously made for the entire
3 minutes.

Drug Intervention in the I/R Protocol
To better understand the mechanisms regulating VO2 over the time course of the abovedescribed I/R protocol, cyanide, nitroglycerin, and L-NAME were used to alter mitochondrial
metabolism. These agents were topically applied prior to measurement in a similar fashion to the
application of the R2 probe. Dose-response pilot experiments derived from concentration values
found in the literature helped establish the most effective concentrations for generating an
appreciable change in VO2.
The pilot dose-response experiments were conducted as follows: First, I/R controls of 1,
5, and 10 minutes were recorded prior to chemical intervention as previously described. Then,
using 10X objective magnification, baseline arteriolar diameters were measured. Next, the
Krehalon layer covering the spinotrapezius muscle preparation was removed and 100 μl of the
lowest dose of an agent was applied to the tissue. Two minutes later a second application of 100
μl of the lowest dose was made. The Krehalon coversheet was reapplied, but before being
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pressed against the tissue, arteriolar diameters were measured (except in the case of cyanide) as
an assessment of chemical action. Sites were then selected based on their proximity to arterioles
and observed rate of capillary perfusion. The 20X objective with attached air-bag, making low
pressure contact with the preparation, was then used and measurements of 1-, 5- and 10-minute
I/R were performed in random order as done previously during the control measurements. Next,
the objective was switched back to 10X and follow-up measurements of arteriolar diameter were
made as an indicator of persisting chemical activity over the ~20 minutes needed to perform a
single series of all I/R durations. For agents with short half-lives, I/R durations of 1 and 5
minutes were measured and then an additional application of the same dose was made in the
fashion of one 100 μl topical application followed 2 minutes later with another 100 μl dose as
described above prior to the 10-minute ischemia protocol. This process of agent application,
arteriolar measurements, and I/R PQM measurements was then duplicated for each subsequent
dose. Agent concentration was raised by a factor of 10 in each succeeding step.
Once an appropriate dose was identified, it was used to assess its effect on VO2 during
the conditions of rest and reperfusion following ischemic durations of 1, 5 and 10 minutes. The
spinotrapezius muscle was mounted and allowed to stabilize for 30 minutes before
experimentation as previously described. Sites were selected with 10X transillumination and
PQM was used to measure both PISFO2 and VO2 (as reported by –dPO2ISF/dt) for 1-, 5- and 10minute ischemia/reperfusion time courses. Following 1-3 randomized series of all control (no
chemical intervention) ischemic time courses, baseline diameter measurements were made under
10X objective magnification immediately prior to agent administration. The dose was then
administered in the fashion of the pilot experiments where 100 μl was topically applied with an
additional 100 μl two minutes later. Arteriolar diameters were then measured again to assess the
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effectiveness of the treatment and then measurements using the 1-, 5- and 10-minute I/R
protocols were conducted in random order for 1-3 rounds. Additional treatments were
administered if there was a noticeable attenuation of their effects.

Data Analysis
VO2
The interstitial space of skeletal muscle tissue contains gradients of oxygen from the
vasculature to the respiring myocytes, which are reported as an average over an octagonal area of
74,619 μm2 using PQM. Although the average PO2 over this size region tends to be stable under
resting conditions, alterations in oxygen supply/demand matching are readily reported by
changes in PISFO2. During conditions where the oxygen supply is completely eliminated (e.g.,
flow-arrest), PISFO2 will shift to a new steady-state that is reflective of the sole action of oxygen
efflux from the system through various activities of consumption. When the oxygen supply is
halted abruptly and totally, the rate of change of PISFO2 can be described by Equation 5:

dPn/dn= -Vn – KPn + Z(pn – Pn)

Equation 5

where dPn/dn is the initial slope of the oxygen disappearance curve, Pn is the average PISFO2
within the 300 μm diameter measurement area after flash n, Vn is the amount of oxygen
consumed by respiring tissue per flash, K is the coefficient of oxygen consumption by the PQM
method, and Z (also referred to as R in this text) is the coefficient of oxygen inflow by passive
diffusion at the periphery of the measurement area. The contribution of oxygen inflow decreases
as the illuminated measurement area’s radius increases and, with an excitation area of 74,619
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μm2, the coefficient of refill was determined to be 2.08x10-4±1.4x10-4 per flash. The driving
force behind Z is the difference in PISFO2 that is generated within the area of PQM illumination
over n flashes. Thus, over time, a high consumption by the method (KPn) might generate a
sufficient driving force for oxygen to make Z(pn – Pn)significant. But as K was found to be
7.16x10-4±1.9x10-4 per flash, and the measurement of dPn/dn did not exceed n=50, then with Z
being small and the PISFO2 difference between outside and inside the excitation area also being
small (see Figure 15), then refill can be practically ignored for the early part of the oxygen
disappearance curve and Equation 5 can be simplified as follows:

dPn/dn = -V0 – KP0

Equation 6

The rate of oxygen disappearance now consists of consumption by the tissue and the
method. After subtracting the consumption by PQM, V0 can be converted to VO2 by accounting
for both flash rate (F) and the solubility of oxygen in skeletal muscle tissue (α):

VO2 = V0Fα

Equation 7

Thus the complete formula for the transformation of dPn/dn into a measurement of tissue oxygen
consumption is as follows:

VO2 = (-dPn/dn – KP0)Fα

PO2

72

Equation 8
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Figure 12: Representative plot of the 5 s x 15 s VO2 sampling profile. A 20-second baseline
measurement at 10 Hz was taken at low pressure to observe PISFO2 as an assessment of the
integrity of the preparation and to create a baseline measurement against which to compare the
PISFO2 following compression recovery. Baseline and recovery PISFO2’s were recorded as the 5second averages prior to each compression as indicated by the blue lines above. The linear fall
in PISFO2 was measured, as shown by the red lines, during compression, and was then related to
VO2 (see Equation 8). Blue and red coloring indicates measurements during low and high
pressure, respectively.
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Figure 13: Representative plot of a 1-minute ischemia/reperfusion protocol with VO2 sampling.
Baseline and recovery PISFO2’s were measured as the 5-second average prior to the induction of
high pressure with the exception of the R5 measurement being the 2-second average prior to
compression due to the limited amount of reperfusion time. The initial induction of ischemia (I)
was considered the baseline VO2 against which reperfusion VO2 measurements could be
assessed. Due to a dependence of VO2 on tissue oxygenation at low PISFO2’s, the data for
measurements of –dPO2/dt where the pre-compression PISFO2 (P0) was <40 mmHg were grouped
into P0 ranges of Hypoxic (P0 < 22 mmHg), Intermediate (22 < P0 < 40 mmHg), and Normoxic
(P0 > 40 mmHg).
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PISFO2 values were calculated as a 5-second average (50 measurements) immediately prior to the
time point of interest. For assessment of the PO2 recovery during the 5 s x 15 s VO2 sampling
profile, this meant that following 10 seconds of low-pressure reperfusion, the final 5 seconds
before compression were averaged to obtain PISFO2 for the VO2 (P0) measurement immediately
following (see Figure 12).

PISFO2-Dependence and Independence of VO2
Values for dPO2/dt were calculated as shown in Figure 12. The linear portion of the fall
in PO2 during compression was selected and fit to a linear function and then converted to VO2
using Equation 8. Only values with a P0 greater than 40 mmHg were found to be reliably
independent of PISFO2 and grouped together for comparison in the category of Normoxia. P0
values less than 40 but greater than 22 mmHg appeared to have both PO2-dependent and
independent components and were thus grouped into the Intermediate category. P0 values lower
than 22 mmHg were considered Hypoxic.

Interpretation of I/R Plots
The ischemia/reperfusion protocol consisted of a low-pressure measurement of baseline
PISFO2 that preceded an ischemic duration of 1, 5 or 10 minutes, followed by a period of
reperfusion that was assessed by quasi-continuous VO2 sampling. The initial baseline PO2 was
compared to subsequent measurements (5-second average immediately prior to each
compression) as an indicator of recovery. The initial drop in PISFO2 at the onset of ischemia
(referred to as “I” or “BL”) was used as a baseline VO2 to which the reperfusion VO2
measurements R5, R25, R45, R65 and R85 could be compared. “R” stands for reperfusion and
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the numerical value indicates the seconds after the start of reperfusion that the measurement was
taken as shown in Figure 13. As it was determined that the oxygen consumption of the tissue
becomes oxygen-dependent at low PISFO2’s, VO2 measurements where the pre-compression PO2
was less than 40 mmHg were found not to be directly comparable with compression
measurements where the PO2 was higher than 40 mmHg and thus the data were grouped into the
P0 ranges of Hypoxic (P0 < 22 mmHg), Intermediate (22 mmHg <P0 < 40 mmHg), and Normoxic
(P0 > 40 mmHg).

Measurements of Oxygen Consumption by the Method
The data derived from the microcapillary and gel measurements were analyzed in terms
of how PISFO2 in the excitation cylinder was altered by the PQM method in the absence of tissue
perfusion and oxygen consumption. The oxygen disappearance curve was fit (see Figure 14)
using Origin 6.1 (OriginLab, Northampton, MA) to the following equation:

P = P0*R*(1+(K/R)*exp(-K+R)*x))/(K+R)

Equation 9

where P0 is the initial PISFO2, K is the coefficient of consumption by the method, and R is the
component of oxygen refill from outside of the excitation area. The PQM setup was optimized
for phosphorescence lifetimes in situations where the PO2 was in the physiological range of 100
to ~0 mmHg and, as such, these consumption data were truncated to begin at 100 mmHg. K was
determined by the rate of decline in PO2 per flash in the absence of other oxygen consumers.
The refill component was determined by the asymptotic approach of –dPO2/dt to a low PO2. As
discussed above and shown in Figure 15, the coefficient of refill and the difference in PISFO2
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Figure 14: Example of Consumption by PQM Analysis. The excitation region was flashed at
100 Hz and fitted with the CONSREFILL function to show the rates of oxygen consumption by
PQM with the R2 probe and refill.
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Figure 15: Simulation of the development of oxygen gradient at measurement periphery in
respiring muscle. The refill coefficient (R) is multiplied against the PISFO2 gradient at the
periphery of the measurement area to determine the influence of refill. As that difference is only
~1.5 mmHg following 50 flashes with an average resting –dPO2/dt of 0.8 mmHg/flash and the
reported K value of 7.16x10-4 per flash, refill’s ability to confound the measurement of –dPO2/dt
is well below 0.01% per flash at the maximum difference between outside and inside, which is
negligible for the early part of the ODC.
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between inside and outside the excitation area were both sufficiently small to be ignored when
fitting the early part of the ODC for VO2 measurements.

Statistical Methods
Data within these experiments are shown as mean ± standard error (SE) unless otherwise noted
in figures and tables. ANOVA was conducted using JMP software version 8.0 (SAS Institute
Inc., Cary NC) to assess statistical significance for the means of each experimental condition.
Tukey’s multiple comparison test used to identify significant differences between groups for I/R
protocols and measurements of arteriolar diameter. Dunnet’s test was used to delineate
differences between control (or baseline) measurements and various time points during
reperfusion. Statistical significance was taken to be p < 0.05.
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RESULTS

VO2 Sampling Technique

Determination of Compression Duration:
Early observations of air-bag compression on the spinotrapezius muscle preparation
indicated that a 5-second duration would be sufficient to obtain a reliable assessment of the
linear decline in oxygen tension of the interstitial fluid (PISFO2). This rate of decrease could then
be related to tissue oxygen consumption (VO2) as described on page 76 of the Methods section
and elsewhere (Golub et al, in revision). The rapid pressurization of the air-bag was revealed
through both direct visualization of the microvasculature under transillumination and
phosphorescence quenching microscopy (PQM) to result in a timecourse of flow-arrest to be <1
second as shown in Figure 16. At each compression onset, there was a sudden and sharp drop in
PISFO2 that followed a linear decline before deviating from linearity and presumably indicating
onset of cellular hypoxia. Given a 10 Hz excitation rate, it was then determined that 5 seconds
would provide an adequate representation of the linear decline in PISFO2 with 50 data points.
This large number of points in the linear region would also allow for some dropping of any data
points that might skew the linear trend, which might occasionally occur due to the intrinsic
variability of the measurement the measurement process.

Determination of Compression Interval for Intermittent VO2 Sampling
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Measurement, by its very nature, disrupts the environment of study. Whether the
magnitude of this disruption is significant enough to generate a false image of reality is
important to understand. As the VO2 sampling technique necessitates a temporary reduction in
PISFO2, it is possible that any mild alterations in the microvasculature could be cumulative.
Thus, several different values of recovery time interval between the 5-second compressions were
assessed for changes in both the return of PISFO2 and VO2 toward baseline.
Figure 16 shows the averaged, raw PISFO2 curves from 5-, 10-, 15- and 20-second
recovery durations following 5 seconds of compression of the spinotrapezius muscle. Some sites
were excluded from this analysis because the baseline PISFO2 values were below 40 mmHg and
therefore would result in skewed VO2 data. It is clear from these measurements that 5 seconds of
recovery was insufficient, since over time there was a cumulative reduction of PISFO2. As shown
in Figure 17, there is a statistically significant drop of 23.2 (SE of Difference 6.7; p<0.05) mmHg
between baseline and the first measurement of recovery that shows a negative trend in
subsequent measurements. For intermittent VO2 sampling profiles using 10 seconds of recovery,
Figure 16 shows an overall return of PISFO2 to baseline following each 5 second compression.
Neither measurements of PISFO2 nor VO2 following compression and 10 seconds of recovery
showed a statistically significant difference from baseline. However, there appeared to be a
slightly negative trend for the return of PISFO2 (see Figure 18). The 15- and 20-second profiles
of recovery showed no significant differences between baseline and VO2 sampling
measurements in terms of PISFO2 and VO2 (see Figures 19 and 20, respectively).
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Figure 16: PISFO2 tracings for 5, 10, 15, and 20 seconds of recovery between 5-second
compressions. Each plot represents the combined average of multiple tracings (5x5, n=9; 5x10,
n=8; 5x15, n=8; 5x20, n=9). Following a baseline assessment, the air-bag was pressurized to
arrest blood flow for 5 seconds and then depressurized to allow reperfusion for varying
durations. 15 seconds of recovery was chosen to accommodate the 5 seconds of compression
and thus a sampling rate of 3 per minute. These data were collected using a low air-bag pressure
of 5 mmHg to squeeze out any interfering fluid accumulation and a high pressure of 140 mmHg
to ensure flow-arrest.

82

83

70

Recovery of PISFO2 after 5 seconds

5x5

60

PISFO2 (mmHg)

50

40

*

*

30

*

*

PO2_3

PO2_4

20

10

0
BL_PO2

PO2_1

PO2_2

Measurement Time Course

3.0

Change in VO 2 during 5x5 Sampling
5x5

2.0

3

VO2 (mlO2/100cm min)

2.5

1.5

1.0

0.5

0.0
BL_VO2

VO2_1

VO2_2

VO2_3

VO2_4

Measurement Time Course

Figure 17: Changes in PISFO2 and VO2 for 5 seconds of recovery following 5 seconds of
compression. Top: Recovery PISFO2 values for 5 seconds of flow restoration after each 5
second compression. The first measurement, BL_PO2, is the baseline PISFO2 prior to initiation
of the compression/recovery cycle. Values for PO2_1, 2, 3, and 4 were found to be significantly
different from baseline, but not each other, with p values of 0.012, 0.005, 0.003, and 0.002,
respectively. Bottom: Measurements of VO2 taken during each compression for the 5x5
sampling profile. BL_VO2 corresponds to the initial compression, or baseline. There are no
statistical differences between baseline and subsequent measurements.
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Figure 18: Changes in PISFO2 and VO2 for 10 seconds of recovery following 5 seconds of
compression. Top: Influence of 10 seconds recovery on return to baseline PISFO2. There are no
statistical differences between baseline (BL_PO2) and measurements following compression
(PO2_n). Bottom: Influence of the 5x10 compression/recovery cycle on VO2. There are no
statistical differences between baseline (BL_VO2) and subsequent measurements (VO2_n).
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Figure 19: Changes in PISFO2 and VO2 for 15 seconds of recovery following 5 seconds of
compression. Top: Influence of 15 seconds of recovery on return to baseline PISFO2. There are
no statistical differences between baseline (BL_PO2) and measurements following compression
(PO2_n). Bottom: Influence of the 5x15 compression/recovery cycle on VO2. There are no
statistical differences between baseline (BL_VO2) and subsequent measurements (VO2_n).
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Figure 20: Changes in PISFO2 and VO2 for 20 seconds of recovery following 5 seconds of
compression. Top: Influence of 20 seconds of recovery on return to baseline PISFO2. There are
no statistical differences between baseline (BL_PO2) and measurements following compression
(PO2_n). Bottom: Influence of the 5x20 compression/recovery cycle on VO2. There are no
statistical differences between baseline (BL_VO2) and subsequent measurements (VO2_n).
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Influence of 5x15 VO2 Sampling on Reperfusion
Although 5-second compressions spaced 15 seconds apart did not appear to negatively
impact tissue oxygenation, this profile of VO2 sampling required testing in the more demanding
situation of reperfusion where both PISFO2 and VO2 had been significantly affected by an
ischemic event. VO2 could not be assessed independently of the 5x15 VO2 sampling technique,
but it was possible to compare the recovery of PISFO2 following a 1-minute arrest of blood flow
with and without the 5x15 compression/recovery cycle (see Figure 21).
Following the establishment of a baseline PISFO2 by which to compare the eventual
recovery during reperfusion, the air-bag was switched to high pressure and blood flow arrested.
After 1 minute of ischemia, the pressure was returned to minimum (i.e., 5 mmHg) and blood
flow was immediately restored. For the control group, the PISFO2 timecourse was observed
without further air-bag compressions (n=17), while the experimental group was subjected to the
5x15 compression/recovery cycle beginning 5 seconds after the onset of reperfusion (n=11).
Both groups showed a rapid rise in PISFO2 during early reperfusion ending in a small increase
over the original baseline. This overshoot was more pronounced in the group exposed to
intermittent compression/recovery cycles, but did not exceed 5% over control at its highest point.
After 100 seconds of reperfusion, both control and 5x15 VO2 sampling groups had similar PISFO2
levels.
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Figure 21: Normalized comparison of a 1-minute ischemia/reperfusion (I/R) tracing of PISFO2
with and without intermittent 5x15 VO2 sampling. These plots represent the combined averages
of their respective groups and have been normalized to their baselines (measurement before
initial induction of flow-arrest). The rise over baseline during reperfusion is consistent with
other data collected from I/R protocols and VO2 sampling appears to slightly enhance this
phenomenon. These data were collected using a low air-bag pressure of 5 mmHg to squeeze out
any interfering fluid accumulation and a high pressure of 140 mmHg for flow-arrest.
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Air Bag Pressure
Early tests of intermittent air bag compression/recovery cycles used a high compression
of 140 mmHg to arrest blood flow for the measurement of the Oxygen Disappearance Curve
(ODC), which provided a sufficient pressure to overcome the rat mean arterial pressure (MAP
recorded for 13 animals was 95.2±2.5 mmHg; Song and Nugent, unpublished results). To
minimize damage done by compression, however, it was deemed necessary to find the minimal
reliable pressure required to arrest blood flow in the microcirculation where arteriolar pressures
are much lower than arterial.
Seven spinotrapezius muscles were subjected to a stepwise increase in air bag
pressurization from 40 to 140 mmHg and assessed for changes in the rate of oxygen
disappearance (-dPO2/dt) (see Figure 23) and the restoration of PISFO2 (see Figure 22) during the
5x15 compression/recovery protocol. A baseline measurement of PISFO2 at the standard low
pressure of 5 mmHg preceded initiation of the 5x15 VO2 sampling protocol. PISFO2 was not
significantly different (p = 0.1) over the range of increasing compression pressures when
compared against each other and baseline. There is a positive trend in recovery PISFO2 beginning
with 50 mmHg compression and leveling off at 80 mmHg, which is consistent with the
previously observed overshoot of baseline when employing the 5x15 compression/recovery
cycle, but it was not statistically different from baseline. The linear drop in PISFO2 (-dPO2/dt)
that occurred with each progressive compression by the air bag was also reported as an absolute
value in terms of mmHg/sec as shown in Figure 23. There was a progressive rise in -dPO2/dt
from 1.6 mmHg/sec at 40 mmHg air bag pressurization to 5.2 mmHg/sec at 80 mmHg, above
which -dPO2/dt leveled off. There was no statistical difference in terms of the rate in PISFO2
decline between groups from 80 mmHg to 140 mmHg. There was a slight, but insignificant,
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elevation in -dPO2/dt for 90 to 100 mmHg which may be indicative of some physiological
interplay between blood extrusion and the tissue respiratory rate. To accommodate the highest
number of tissues and ensure that both blood flow-arrest and red blood cell extrusion took place
rapidly and effectively, 120 mmHg was chosen as the minimum pressure for the 5x15 VO2
sampling protocol.
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Figure 22: PISFO2 restoration during 5x15 compression/recovery cycle vs air bag pressure in the
spinotrapezius muscle. Measurements were made using the 5x15 VO2 sampling profile with
each compression receiving a 10 mmHg increment above the previous one from 40 to 140
mmHg. After an initial baseline reading at 5 mmHg (minimum pressure), each PISFO2 was
related to the recovery following the compression pressure for which it was listed. Thus, a PO2
reading at 40 indicates that the PO2 returned to that level following the 5 second compression of
40 mmHg. The *** indicates that no significant difference was found between the
measurements it covers (n=26 for measurements at 5, and 80-130 mmHg; n=23 for
measurements at 40-70 mmHg; n=24 for measurement at 140 mmHg.) These data represent
measurements from 26 sites over 7 animals.
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Figure 23: O2 disappearance rate vs. air bag pressurization during the 5x15 VO2 sampling
profile in the spinotrapezius muscle. Each measurement represents the linear portion of O2
disappearance time course observed during a 5-s compression at the pressure indicated. Data
were not converted to VO2 because in the cases of lower pressure, flow did not appear to be fully
arrested and therefore no valid comparison of VO2 could be made. The *** indicates that there
are no statistical differences between the measurements beneath it (n=23 for measurements at 4080 mmHg; n=26 for measurements at 90-140 mmHg.) These data represent measurements from
26 sites over 7 animals.
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Oxygen Consumption by PQM
Development of a correction for the observed O2 consumption caused by the conversion
of O2 to singlet oxygen during interaction with the R2 probe in its triplet state required a system
that offered an exclusive observation of the probe-dependent depletion of oxygen during
excitation. Initially, the idea of performing measurements on dead tissue harvested after
experimentation was pursued, since these tissues had already been loaded with the probe and
retained a similar matrix to the original living tissue. However, complications related to necrotic
tissue pH and lingering sources of oxygen utilization would have confounded measurements of
PQM oxygen consumption. Instead, the in vitro microslide and gel models were considered
superior for their lack of endogenous oxygen consumers and their ability to closely mimic the
concentration of the R2 probe as it is averaged in tissue for direct measurement of PQM’s
oxygen consumption.
The microslide model, loaded with 20 μg/ml of R2 probe bound to 5% human serum
albumin (HSA), was exposed to full intensity 10 Hz excitation for 3000 flashes and the
coefficient of PQM oxygen consumption (K) was found to have a mean value of 8.08 ± 2.98
(SE) x 10-4 mmHg/flash (n=9). The 2% alginate gel experiments, which matched tissue
thickness and were also loaded with the measured R2 concentration in tissue of 20 μg/ml bound
to 5% human serum albumin, produced a mean K value of 7.16 ± 1.87 (SE) x 10-4 mmHg/flash
(n=10) for 3000 flashes at 10 Hz (see Table 1). These two PQM coefficients were not found to
be statistically different (P = 0.05), thus lending utility to both approaches. For the purpose of
correcting VO2 sampling technique measurements, the coefficients from gel were used due to the
similarity in molecular distribution of the phosphor to that of the tissue. Using the gel’s K
coefficient and an initial PO2 of 60 mmHg in a solution loaded with the R2 probe at 20 μg/ml
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bound to a physiological concentration of albumin, PQM's share of oxygen consumption is 0.1
mlO2/cm3min or 5.1% of resting skeletal muscle oxygen consumption (as measured to be 1.97 ±
0.11 mlO2/cm3min by the VO2 sampling technique). This allowed for a relatively simple
correction to be applied to measurements of the rate of oxygen disappearance in the
spinotrapezius muscle during flow arrest.
The component of oxygen refill (R) into the 300 μm diameter excitation area was
determined from the ODC of both microslide and gel measurements as the approach of the
measured PO2 to the asymptotic equilibrium between PQM depletion within the excitation region
and oxygen diffusion from outside it (see Eq. 9). Both the gel and microslide models produced
similar mean values for R of 2.08 ± 1.39 (SE) x 10-4 mmHg/flash (n=10) and 2.80 ± 0.56 (SE) x
10-4 mmHg/flash (n=9), which showed no significant difference (P=0.05). This factor R, which
is the coefficient by which the PO2 difference between inside and outside of the measurement
area is multiplied to determine the rate of refill, is of greater importance to measurements of
consumption by PQM with R2 in the absence of other oxygen consumers so that the only decline
in PO2 occurs within the excitation area—leading to a larger gradient between inside and outside
over time. In tissue, however, the consumption of oxygen is large and the region of blood flow
arrest is several times larger than that of the excitation area. This means that there is a
concomitant decrease in PO2 both inside and outside the excitation area, which results in a
smaller driving force—basically the cumulative consumption per flash by the PQM method—for
oxygen refill into the measurement window. This indicates that refill is unlikely to skew
measurements taken at the early part of the ODC, which are the ones used to calculate VO2.
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Medium

P0± SE (mmHg)

Microslide
Gel

78.3±9.7
84.7±5.4

R± SE
mmHg/flash
2.80±0.56x10-4
2.08±1.39x10-4

K± SE
mmHg/flash
8.08±2.98x10-4
7.16±1.87x10-4

N
9
10

Table 1: In vitro measurement of O2 consumption by PQM and refill. The coefficient of the
PQM consumption rate (K) of 20 μg/ml R2 bound to 5% human serum albumin was determined
in both microslide and 2% alginate gel vehicles at 10 Hz excitation frequency. From the PO2
ODC, the component of oxygen refill (R) into the 300 μm in diameter excitation area was also
calculated. P0 was the initial PISFO2. Measurements in both media were calculated per flash and
were not significantly different from each other for all variables.
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In Vivo Resting VO2 of the Rat Spinotrapezius Muscle
Once the parameters of the VO2 Sampling Technique had been optimized, its utility was
tested in the exteriorized rat spinotrapezius muscle preparation for the measurement of VO2
during resting conditions. Early data analysis of randomized sites indicated that for various
levels of perfusion, as indicated by the PISFO2 prior to the rapid onset of compression (P0), there
existed a range of PISFO2-dependence for VO2. Further study (see Figure 24) showed a negative
trend in VO2 as P0 fell below 40 mmHg, whereas VO2 remained steady for values of P0 above 40
mmHg—even into what might be considered the range of hyperoxia (>75 mmHg data not
shown) for some measurements of PO2 that had clearly received some degree of atmospheric
contamination. Given the detection of PO2 gradients both longitudinally along the
microvasculature and in the interstitial fluid of skeletal muscle tissue (Tsai AG, et al. 2003), the
hypoxic situation is likely a variable physiological occurrence at rest. But, in order to determine
the resting VO2 for the well-perfused state where it is not limited by the activity of cytochrome c
oxidase, the data were divided into three different ranges for analysis: hypoxic (P0 < 22 mmHg);
intermediate (22 mmHg < P0 < 40 mmHg); and normoxic (P0 > 40 mmHg and therefore PO2
insensitive).
The assessment of VO2 in the range of hypoxia revealed a mean value of 0.59 ± 0.10
(SE) x 10-2 mlO2/cm3min (n= 33) for an average PISFO2 of 13.5 ± 0.4 (SE) mmHg (n= 33). Due
to practical limitations of the VO2 Sampling Technique when employed with the R2 probe,
assessment of the linear fall in PISFO2 was restricted to P0 values above 9 mmHg. A further
reduction in the oxygen tension could be and was achieved, but those measurements were
associated with a reduction in the signal-to-noise ratio. The mean value of P0 in the intermediate
range, where some normoxic data likely mixed with the hypoxic situation, was 30.3 ± 0.9 (SE)
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mmHg (n= 50) and produced a VO2 of 1.71 ± 0.10 (SE) x 10-2 mlO2/cm3min (n= 50). For the
range of P0 values above 40 mmHg (mean P0= 59.6 ± 1.2 (SE) mmHg, n= 74) where the VO2
Sampling Technique data could be reliably considered insensitive to PISFO2, the mean VO2 was
measured to be 1.97 ± 0.08 (SE) x 10-2 mlO2/cm3min (n= 74). As indicated in Figure 24, the
VO2 values for the PISFO2-insensitive and intermediate ranges were not significantly different (p
= 0.11). However, the VO2 values in the hypoxic range were significantly different from both
the intermediate and the PISFO2-insensitive groups (p<0.0001 for both groups).
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Figure 24: PISFO2 vs resting VO2 in the rat spinotrapezius muscle. Measurements were divided
by initial PISFO2 values immediately prior to compression (P0) into hypoxic (P0= 13.5 ± 0.4;
VO2= 0.59 ± 0.10, n=33), intermediate (P0= 30.3±0.9; VO2= 1.71±0.10; n= 50), and PISFO2insensitive ranges (P0= 59.6±1.2; VO2= 1.97±0.08; n= 74). The * indicates a lack of significant
difference between groups at p=0.05. The hypoxic measurement of VO2 is significantly different
from both the intermediate and PISFO2-insensitive ranges (p < 0.0001 in both cases).
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Ischemia/Reperfusion
VO2 was assessed prior to and after longer durations of blood flow arrest to develop an
understanding of the metabolic changes that can occur during ischemia. Following a baseline
assessment of PISFO2, blood flow to the measurement area was arrested and red blood cells
extruded by a rapid and continued pressurization of the air-bag at 140 mmHg. PISFO2 declined to
the point of hypoxia within ~20 seconds and the early part of this initial oxygen disappearance
curve (ODC) was used as a baseline VO2 for comparison with post-ischemic VO2 values. After
1, 5 and 10 minutes of ischemia—depending on the measurement—the air-bag was
depressurized to 5 mmHg and blood flow restored to initiate the reperfusion phase.
Measurements via the VO2 Sampling Technique were taken at 5, 25, 45, 65, and 85 seconds after
the onset of reperfusion as per the 5x15 compression/recovery intermittent sampling cycle. The
VO2 data were divided into groups of hypoxic (<22 mmHg), intermediate (22-40 mmHg), and
high (normoxic: >40 mmHg) PISFO2 values and plotted as shown by plots A, B, and C of Figures
25, 26, and 27.

VO2 During Early Reperfusion Following 1 Minute of Ischemia
Baseline values taken from the initial, linear component of the ODC at the onset of
ischemia were averaged for all ischemia/reperfusion (I/R) experiments regardless of the
subsequent duration since they were reflective of the tissue’s resting state. The mean values for
baseline (BL) VO2 were determined to be 1.97 (SE: 0.10; n=72) for the normoxic range (mean
PISFO2 = 59.7 ± 1.2 mmHg; n=72), 1.49 (SE: 0.20; n=21) for the intermediate range (mean
PISFO2 = 32.2 ± 2.2 mmHg; n=21), and 0.9 (SE: 0.4; n=6) for the hypoxic range (mean PISFO2 =
16.4 ± 4.1 mmHg; n=6). Following 1 minute of ischemia and 5 seconds of reperfusion, VO2 had
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significantly increased to 149% (mean=2.93 ± 0.27 ml O2/100 cm3min; n=11) over baseline
(p=0.046) for normoxic measurements (mean PISFO2 = 54.8 ± 3.0 mmHg; n=11) and 197%
(mean = 2.93 ± 0.2 ml O2/100 cm3min; n=14) over baseline (p=0.0002) for the intermediate
range of tissue oxygenation (mean PISFO2 = 33.2 ± 2.7 mmHg; n=14). By 25 seconds after the
onset of reperfusion, VO2 had been reduced to 116 and 157% over baseline for the normoxic and
intermediate ranges of PISFO2. While this demonstrated a slight trend in continued elevation of
tissue respiration at this time point, the data were not statistically significant over baseline (p=
0.997 for normoxic; p=0.83 for intermediate). By the R45 measurement point, VO2 had
approximately returned to baseline values. As illustrated in Figure 25, plot A, the hypoxic
measurements showed no apparent change in VO2 over the timecourse of reperfusion compared
with baseline.

VO2 During Early Reperfusion Following 5 Minutes of Ischemia
Baseline values, as indicated above, were assessed from all ODCs at the onset of
ischemia regardless of the ischemic duration. Following 5 minutes of complete flow arrest of the
measurement area, reperfusion was initiated and VO2 sampling was begun 5 seconds later. Since
the recovery of PISFO2 is a function of oxygen demand, as well as supply, the R5 measurement
point did not yield values above 40 mmHg due to a high degree of oxygen utilization. The
intermediate PISFO2 range, however, did contain some data for the R5 measurement and revealed
a significant increase in VO2 by 262% of baseline (mean= 3.91 ± 0.45 mlO2/100 cm3min; p<
0.0001; n=4). Twenty-five seconds of reperfusion showed significantly elevated VO2 values for
both normoxic (mean= 4.31 ± 0.36 mlO2/100 cm3min; PISFO2= 62.7± 4.1 mmHg; n=6) and
intermediate (mean= 3.35 ± 0.30 mlO2/100 cm3min; PISFO2=27.5 ± 3.4 mmHg; n=9)
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measurements of 218% and 225% over baseline, respectively (p<0.0001 for both). By a
reperfusion time of 45 seconds, VO2 for the normoxic (mean= 3.23 ± 0.3 mlO2/100 cm3min;
PISFO2 = 66.4± 3.4 mmHg; n=9) and intermediate (mean= 2.92± 0.30 mlO2/100 cm3min; PISFO2
= 30.76 ± 3.4 mmHg; n=9) ranges had fallen slightly, but remained significantly elevated at
163% (p=0.0038) and 196% (p=0.0032) over baseline values, respectively. As illustrated by
Figure 26, plots C and B, there is a continued trend in reduction of the oxygen consumption rates
back to resting values for both the normoxic and intermediate measurements over the subsequent
R65 and R85 time points. VO2 showed no statistical difference from baseline for these last two
measurements. Measurements taken during hypoxic conditions (Figure 26, plot C) show a lack
of change in VO2 over the time course of reperfusion as compared to baseline.

VO2 during Early Reperfusion Following 10 Minutes of Ischemia
Baseline values, as indicated above, were assessed from all ODCs at the onset of
ischemia for each ischemic duration. Following 10 minutes of complete flow arrest of the
measurement area, reperfusion was initiated and VO2 sampling was begun 5 seconds later. Since
the recovery of PISFO2 is a function of oxygen demand, as well as supply, the R5 measurement
point did not yield values above 40 mmHg due to a high degree of oxygen utilization. The
intermediate range, however, did contain data points for the R5 measurement and revealed an
increase in VO2 by 254% of baseline (mean= 3.79±0.80 mlO2/100 cm3min; n=2). Due to the low
sample size, statistical analysis was not performed. Twenty-five seconds of reperfusion showed
significantly elevated VO2 values for both normoxic (mean= 5.75 ± 0.40 mlO2/100 cm3min;
PISFO2 = 56.0 ± 5.1 mmHg; n=4) and intermediate (mean = 3.18 ± 0.30 mlO2/100 cm3min;
PISFO2 = 27.1± 3.8 mmHg; n=7) measurements of 292% and 213% over baseline, respectively (p
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< 0.0001 and p = 0.0009 ). By a reperfusion time of 45 seconds, VO2 for the normoxic (mean=
3.45 ± 0.36 ml O2/100 cm3min; PISFO2 = 64.38 ± 4.1 mmHg; n=6) and intermediate (mean =
2.75± 0.30 mlO2/100 cm3min; PISFO2 = 32.0 ± 3.4 mmHg; n=9) ranges had fallen slightly, but
remained significantly elevated at 175% (p = 0.0057) and 185% (p = 0.02) over baseline values,
respectively. As illustrated by Figure 27, plots C and B, there is a continued trend reduction of
the oxygen consumption rates back to resting values for both the normoxic and intermediate
PISFO2 measurements over the subsequent R65 and R85 time points. The normoxic R65 time
point showed a reduced VO2 (as compared to R45), but still significantly elevated VO2 over
baseline (mean = 3.19± 0.27 mlO2/100 cm3min; PISFO2 = 60.7 ± 3.0 mmHg; p= 0.0014; n=11).
The remaining values showed no statistical difference from baseline for these last two
measurements. Measurements taken during hypoxic conditions (Figure 27 plot C) show a lack
of change in VO2 over the time course of reperfusion as compared to baseline.
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Figure 25: Comparison of VO2 during early reperfusion following 1 minute of total ischemia.
BL indicates the pooled and averaged measurements from the initial ODC at the onset of
ischemia and acts as a control for resting skeletal muscle VO2. R5-R85 indicate the time points
of measurement using the VO2 Sampling Technique during reperfusion. A: Hypoxic
measurements of VO2 during reperfusion showed no change compared with BL. B: The
intermediate range of PISFO2 measurements show an elevated VO2 at R5 with a progressive
decline back to baseline by ~R45. C: Normoxic measurements also show an elevated R5 VO2
with a decline back to baseline by ~R45.
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VO2 Following 5 minutes of Ischemia vs Baseline for Intermediate PISFO2
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Figure 26: Comparison of VO2 during early reperfusion following 5 minutes of total ischemia.
BL indicates the pooled and averaged measurements from the initial ODC at the onset of
ischemia and acts as a control for resting skeletal muscle VO2. R5-85 indicate the time points of
measurement using the VO2 Sampling Technique during reperfusion. A: Hypoxic
measurements of VO2 during reperfusion showed no change compared with BL. B: The
intermediate range of PISFO2 measurements show elevated VO2 readings at R5, R25, and R45
that progressively fall back towards BL with R65 and R85 showing no difference from BL. C:
Normoxic measurements show elevated VO2 readings at R25 and R45 that trend toward a
decline back to baseline with R65 and R85 not significantly different from BL. Normoxic R5
measurements could not be made due to a slow recovery of PISFO2.
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Figure 27: Comparison of VO2 during early reperfusion following 10 minutes of total ischemia.
BL indicates the pooled and averaged measurements from the initial ODC at the onset of
ischemia and acts as a control for resting skeletal muscle VO2. R5-85 indicate the time points of
measurement using the VO2 Sampling Technique during reperfusion. A: Hypoxic
measurements of VO2 during reperfusion showed no change compared with BL. B: The
intermediate range of PISFO2 measurements show elevated VO2 readings at R5 (not significant),
R25, and R45 that progressively fall back towards BL with R65 and R85 showing no difference
from BL. C: Normoxic measurements show elevated VO2 readings at R25, R45, and R65 that
trend towards a decline back to baseline with R85 not significantly different from BL. Normoxic
R5 measurements could not be made due to a slow recovery of PISFO2.
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Results: Influence of Cyanide on I/R
Cyanide Dose-Response
As a confirmation that the changes in VO2 for the I/R protocols were linked to
cytochrome c oxidase oxygen utilization, the mitochondrial respiratory inhibitor cyanide (CN)
was used for comparison against control. Given that systemic administration of CN would be
inappropriate, a topical application to the skeletal muscle was carried out. A range of three doses
from 0.01 mM to 1 mM was chosen for a dose-response assessment (see Figure 28) in one pilot
experiment to determine the minimum effective concentration for comparison against control I/R
measurements.
Control measurements using the I/R protocol preceded the applications of increasing CN
concentrations. Resting VO2 (BL) in the spinotrapezius muscle changed progressively from 1.95
(control) to 1.63 mlO2/100 cm3min (CN 0.01), to 1.65 mlO2/100 cm3min (CN 0.1) to 0.72
mlO2/100 cm3min (CN 1mM). A 1-minute ischemic duration was chosen to precede the
measurements of reperfusion in order to keep measurements in the normoxic range for ease of
comparison. At 5 seconds of reperfusion, the same inverse relationship between CN
concentration and VO2 existed (control: 4.29; CN 0.01mM: 4.04; CN 0.1 mM: 3.08; and CN 1
mM: 1.15 mlO2/100cm3min) with 1 mM having only a slight elevation compared to resting
conditions. Measurements of VO2 beyond the R5 time point steadily declined back to their
baselines for control and CN concentrations of 0.01 and 0.1 mM. CN 1 mM, however, did not
appear to show any trend in VO2 over its entire timecourse, indicating that any elevation or
depression was due to noise. This profile of VO2 for the 1 mM dose of CN was similar to that of
the hypoxic controls for the 1-minute I/R protocol.
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Figure 28: Dose response pilot to 0.01, 0.1, and 1 mM Cyanide (CN) during 1 minute I/R. The
data plotted for control are specific to this study and preceded the application of CN. Following
control measurements, each dose of CN was topically applied to the tissue in the order of
increasing concentration. All plotted measurements satisfied the condition of normoxia. There
is a progressive decline in VO2 with increasing concentrations of CN. The 1 mM concentration
produced an apparent insensitivity to the 1 minute ischemic intervention.
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Influence of 1 mM Cyanide on Resting VO2
The influence of 1 mM Cyanide (CN) on the resting state VO2 of the rat spinotrapezius
muscle was measured and compared to control conditions to assess whether mitochondrial
respiration is responsible for the increased oxygen consumption rates measured during
reperfusion following blood flow arrest. Cyanide was chosen due to its function as a
mitochondrial respiratory chain inhibitor that acts at the level of cytochrome c oxidase. At a
sufficient concentration, it was expected to reduce or eliminate the consumption of oxygen for
the purpose of ATP generation. It was not predicted to quench all sources of VO2, as processes
like ROS generation would still occur at normal or possibly accelerated rates.
Figure 29 shows a comparison of VO2 between control and tissue topically treated with 1
mM cyanide during resting conditions. CN-treated tissue showed a 36% reduction in VO2
(mean= 1.26±0.15 mlO2/100 cm3min; PISFO2= 83.0±2.6 mmHg; n= 30) as compared to control
(mean= 1.97±0.1 mlO2/100 cm3min; PISFO2= 59.8±1.6; n= 72) that was statistically significant (p
= 0.0023). The CN measurements also demonstrated a profound increase in PISFO2 by 139% of
control (p < 0.0001), which was consistent with a widespread reduction in the oxygen demand of
the spinotrapezius muscle.
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Figure 29: Resting VO2 of Control vs 1 mM cyanide (CN)-treated skeletal muscle. The topical
application of 1 mM CN resulted in a reduction of resting state VO2 in skeletal muscle of 36% (p
= 0.0023). These measurements were derived from initial compression of ischemic induction for
the 1-, 5- and 10-minute I/R protocols and used as baselines for comparison against the
reperfusion time course. Due to the PISFO2-enhancing effect of CN, these values are
representative of the normoxic situation only.
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Influence of 1 mM Cyanide during Hypoxia and Intermediate PISFO2
Measurements of resting state VO2 under hypoxic conditions were difficult to obtain
following treatment with 1 mM CN due to the elevated PISFO2 in response to a reduction in
oxygen demand. Thus, the hypoxic comparisons for CN vs control were made following 5 and
10 minute periods of ischemia at the R5 time point. These data were plotted alongside the
intermediate PISFO2 range as a reference of higher oxygen availability.
As shown in Figure 30, the two ischemic durations sufficient to produce hypoxic data
were 5 (top) and 10 (bottom) minutes. First, following 5 minutes of ischemia conducted under
the standard I/R protocol, measurements of the R5 time point during hypoxia revealed a 186%
increase in VO2 for tissue treated with 1 mM CN (mean = 1.45 ± 0.30 mlO2/100 cm3min; PISFO2
= 15.3 ± 5.1 mmHg; n=6) over control (mean = 0.78 ± 0.15 mlO2/100 cm3min; PISFO2 =
10.58±2.42 mmHg; n= 27) that was statistically significant (p= 0.037). The average PISFO2 was
statistically different between CN and Control measurements by about 5 mmHg (p=0.007), but
as all measurements had P0 values below the 22 mmHg threshold for inclusion in the category of
hypoxia, this difference should not have affected VO2. For the hypoxic R5 measurement
following 10 minutes of ischemia, there was a similar increase in VO2 (164%) found in 1 mM
CN-treated muscles (mean: 1.36 ± 0.33 mlO2/100 cm3min; PISFO2 = 16.3 ± 5.1 mmHg; n= 6)
over control (mean: 0.83 ± 0.15 mlO2/100 cm3min; PISFO2 = 10.2±2.3 mmHg; n=30), but there
appeared to be insufficient data to establish significance (p= 0.14). In this case, the PISFO2 values
were also significantly higher for the CN group (p= 0.0001), but all measurements still fell
within the range of hypoxia (<22 mmHg).
For the intermediate range of PISFO2 for the R5 measurement point following 5 minutes
of ischemia, there appeared to be no difference in VO2 between 1 mM CN-treated tissue (mean=

110

111
4.03±0.40 mlO2/100 cm3min; PISFO2 = 29.8±6.3 mmHg; n= 4) and control (mean= 3.91±0.40 ml
O2/100 cm3min; PISFO2 = 28.1 ± 6.3 mmHg; n=4). Following 10 minutes of ischemia, there were
insufficient control data to make a statistical comparison, but 1 mM CN-treated tissue had a VO2
of 2.64 ml O2/100 cm3min (SE: 0.46; PISFO2 = 23.6 ± 7.2 mmHg).
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Figure 30: Influence of 1 mM CN on R5 VO2 for the hypoxic and intermediate PISFO2 range.
The R5 measurement following the 5 and 10 minute durations of ischemia were the only reliable
source of hypoxic VO2 measurements for 1 mM CN-treated tissue. Top: The hypoxic R5 VO2
in the CN group following 5 minutes of ischemia showed a significant elevation over control.
VO2 for the intermediate PISFO2 group was not significantly different from that of the control
situation. Bottom: The hypoxic R5 VO2 in the CN group following 10 minutes of ischemia
trended towards an elevation over control, but the difference was not significant. The
intermediate group lacked sufficient measurements for statistical analysis.
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Influence of Cyanide on VO2 Profile during Reperfusion
Tissues to which 1 mM CN had been topically applied were observed over the
reperfusion timecourse of 1-, 5- and 10-minute durations of ischemia in terms of VO2 and
compared against control. Since CN causes an overall rise in PISFO2 by decreasing the tissue’s
demand for oxygen, there were few measurements made beyond reperfusion time point R5 that
fell within either the intermediate or hypoxic range. Therefore, only measurements made under
normoxic conditions were analyzed for the entire reperfusion timecourse.
The reperfusion profile of 1 mM CN-treated tissue following 1 minute of ischemia
showed an overall reduction in VO2 that was significantly different from control at time point
R25 (1 mM CN, mean = 1.40 ± 0.22 ml O2/100 cm3min; n=11; Control, mean = 2.29 ± 0.21 ml
O2/100 cm3min; n= 24; p= 0.015). All other values, although not statistically different from their
control counterparts, did show a trend towards attenuation of VO2 for tissue treated with 1 mM
CN. Comparison amongst the CN measurement time points during reperfusion with Tukey’s
HSD revealed no significant difference in measured VO2 rates. There was, however, a positive
trend in measurements for the R5 time point compared to baseline.
The time course of VO2 during reperfusion for tissue treated with 1 mM CN following 5
minutes of ischemia showed an overall reduction in VO2 that was significantly different from
control at time points R45 (1 mM CN, mean=2.08 ± 0.21 ml O2/100 cm3min; n= 8; Control,
mean= 3.23 ± 0.3 ml O2/100 cm3min; n=9; p= 0.005) , R65 (1 mM CN, mean= 1.48 ± 0.15 ml
O2/100 cm3min; n= 10; Control, mean= 2.60 ± 0.27 ml O2/100 cm3min; n= 13; p= 0.003) , and
R85 (1 mM CN, mean= 1.35 ± 0.45 ml O2/100 cm3min; n= 10; Control, mean= 2.57 ± 0.32 ml
O2/100 cm3min; n= 7; p= 0.006). Measurements at time points R5 and R25, although not found
to be significantly different between control and CN groups, did show a trend towards the
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attenuation of VO2 in CN treated tissue as compared with control. The reperfusion time course
of the CN groups showed a clear elevation in VO2 at R25, as compared to baseline, which then
returned to baseline by R65.
The reperfusion profile of 1 mM CN-treated tissue following 10 minutes of ischemia
showed an overall reduction in VO2 that was significantly lower than control at time points R65
(1 mM CN, mean= 2.27 ± 0.22 ml O2/100 cm3min; n= 8; Control, mean = 3.19 ± 0.29 ml O2/100
cm3min; n= 11; p= 0.033) , and R85 (1 mM CN, mean= 1.95 ± 0.18 ml O2/100 cm3min; n= 8;
Control, mean= 2.73 ± 0.27 ml O2/100 cm3min; n= 12; p= 0.047). The measurements at time
point R25, although not found to be significantly different between control and CN groups, did
show a trend towards the attenuation of VO2 in CN-treated tissue as compared with control. The
R45 measurement was not different from control. The reperfusion time course of the CN groups
showed a clear elevation in VO2 at R25, as compared to baseline, which then returned towards
baseline (see Figure 31).
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Figure 31: Influence of 1 mM CN on VO2 for 1-, 5- and 10-minute I/R protocols. 1 mM CN
was topically applied to the spinotrapezius muscle and measurements were made with the
standard I/R protocol with varying ischemic durations of 1, 5, and 10 min. A: There was a brief
elevation in VO2 for the CN-treated group at R5 compared to BL, but this was not significant.
The R25 time point was the only measurement to show a significant difference from control. B:
Following 5 minutes of ischemia, the CN group had a VO2 profile similar to that of the control
group, but with reduced magnitude. C: Following 10 minutes of ischemia, the CN group
showed a VO2 time course similar to that of the control group, but with a reduced magnitude.
Incomplete inhibition of VO2 by CN likely explains some of the continued oxygen consumption
by the treated tissue.
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Influence of Nitroglycerin on I/R
The mechanism of preconditioning that confers protection against long term ischemic
durations is activated during brief periods of ischemia with reperfusion similar to those
conducted in this study and has been associated with changes in the tissue distribution of nitric
oxide. Therefore, to better understand the mechanisms responsible for the observed reperfusion
time course of VO2 following ischemia, nitric oxide (NO) levels were pharmacologically
elevated by the topical application of nitroglycerin (NTG) during the I/R protocols. Arteriolar
diameter was measured as an indicator of changing NO concentrations in the tissue.

Time course of NTG Activity on Arteriolar Diameter
The effect of altered nitric oxide (NO) concentration on the responses observed during
the I/R protocol was tested by topically applying the NO donor nitroglycerin (NTG) to the
spinotrapezius muscle. A dose-response curve was generated over the range of 0.01 to 1 mM
NTG. To assess whether NO was being delivered to the tissue in appropriate concentrations,
changes in arteriolar diameter were related to the applied NTG concentration and time of dosing.
In one pilot animal, 5 arterioles of 50-90 μm in diameter were selected and their
diameters were measured to establish a baseline. Next, 100 μl of PBS was dripped onto the
tissue. A 2-minute incubation period was allowed to pass before another 100 μl of PBS was
applied and the tissue was recovered with the Krehalon film. The diameters of the 5 arterioles
were then measured every minute for 15 minutes to establish a baseline to which the diameters
following NTG applications would be compared. This procedure was then repeated for each
dose of NTG starting with 0.01 mM and increasing to 1 mM for the same 5 arterioles. The data
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were assessed semi-quantitatively for the time required to achieve the maximum response and
the duration of the effect, but were not otherwise subjected to statistical analysis.
As plotted in Figure 32, plot A, following the topical application of 0.01 mM NTG, the
arterioles reached a maximum dilation (mean diameter = 93 ± 4 μm) 3 minutes after the
application procedure was completed. This level of dilation lasted another 2 minutes when a
rapid return to baseline occurred (mean diameter at 6 minutes post application = 86 ± 3 μm;
minute 6 control mean diameter = 84 ± 4 μm). Baseline values persisted for both control and
0.01 mM NTG-treated groups beyond this point.
As plotted in Figure 32, plot B, following the topical application of 0.1 mM NTG,
arteriolar dilation reached a maximum (mean diameter = 93 ± 4 μm) by the 3 minute time point.
This level of dilation persisted for another 3 minutes (mean diameter = 92 ± 4 μm) and then
declined back to baseline by minute 11 (mean diameter at 11 minutes post application = 87 ± 5
μm; minute 11 control mean diameter = 86 ± 4 μm). Baseline values persisted for both control
and 0.1 mM NTG-treated groups beyond this point.
As plotted in Figure 32, plot C, the topical application of 1 mM NTG resulted in a
maximum arteriolar dilation (mean diameter = 94 ± 4 μm) by minute 5 of measurement. This
level of dilation persisted for 2 minutes (7-min mean diameter = 90 ± 3 μm) and then declined to
baseline by minute 11 (11-min mean diameter = 85 ± 4 μm; 11-min control mean diameter = 86
± 4 μm). Approximate baseline values persisted beyond this time point, but 1 mM NTG-treated
arterioles appeared to be slightly dilated when compared to the lower doses for the 12- to 15minute measurements.
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Figure 32: Time course of arteriolar diameter response to 0.01-1 mM NTG. In a single pilot
experiment, phosphate buffered saline (control) was topically applied to the spinotrapezius
muscle and arteriolar diameters were measured for 15 minutes. This process was then repeated
with 0.01, 0.1, and 1 mM doses of NTG applied in the same fashion. Each plotted line
represents the mean values of 5 arterioles, which were observed over the different doses. Error
bars were not included in the interest of visual clarity.
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Dose-Response of Arteriolar Diameter to NTG
Each assessment of NTG’s influence on VO2 for both resting and reperfusion conditions
was coupled with observations of arteriolar diameter (see Figure 33). This was done to ensure
that measurements were conducted on tissue where NO levels had observably changed. Baseline
values were measured prior to and following the untreated control VO2 measurements to ensure
that the VO2 Sampling Technique did not appreciably alter the vasculature. With a mean initial
BL value of 73 ± 3 μm and a subsequent mean value of 73 ± 4 μm following measurements of
VO2 over resting and various I/R protocols, there was no significant change in arteriolar
diameter. Application of the 0.01 mM dose of NTG resulted in an average dilation to 106% of
baseline (mean diameter = 77 ± 4 μm), which was not significant. After all VO2 measurements
were completed, arteriolar diameter returned approximately to baseline (mean diameter = 73 ± 3
μm before the next dose. It should be noted that an extra dose of the same concentration was
applied before the 10 minute ischemic duration based on the time course of NTG effectiveness as
determined by results of the pilot experiment presented in Figure 32.
The topical application of 0.1 mM NTG resulted in a 117% arteriolar dilation (mean
diameter = 85 ± 5 μm) from baseline (mean diameter = 73 ± 3 μm), which did not quite achieve
significance (p=0.0525), but showed a strong trend. Following all subsequent VO2
measurements during rest and various I/R protocols and a brief pause, the arteriolar diameters
had returned approximately to baseline (mean diameter = 74 ± 4 μm). As with the previous
concentration, an extra dose of this concentration was applied immediately prior to the 10-minute
ischemic duration. Finally, 1 mM NTG was applied topically to the tissue and elicited a 120%
dilation (mean diameter = 87 ± 6 μm) from the initial average baseline value (mean diameter =
73 ± 3 μm), which was found to be significant (p= 0.034). Arteriolar diameter was not measured
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at the conclusion of this round of resting and I/R VO2 measurements, but an assessment was
made prior to the application of the second 1 mM dose of NTG that preceded the 10-minute
ischemic duration. Average arteriolar diameter (mean diameter = 75 ± 4 μm) had returned close
to the baseline value.
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Figure 33: Arteriolar diameter dose-response to topical application of NTG. These data
represent 16 different arterioles over 4 animals. The same sites for the same 4 arterioles were
measured in each animal over the range of NTG concentrations. Baseline measurements were
made prior to the topical application of NTG and used as a comparison for the magnitude of
dilation. * indicates significance at the p = 0.05 level.
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Dose-Response of Resting VO2 to NTG
Three doses of NTG—0.01, 0.1, and 1 mM—were topically applied to the spinotrapezius
muscle and their influence on VO2 was determined (see Figure 34). The 0.01 mM dose caused a
25% (mean VO2 = 1.48±0.10 ml O2/100 cm3min; PISFO2 = 58 ±3 mmHg; n= 13) reduction in
VO2 compared to control (mean VO2 = 1.97±0.10 ml O2/100 cm3min; PISFO2 = 59.8 ± 1.5
mmHg; n= 72), which showed a strong trend (p= 0.079). The control vs 0.01 NTG PISFO2 values
did not show any statistically significant difference. The next stepwise dose of 0.1 mM NTG
caused a similar reduction in VO2 by ~27% (mean VO2 = 1.43 ± 0.30 ml O2/100 cm3min; PISFO2
= 70.8±3.9 mmHg; n=11) of control (mean VO2 = 1.97 ± 0.10 ml O2/100 cm3min; PISFO2 = 59.8
± 1.5 mmHg; n= 72), which showed a strong trend (p= 0.095). The average PISFO2 for the 0.1
mM dose was significantly elevated to 122% of control (p= 0.013), which was consistent with a
reduced tissue respiration rate. The final dose of 1 mM NTG produced a substantial 43%
reduction in VO2 (mean VO2 = 1.13 ± 0.20 ml O2/100 cm3min; PISFO2 = 64.7±5.1 mmHg; n=9)
from control (mean VO2 = 1.97 ± 0.1 ml O2/100 cm3min; PISFO2 = 59.8±1.5 mmHg; n= 72),
which was significant (p= 0.013). PISFO2 for measurements made during the 1 mM application
of NTG were slightly elevated at 108% of baseline, but this difference was not found to be
significant.
According to the mean arteriolar diameter vs. time data (see Figure 32), the observable
effects of each NTG dose lasted only 6 to 11 minutes before baseline conditions returned.
Therefore, following each series of measurements, the measured reductions in VO2 were unlikely
to be additive when stepping upwards to the next dose.
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Figure 34: VO2 of Control vs NTG-treated skeletal muscle tissue. 4 spinotrapezius muscles
were subjected to increasing doses of 0.01, 0.1 and 1 mM NTG and assessed for their resting
state VO2 rates. Measurements here are representative of normoxic conditions only. * indicates
a significant difference as compared to control at p= 0.05.

123

124
Influence of NTG on I/R
The effect of 0.01, 0.1, and 1 mM doses NTG on VO2 was measured during reperfusion
following 1-, 5- and 10-minute durations of ischemia. These doses were administered topically
to the rat spinotrapezius muscle as 2 rounds of 100 μl applications spaced 2 minutes apart. The
resulting data were then divided into groups of hypoxic, intermediate and normoxic oxygen
tensions by their P0 (PISFO2 immediately prior to air-bag pressurization. NTG resulted in an
across the board reduction in VO2, but, as shown by Figure 35, consistent statistical differences
over the reperfusion time course could only be demonstrated between control VO2 and that for
the 0.1 mM dose in the intermediate range of P0 (22 < P0 <40 mmHg).
Baseline (BL) measurements of VO2 over the intermediate range of P0 for control (1.49 ±
0.23 ml O2/100 cm3min; P0 = 32.2±0.9 mmHg; n= 21) and 0.1 mM NTG-treated muscles (mean
VO2 = 0.39 ± 0.06 ml O2/100 cm3min; P0 = 28.6 ± 6.5 mmHg; n= 2) were not significantly
different from each other (p= 0.16), but did appear to show a trend in the reduction of VO2 by 0.1
mM NTG. Values for P0 were not found to be significantly different between control and NTGtreated tissue. Attainment of a more accurate VO2 for resting skeletal muscle in the intermediate
range of P0 would likely occur with a larger number of observations.
Figure 35, plot A, shows the VO2 time course during reperfusion following 1 minute of
ischemia for control vs 0.1 mM NTG-treated tissue. At 5 seconds after the onset of reperfusion
(R5) the NTG group exhibited a 66% reduction in VO2 (mean VO2 = 0.98 ± 0.29 ml O2/100
cm3min; P0 = 28.6 ± 6.5 mmHg; n= 3) compared to the R5 control measurements (mean VO2 =
2.93 ± 0.33 ml O2/100 cm3min; P0 = 33.2 ± 1.4 mmHg; n= 14), which was found to be significant
(p= 0.019). P0 for the NTG group was also found to be significantly lower than control (p=
0.048), but all measurements remained within the intermediate range of P0. At 25 seconds after
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the onset of reperfusion (R25) the NTG group showed an 82% reduction in VO2 (mean VO2 =
0.38 ± 0.29 ml O2/100 cm3min; P0 = 28.0 ± 2.5 mmHg; n= 3) compared to the R25 control
measurements (mean VO2 = 2.15 ± 0.37 ml O2/100 cm3min; P0 = 31.3 ±2.8 mmHg; n= 5), which
was found to be significant (p= 0.012). There was no statistically significant difference for P0
between control and NTG groups. At 45 seconds after the onset of reperfusion (R45) the NTG
group demonstrated an 87% reduction in VO2 (mean VO2 = 0.14 ± 0.09 ml O2/100 cm3min; P0 =
30.3 ± 5.8 mmHg; n= 3) compared to the R45 control measurements (mean VO2 = 1.07 ± 0.23
ml O2/100 cm3min; P0 = 32.6 ± 3.1 mmHg; n= 4), which was found to be significant (p= 0.008).
There was no statistically significant difference for P0 between control and NTG groups. At 65
seconds after the onset of reperfusion (R65) the NTG group demonstrated an 96% reduction in
VO2 (mean VO2 = 0.06 ± 0.06 ml O2/100 cm3min; P0 = 29.4 ± 4.7 mmHg; n= 2) compared to the
R65 control measurements (mean VO2 = 1.43 ± 0.27 ml O2/100 cm3min; P0 = 32.4 ± 2.3 mmHg;
n= 6), which was found to be significantly different (p= 0.004). There was no statistically
significant difference for P0 between control and NTG groups. At 85 seconds after the onset of
reperfusion (R85) the NTG group showed a 94% reduction in VO2 (mean VO2 = 0.09 ± 0.08 ml
O2/100 cm3min; P0 = 30.2 ± 5.0 mmHg; n= 2) compared to the R85 control measurements (mean
VO2 = 1.56 ± 0.29 ml O2/100 cm3min; P0 = 33.9 ± 2.5 mmHg; n= 6), which was found to be
significantly different (p= 0.033). There was no statistically significant difference for P0
between control and NTG groups.
Figure 35, plot B, shows the VO2 timecourse during reperfusion following 5 minutes of
ischemia for control vs 0.1 mM NTG-treated tissue. There were insufficient NTG measurements
at the R5 time point for a comparison against control due to hypoxic P0’s. At 25 seconds after
the onset of reperfusion (R25) the NTG group showed a 46% reduction in VO2 (mean VO2 =
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1.80 ± 0.32 ml O2/100 cm3min; P0 = 29.3 ± 5.2 mmHg; n= 3) compared to the R25 control
measurements (mean VO2 = 3.35 ± 0.36 ml O2/100 cm3min; P0 = 27.5±1.3 mmHg; n= 9), which
was found to be significant (p= 0.043). There was no statistically significant difference for R25
P0 between control and NTG groups. Measurements of VO2 for NTG-treated tissue at the R45
and R65 time points were lower than control on average, but these differences were not
significant (p= 0.39 and 0.71 respectively). There were also no significant differences in P0
found between NTG and control groups for either R45 or R65 time points. At 85 seconds after
the onset of reperfusion (R85) the NTG group showed a 70% reduction in VO2 (mean VO2 =
0.51 ± 0.09 ml O2/100 cm3min; P0 = 29.6 ± 2.2 mmHg; n= 2) compared to the R85 control
measurements (mean VO2 = 1.68 ± 0.71 ml O2/100 cm3min; P0 = 33.4 ± 2.9 mmHg; n= 5), which
was found to be significant (p= 0.0098). There was no statistically significant difference for P0
at R25 between control and NTG groups.
Figure 35, plot C, shows the VO2 time course during reperfusion following 10 minutes of
ischemia for control vs 0.1 mM NTG-treated tissue. There were insufficient measurements of
the NTG group at both the R5 and R25 time points for a comparison against control due to
hypoxic P0’s. At 45 seconds after the onset of reperfusion (R45) the NTG group showed a 55%
reduction in VO2 (mean VO2 = 1.23 ± 0.22 ml O2/100 cm3min; P0 = 25.6 ± 4.5 mmHg; n= 3)
compared to the R45 control measurements (mean VO2 = 2.75 ± 0.31 ml O2/100 cm3min; P0 =
32.0±1.3 mmHg; n= 9), which was found to be significant (p= 0.022). There was no statistically
significant difference for P0 at R25 between control and NTG groups. Measurements of VO2 for
NTG-treated tissue at R65 and R85 were lower than control on average, but these strong trends
were not significant (p= 0.09 and 0.23, respectively). There were also no significant differences
in P0 found between NTG and control groups for either R65 or R85 time points.
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Figure 35: Control vs 0.1 NTG-treated tissue for 1-, 5- and 10-minute I/R protocols. The
reperfusion time course of VO2 was plotted against control following 1-, 5- and 10-minute
ischemic durations for the intermediate PISFO2 range. BL measurements were derived from the
initial drop in PISFO2 from the ODC at the onset of ischemia. NTG showed a tendency to reduce
VO2 across the board, but the 0.1 mM dose with measurements in the intermediate range of
PISFO2 contained the most complete data for statistical comparisons against control. * indicates a
statistically significant difference between control and experimental measurements for that
measurement time point (p= 0.05).
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Influence of L-NAME on I/R
Following the assessment of VO2 dynamics during rest and various durations of ischemia
with reperfusion with pharmacologically elevated levels of NO from topically applied NTG,
similar measurements were made for the condition of reduced NO concentration. L-NAME, a
non-specific inhibitor of NOS, was topically applied to the exteriorized spinotrapezius muscle
preparation and the changes in arteriolar diameter were observed as an indicator of the effective
action of L-NAME to alter microvascular NO concentration. A pilot study was conducted to
determine the best dosage of L-NAME that clearly influenced arteriolar diameter and VO2, but
did not cause such a degree of vasoconstriction that the reduced oxygen supply would severely
depress PISFO2. Following the selection of the appropriate dosage, L-NAME’s influence on VO2
during conditions of rest and reperfusion following 1-, 5- and 10-minute durations of ischemia
was measured using the VO2 Sampling Technique.

L-NAME Pilot
A single animal was used as a pilot to study the effects of L-NAME on arteriolar
diameter and VO2 over a range of doses. The intact, exteriorized spinotrapezius muscle was
treated with 200 μl over two topically applied doses (PBS or L-NAME) of 100 μl each spaced
two minutes apart. Following observation of selected arterioles for changes in diameter (see
Figure 36), measurements of resting (see Figure 37) and reperfusion VO2 dynamics were made
via the 1-minute I/R protocol (see Figure 38). All measurements falling below the normoxic
range were excluded from comparison for this pilot, since any oxygen-dependence of VO2 would
obscure the effects of L-NAME in this limited study.
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Arterioles with diameters in the range of 40-100 μm showed a baseline average of 94 ± 4
μm (n=2). Following the application of 0.0015 mM L-NAME, the same arteriolar sites showed
an immediate (<1min) reduction in diameter by ~10% (86 ± 4 μm). This level of
vasoconstriction was maintained through the next dose (86 ± 4 μm) as 0.015 mM showed no
further reduction in diameter. Application of 0.15 mM L-NAME further reduced arteriolar
diameters by an additional 11% (76 ± 4 μm; 21% total reduction from BL). The final dose of 1.5
mM L-NAME did not result in a further decrease in vessel diameter at the measured sites.
Additional measurements were made for both larger (>100 μm) and smaller (<40 μm) arterioles
(data not shown) and they demonstrated similar profiles of constriction compared to the 40 to
100 μm range.
Resting skeletal muscle VO2 was assessed over Control and L-NAME treatments for
normoxic conditions. Three measurements were taken per dose as plotted in Figure 37. Control
measurements were specific to this experiment. Application of 0.0015 mM L-NAME resulted in
an elevation of VO2 to 114% of baseline (Control, mean VO2 = 1.91 ± 0.18 ml O2/100 cm3min;
n=3; 0.0015 mM dose, mean VO2 = 2.18 ± 0.16 ml O2/100 cm3min; n=3). The 0.015 mM dose
of L-NAME reduced VO2 by 35% (0.015 mM dose, mean VO2 = 1.24 ± 0.08 ml O2/100 cm3min;
n=3) compared to baseline. The 0.15 mM dose of L-NAME reduced VO2 by 38% (0.15 mM
dose, mean VO2 = 1.17 ± 0.08 ml O2/100 cm3min; n=3) compared to baseline. The final and
most potent dose of 1.5 mM L-NAME reduced VO2 by 42% (mean VO2 = 1.11 ± 0.12 ml O2/100
cm3min; n=3) compared to baseline. No statistical analyses were performed as this dose
response study was not repeated in additional animals.
The VO2 profile during reperfusion following 1 minute of ischemia was assessed for
increasing doses of L-NAME from 0.0015 to 1.5 mM. VO2 values that did not meet the
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requirement of having a corresponding P0 in the normoxic PISFO2 range were excluded from
comparisons (see Figure 38). The lack of control measurements for the reperfusion timecourse
made for a difficult comparison to resting conditions, but over the range of L-NAME doses there
was a trend towards a reduction in VO2 for the various measured time points. The largest
difference appeared to follow the application of the 0.015 mM dose with marginal reductions
following the 0.15 and 1.5 mM concentrations. This trend was consistent and sustained with the
result being a dose-dependent reduction in VO2 by the topical application of L-NAME.
The arteriolar diameter, resting VO2, and I/R response to the range of topically applied
doses of L-NAME were compared in terms of measured effectiveness and a single dose was
selected for more rigorous study with the I/R protocols. Arteriolar diameters appeared to show a
maximum dilation at 0.15 mM L-NAME and, although 1.5 mM showed a slightly higher effect
on VO2, the 0.15 mM dose was deemed most practical in terms of effectiveness at the lowest
concentration.
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L-NAME Pilot Arteriolar Response
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Figure 36: Arteriolar diameter dose-response to topically applied L-NAME. Arteriolar
diameters were measured in response to increasing doses of L-NAME and are plotted here for
the size range of 40-100 μm (n=2). This pilot study was performed in one animal.
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Dose Response of VO2 to L-NAME During Rest under Normoxic Conditions
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Figure 37: Dose-response of resting VO2 to L-NAME. Measurements of resting VO2 are
reported here for control and L-NAME-treated tissue. The symbols each represent a single
measurement in the order they were made with Black being first, Red being second, and Green
being third for each dose of L-NAME. All measurements of resting VO2 had corresponding P0
values in the range of normoxia (>40 mmHg).
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Normoxic VO2 Dose Response to L-NAME Following 1 min Ischemia
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Figure 38: L-NAME pilot study for VO2 dose response following 1 minute of ischemia. For
each measurement, the relevant dose (PBS for Control) was applied and the tissue subjected to
the 1-minute I/R protocol. During reperfusion, the VO2 Sampling Technique was used to assess
changes in tissue respiration. This pilot experiment was conducted in 1 animal and some control
values that fell below the 40 mmHg criteria for inclusion in the normoxic range were excluded.
The R85 value for the highest dose of L-NAME also failed to meet this P0 requirement.
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Nitric Oxide Synthase Inhibition by L-NAME
L-NAME’s Influence on Arteriolar Diameter
L-NAME’s inhibition of NO production by NOS was confirmed by the vascular
consequences of reducing overall [NO]. 11 arterioles with an initial mean diameter of 66 ± 4 μm
were measured over 6 animals for their responsiveness to 0.15 mM L-NAME. Following the
topical application of L-NAME to the spinotrapezius muscle, vessel diameters for the same sites
were measured within 2 minutes of the dosing procedure completion and revealed a 30%
reduction in size (treated mean= 46 ± 7 μm). This vasoconstrictor response was significant from
baseline values (p=0.017) and indicative of a reduction in NO production by NOS (see Figure
39).

L-NAME’s Influence on Resting VO2
Resting VO2 following treatment with 0.15 mM L-NAME was measured and compared
to Control measurements in the range of PISFO2 for which VO2 is PO2-independent. Resting VO2
data were calculated from the initial drop in PISFO2 recorded during the onset of ischemia for the
1-, 5- and 10-minute I/R protocols. A total of 35 normoxic measurements conducted on 6
animals revealed that 0.15 mM L-NAME-treated tissue showed a 14% reduction in resting VO2
(1.69 ± 0.14 ml O2/100 cm3min; P0 = 71.2 ± 2.6 mmHg; n=35) from Control (1.97 ± 0.1 ml
O2/100 cm3min; P0 = 59.8 ± 1.5 mmHg), but this trend was not found to be significant (p= 0.15;
see Figure 40). P0 was significantly higher for L-NAME-treated tissue (p<0.0001) for the
assessment of resting VO2, but all measurements remained within the normoxic range.

L-NAME’s Influence on Hypoxic Reperfusion
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For an assessment of the suppression of NO production during hypoxia, the R5
measurements following 5 and 10 minutes of ischemia were chosen (see Figure 41). These time
points contained a sufficiently large number of values in the hypoxic range, by the nature of the
slow recovery of PISFO2 following 5 and 10 minutes of ischemia, for both Control and L-NAMEtreated tissues for statistical comparison. The R5 measurement of L-NAME-treated tissue for the
5-minute I/R protocol revealed an increase in VO2 to 155% (mean VO2 = 1.13 ± 0.25 ml O2/100
cm3min; P0 = 13.4±1.0 mmHg, n=10) of Control (mean VO2 = 0.73 ± 0.10 ml O2/100 cm3min; P0
= 10.2 ± 0.6 mmHg, n= 26), but this strong trend was not found to be significant (p= 0.11). P0
was slightly, but significantly, higher than the Control value for L-NAME-treated tissue (p=
0.011) and all measurements were confined to the hypoxic range. The R5 measurement of LNAME-treated tissue for the 10-minute I/R protocol demonstrated an increase in VO2 to 182%
(mean VO2 = 1.59 ± 0.30 ml O2/100 cm3min; P0 = 15.5±1.0 mmHg, n=12) of Control (mean VO2
= 0.83 ± 0.10 mlO2/100 cm3min; P0 = 10.2 ± 0.5 mmHg, n= 30), which was significant (p=
0.015). P0 was slightly, but significantly, higher than Control for L-NAME-treated tissue
(p<0.0001) and all measurements were confined to the hypoxic range.

L-NAME’s Influence during Normoxic Reperfusion
The suppression of NO during the reperfusion phases following 1, 5, and 10
minute ischemic durations was evaluated for changes in VO2 from Control for the R5-R85 time
points. Measurements were exclusive for normoxic P0’s.
Following 1 minute of ischemia (see Figure 42, plot A), measurements of 0.15 mM LNAME-treated tissues at R5 showed a strong trend towards a reduction in VO2 (1.93 ± 0.40 ml
O2/100 cm3min; P0 = 49.2 ± 1.9; n= 7) compared to Control R5 (2.93 ± 0.30 ml O2/100 cm3min;
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P0 = 54.8 ± 2.3 mmHg; n= 11), which was not statistically significant (p= 0.07). P0 values did
not show a statistically significant difference either (p= 0.10). Mean VO2 values for
measurements at R25 through R85 continued to appear depressed, but none were found to be
statistically different from their Control counterparts. P0 values were likewise statistically the
same for both Control and L-NAME-treated tissue.
Following 5 minutes of ischemia (see Figure 42, plot B), measurements of 0.15 mM LNAME-treated tissues at R5 were not possible for the normoxic range due to a slower timecourse
of PISFO2 recovery. R25 measurements for Control and L-NAME-treated tissues were not
significantly different from each other in terms of both VO2 and P0. R45 for L-NAME showed a
trend towards a reduction in VO2 (2.39 ± 0.30 ml O2/100 cm3min; P0 = 58.3 ± 4.8 mmHg; n= 13)
compared to Control R45 (3.23 ± 0.30 ml O2/100 cm3min; P0 = 66.4±25.7 mmHg; n= 9), which
was not statistically significant (p= 0.083). P0 values were also statistically the same (p= 0.29).
Mean VO2 values for measurements at R65 and R85 continued to appear depressed, but none
were found to be statistically different from their Control counterparts. P0 values were likewise
statistically the same for both Control and L-NAME-treated tissue.
Following 10 minutes of ischemia (see Figure 42, plot C), measurements of 0.15 mM LNAME-treated tissues at R5 were not possible for the normoxic range due to a slower timecourse
of PISFO2 recovery. Mean VO2 values for measurements at R25 through R85 consistently
appeared depressed, but none were found to be statistically different from their Control
counterparts or to show any strong trends. P0 values were likewise statistically the same for both
Control and L-NAME-treated tissue.
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Figure 39: Influence of L-NAME on arteriolar diameter. 0.15 mM L-NAME was topically
applied to the tissue and the resultant change in arteriolar diameter was measured during
transillumination observation of the microvasculature. The application of L-NAME produced a
significant vasoconstriction that was presumably associated with a decrease in NO production by
NOS.
* indicates a significant difference from baseline (p<0.05).
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Figure 40: L-NAME vs. Control for resting skeletal muscle VO2. Resting VO2 measurements
for L-NAME-treated muscles were taken from the initial fall in PISFO2 during the onset of
ischemia over the three I/R protocols and compared to Control. VO2 showed a slightly negative
trend when exposed to L-NAME, but this difference was not significantly different (p=0.15).
Average P0 was significantly higher for measurements in L-NAME-treated tissue (p<0.0001)
over Control, but measurements from both groups remained confined to the normoxic range
which exhibits a PISFO2-independent VO2.

138

139

3

VO2 (mlO2/100cm min)

Control vs LNAME during Hypoxic R5 Measurement
2.0
1.9
1.8
1.7
1.6
1.5
1.4
1.3
1.2
1.1
1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0

*

Control
0.15 mM LNAME

R5 5 min

R5 10 min

Reperfusion Time Point

Figure 41: VO2 for L-NAME vs Control during hypoxia. The R5 time point following 5-and
10-minute durations of ischemia provided evidence of how L-NAME alters VO2 in comparison
with control. For both L-NAME treated groups, there was an observable rise in VO2 over
control with the 10 minute duration showing significance (p= 0.015). * indicates a significant
difference from the associated control measurement.
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Figure 42: VO2 for Control vs. LNAME during reperfusion. The reperfusion time course of
VO2 was assessed with the VO2 Sampling Technique following 1-, 5- and 10-minute durations of
ischemia in 0.15 mM L-NAME-treated tissue compared to Control. No significant differences
were observed for any of the measured time points among the various reperfusion periods shown
above, however strong trends showing a depression in VO2 for L-NAME-treated tissue vs.
control exist where a clear separation occurs between the means. P0 values were not found to be
significantly different between Control and L-NAME groups at similar time points and were all
within the normoxic range.
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DISCUSSION
Summary of Study
A novel technique for multiple and quasi-continuous measurements of VO2 dynamics in
thin tissues was developed and employed in the rat spinotrapezius muscle under various
metabolic conditions. The VO2 measurement technique was adapted from a previously
described method that utilized externally transduced pressure to rapidly arrest blood flow while
concurrently observing the resultant drop in interstitial fluid oxygen tension (PISFO2) with
Phosphorescence Quenching Microscopy (PQM) (Golub et al, in revision). Originally designed
to measure the entire oxygen disappearance curve (ODC) during flow-arrest produced by rapid
compression of a transparent, pressurized air-bag, this system was upgraded by the addition of an
Automatic Dual Pressure System providing it with the capabilities necessary for the continuous
VO2 Sampling Technique. This control circuit rapidly (<1 s) and repeatedly toggled the airbag’s pressurization between high and low pressures, enabling brief periods of compression to
assess VO2, followed by a recovery period to restore PISFO2 to near its baseline value. In its
current configuration, the cycling profile for the VO2 Sampling Technique was determined to be
ideal at 5 seconds of high pressure followed by 15 seconds of recovery in terms of a sufficient
recovery of PISFO2 to baseline, no cumulative effect on serial VO2 measurements, and a maximal
number of VO2 measurements per minute (3/min). This technique was further assessed
following 1 minute durations of complete flow arrest (ischemia)—produced by a sustained airbag pressurization—for its influence on the recovery of PISFO2 during reperfusion. There was a
slight indication of hyperemia for recovery profiles exposed to the VO2 Sampling Technique, but
this was neither significant nor should have altered VO2. The upper compression pressure was

141

142
also found to be optimal from 120-140 mmHg, with minimal perturbation of the tissue for the 5 s
x 15 s compression/recovery cycle.
Assessment of the linear fall in PISFO2 was found to have 3 components: tissue VO2,
consumption by PQM (characterized by the constant K; see Eq. 9), and refill by passive O2
diffusion into the excitation region (characterized by the constant R; see Eq. 9). Using an in
vitro analysis, both K and R values were determined and a correction factor was developed to
directly relate the initial part of the ODC to VO2 with minimal noise. This correction was
universally applicable to PQM measurements made with the R2 probe under the conditions of
topical application described in the Materials and Methods section of this dissertation.
Resting skeletal muscle VO2 was assessed and plotted against PISFO2 to determine over
what range cytochrome c oxidase became a limiting factor for respiration as measured through
PQM’s assessment of PISFO2. VO2 data were then separated into three categories: Hypoxic,
Intermediate, and Normoxic, according to the PISFO2 immediately prior to bag compression and
flow arrest (P0). This allowed data within those groups to be compared on equal terms. The
resting state VO2 of the rat spinotrapezius muscle was then pharmacologically altered with
cyanide, nitroglycerin, and L-NAME and compared to baseline values in the same preparations.
The VO2 time course for 5 through 85 seconds of reperfusion following ischemic
durations of 1, 5 and 10 minutes was assessed with the VO2 Sampling Technique and
measurements were similarly compared within the categories of Hypoxia, Intermediate, and
Normoxia. Ischemia clearly produced a rise in VO2 over baseline during early reperfusion that
was related to the duration of the ischemic period. This effect was attenuated, but not abolished,
with the treatment of cyanide, which helped attribute at least some of the ischemia-induced
elevation to cytochrome c oxidase activity. Treatment with the nitric oxide donor nitroglycerin
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produced a similar reduction in VO2 and a corresponding enhancement in PISFO2. L-NAME, an
inhibitor of nitric oxide synthase (NOS), functioned to slightly reduce tissue PO2 through a
reduction in vascular oxygen delivery by vasoconstriction of arterioles, but lower [NO] did not
appear to stimulate tissue respiration in the normoxic PISFO2 range as might be expected. It did,
however, produce a significant rise in VO2 during hypoxia, which may indicate that NO has a
greater influence on respiration during hypoxia.

Determination of Compression Duration
The development of rapid blood flow arrest, along with the extrusion of red blood cells
(RBCs), to minimize the confounding influence of the oxygen carrier hemoglobin on the ODC,
required an externally applied force to be directed onto the measurement area. A transparent
Krehalon bag was designed and fitted to the 20X microscope objective of the PQM setup (see
Figure 10) and regulated by an Automatic Dual Pressure System for rapid switching between
high and low pressures (see Figure 11). The necessary pressure was initially set by the need to
overcome the rat systemic pressure pressure (based on existing measurements of MAP, which
indicated that the air-bag’s upper pressure setting should be 140 mmHg. Once applied to the
tissue, the immediate effects of compression (i.e., rapid flow-arrest in <1 s and RBC extrusion)
were evidenced by direct observation of the microcirculation through transillumination and by
use of PQM (see Figure 16 for development of ODC upon compression). The result of flowarrest and RBC extrusion on interstitial fluid PO2 was recorded with PQM as a linear fall in
PISFO2 until reaching the level of hypoxia, where the ODC began to curve towards the “zero”
PISFO2 asymptote. At a 10 Hz excitation frequency, 5 seconds of compression covered most of
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the linear range of the ODC (P0= ~60 mmHg) and provided 50 data points, which were more
than sufficient to produce an accurate linear fit of –dPO2/dt for eventual conversion to VO2.
The 5-second duration of compression for this new technique was a conservative choice
to allow for an adequate amount of time to obtain an accurate estimate of VO2 from the initial
decline in PO2. Shorter durations of compression down to ~2 seconds are likely possible in
future studies as 20 points would be sufficient to obtain an accurate estimate of the linear trend
of the early ODC with good signal-to-noise ratio.

Determination of Compression Interval for the Rate of VO2 Sampling
Any measurement by its very nature is invasive and, as such, one measurement can often
influence the results of a subsequent one. As the VO2 Sampling Technique requires repeated
measurements that necessitate brief reductions in tissue oxygenation at the same site, an
assessment of the amount of time between each compression needed for the recovery of PISFO2
back to baseline was needed to determine the optimal sampling rate that did not bring about
appreciable and cumulative changes in both PISFO2 and VO2.
The compression/recovery cycle of 5 seconds high pressure (120-140 mmHg) and 15
seconds of low pressure (5 mmHg) was determined for the resting state of the exteriorized
spinotrapezius muscle to allow for the complete recovery of PISFO2 back to baseline. No
cumulative impact on VO2 over repeated measurements with an excellent sampling rate of 3 per
minute (see Figure 16) was also demonstrated. A reduction of this time course, in future studies,
may allow for an even better temporal resolution when coupled with lower compression
duration. Based on overall experience with the technique, with a 2-second compression, it may
be possible to reduce the recovery period to 8 seconds, thereby achieving twice as many samples
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of VO2 per minute in the normoxic range of P0’s. Additionally, a shorter recovery time, as
shown by the 5 s x 5 s measurements (Figure 16, plot A), would allow for quasi-continuous VO2
measurements in the hypoxic or intermediate PO2 ranges without additional interventions to
artificially lower PISFO2.

Influence of the 5x15 VO2 Sampling Profile on Reperfusion
The 5 s x 15 s compression/recovery cycle appeared sufficiently suited to quasicontinuous measurements of VO2 during resting conditions of the exteriorized rat spinotrapezius
muscle, but whether its utility extended to situations of reperfusion following ischemia was not
clear. Measurements of PISFO2 were thus taken during the early reperfusion phase following 1minute durations of ischemia with and without (Control) VO2 sampling. The results were
averaged and normalized to their initial baseline measurements. The PISFO2 recovery during
reperfusion was then compared between Control and VO2 Sampling Technique groups (see
Figure 22).
Following reperfusion, the Control group (no VO2 sampling) showed a rapid rise in
PISFO2 that reached a plateau by 40 seconds post reperfusion onset. This plateau was higher than
the initial baseline PISFO2 and likely a demonstration of the reactive hyperemic response to the
prolonged arrest in blood flow. The group with intermittent VO2 sampling showed a similar
profile to Control with a slightly higher (5%) hyperemic response over Control. This overshoot
gradually relaxed back to Control levels by 85 seconds post-reperfusion onset. It was likely the
case that multiple 5-second compressions induced a slightly higher magnitude of reactive
hyperemia, but this difference had no bearing on normoxic measurements of VO2 since VO2 was
insensitive to PO2 in the range of the overshoot.
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Air Bag Pressurization on PISFO2 Recovery and –dPO2/dt
Early measurements with the air bag used an upper compression pressure of 140 mmHg
to arrest blood flow for the assessment of the ODC under various conditions with the
understanding that this pressure would be sufficient to overcome the arterial systolic pressure.
To minimize the impact of each compression, and thereby maximize the VO2 Sampling
Technique’s relevance over time, a range of pressures from 40 to 140 mmHg was tested using
the 5x15 sampling profile for the recovery of PISFO2 (see Figure 22) and the rate of oxygen
disappearance during compression (-dPO2/dt; see Figure 23).
No significant difference was found for the recovery of PISFO2 over the range of
compression pressures from 40 to 140 mmHg. It was expected that, at some point, recovery
would either show a pronounced hyperemic response or begin to show protracted recovery times
if compression pressure brought about vascular damage. Neither situation occurred, though there
did appear to be a statistically insignificant elevation in PISFO2 during recovery from about 70
mmHg of pressure. Likely, the detrimental effects of compression would have occurred at
higher pressures, but they were not tested as anything over 140 mmHg greatly increased the
probability of air bag rupture.
Stepwise increases in compression pressure of 10 mmHg, starting with 40 mmHg and
ending with 140 mmHg (5 mmHg was considered low pressure for the purpose of extrusion of
any surface fluid layer that might confound PQM measurements), showed the corresponding rise
in –dPO2/dt that one might expect as flow-arrest became more and more complete until reaching
a plateau. Compressions from 80 mmHg to 140 mmHg did not yield a significant change in –
dPO2/dt as shown in Figure 23, which indicated that complete flow arrest had been achieved.
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Measurements at 90 and 100 mmHg appeared to be slightly elevated over measurements made
from 110 to 140 mmHg, but this difference was not statistically significant (see Figure 22).
Since higher pressures did not appear to have any adverse consequences on either VO2 or
the recovery of PISFO2, and the VO2 sampling interval was determined using 140 mmHg, the
decision to use a range of compression pressures from 120 to 140 was deemed appropriate. This
allowed for a justifiable adjustment in compression pressure to accommodate a range of tissue
sizes and sensitivities. The effectiveness of flow arrest was always visualized prior to
measurement and 120 to 140 mmHg had a consistently high success rate over the course of
experimentation.
Another point of interest was the relevance of the –dPO2/dt vs pressure profile on the
microvasculature below complete flow arrest. As pressure rose, perfusion declined
approximately linearly. If these pressures had been continued beyond 5 seconds, an eventual
point where the reduction in perfusion could no longer keep up with oxygen demand would be
reached—inevitably resulting in hypoxia. This sort of situation has been found to occur in
Compartment Syndrome and a study looking into the pressure needed to exceed this “tipping
point” in the development of hypoxia using the present approach would appear to be warranted.

Oxygen Consumption by the Method
PQM’s determination of the oxygen tension of a particular measurement region relies on
the ability of oxygen to quench the phosphorescence of an excited phosphorescent probe (R2 in
this case). In doing so, there is a certain probability that oxygen will quench this
phosphorescence signal by its own conversion to singlet oxygen resulting in a PQM-induced
consumption of oxygen. This effect has been previously reported (Golub and Pittman, 2008),
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but quantification is instrument-specific. To observe the rate of oxygen consumption exclusively
by PQM, an in vitro alginate gel (0.5 mm thick) was loaded with the R2 probe bound to 5%
human serum albumin and treated similarly to an intact, perfused spinotrapezius muscle
preparation. It was thermo-equilibrated to ~38 oC on the thermostatic animal platform’s heated
pedestal and wrapped in a Krehalon sheet to isolate it from contamination by atmospheric
oxygen. Measurements were then conducted with PQM for the same excitation intensity and
region diameter as performed in the in vivo setting with an exteriorized, perfused spinotrapezius
muscle. In this case, however, there were no sources of oxygen consumption in addition to that
of the triplet state interaction and conversion of oxygen to singlet oxygen by PQM. Furthermore,
similar to the situation of flow-arrest, the only oxygen inflow came from that of refill at the
periphery of the excitation area by passive oxygen diffusion as an oxygen gradient was
developed over successive flashes. These two conditions provided data that could be analyzed to
yield the coefficient of PQM’s oxygen consumption (K) and the coefficient of oxygen refill (R),
respectively.
K was found to be 7.16x10-4±1.87x10-4 per flash (n=10), which can be converted to
approximately 5.1% of resting skeletal muscle oxygen consumption. This value corresponds to
the measured tissue concentration of the R2 albumin-bound probe of 19.5±2.3 μg/ml (prepared
and measured at 20 μg/ml) for a 300 μm diameter octagon with an excitation energy of
5.366±0.0078 μW per flash. This 5% consumption by the method was considered tolerable in
terms of the invasiveness of the technique and used to correct all VO2 values derived from the –
dPO2/dt data. Further studies using physical quenchers reactive oxygen species (ROS) formation
to reduce the probability of singlet oxygen formation have resulted in an appreciable decrease in
oxygen consumption by PQM (data not shown). These studies were conducted for much higher
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concentrations of the phosphorescent probe (approximately 5-fold), indicating a utility for the
simple assessment of the effectiveness of anti-oxidants using PQM. Additionally, no difference
in the reported K value was seen when this experiment was repeated in 100 μm thick sealed
microslides (see Table 1), which lends credence to the relevance of the gel measurements and
demonstrates the consistency of R2’s behavior in different media and settings.
The coefficient of refill (R) was measured by the magnitude of the offset from zero where
the ODC approached its asymptote. This offset was attributed to a balance between oxygen
consumption by the method and diffusive refill. As indicated in Table 1, R was found to be
small in the cases of gel and microslide measurements. Additionally, as shown by Figure 15, the
difference in PISFO2 between inside the excitation area and outside—the driving force for refill—
is slow to progress and only reaches about 1.5 mmHg after 50 flashes under resting conditions.
This calculation was based on existing –dPO2/dt measurements and extrapolated to outside the
excitation area (which could not be measured directly) by factoring out PQM’s oxygen
consumption. As both the difference in PISFO2 between inside and outside the excitation area
and the measured R were both small (<0.01% of total VO2), even after 50 flashes, it was
determined that Equation 5 could be simplified, by removal of the refill component, to Equation
8 for the conversion of –dPO2/dt to VO2. Smaller excitation areas would have a greater surface
to volume ratio and thus have larger refill components. Eventually a tipping point would be
reached with smaller excitation regions where refill became relevant and would need to be
accounted for in future studies.

In Vivo VO2 of the Rat Spinotrapezius Muscle at Rest
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Application of the quasi-continuous VO2 Sampling Technique during resting conditions
in the intact, exteriorized rat spinotrapezius muscle produced an average VO2 of 1.97 ± 0.1 ml
O2/100 cm3min for measurements in the high or “normoxic” range of PISFO2. As a comparison,
measurements using Fick’s Principle have produced mean values for VO2 ranging from 0.054 to
0.92 ml O2/100 g min (Edmunds et al, 2001; Hoy et al, 2009), which are somewhat lower than
those values produced by the VO2 Sampling Technique. A possible explanation for this
discrepancy involves the range of PISFO2 in which the measurements were made. Employing the
VO2 Sampling Technique, it soon became apparent that not all measurements of P0 were equal as
sites varied in terms of perfusion and functional capillary density. It was realized that as P0
dropped below 40 mmHg, VO2 concomitantly decreased as well, indicating an approximate
region of oxygen dependence for VO2 using this technique. Measurements of VO2 were plotted
against P0 and then divided into three categories for comparison: Normoxic (P0>40 mmHg),
Intermediate (22<P0<40 mmHg), and Hypoxic (P0<22 mmHg) as shown in Figure 24. VO2 was
clearly depressed for situations where PISFO2 dropped below 22 mmHg. Since the VO2 Sampling
Technique makes direct assessments of the interstitial PO2 that bathes the muscle fibers, it is
more localized and tissue-specific than measurements made with the Fick Principle. This means
that physiologically hypoxic regions can be separated from normoxic regions and are not subject
to mixing, which would tend to reduce overall VO2 values. Since these regions are considered
physiological in terms of the acknowledgement that oxygen gradients exist in tissue (Popel et al,
1989, Bertuglia and Guisti, 2005), an assessment of VO2 using Fick’s Principle is accurate in
determining the physiological oxygen consumption of a whole organ at rest. But the VO2
Sampling Technique goes a step further to break down those respiratory rates into tissue
conditions of normoxia through hypoxia.
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Measurements of resting skeletal muscle VO2 have also been made under conditions of
hyperoxia in an attempt to eliminate the confounding influence of hypoxic regions on the
measurement. Values consistent with the high-end values found with Fick’s Principle have been
reported (Honig et al. 1971), and while this may invalidate the idea of hypoxic regions driving
down whole organ VO2 measurements, it is possible that hyperoxia also depresses VO2. As
shown by Figure 2, ROS production is enhanced under hypoxic and hyperoxic conditions
(Clanton 2007). As ROS is destructive to the mitochondrial electron transport chain, there is a
possibility that hyperoxic conditions could result in a significant reduction in VO2. Further study
would be needed to confirm this by exposing skeletal muscle tissue to conditions of high
oxygenation prior to usage of the VO2 Sampling Technique. In the meantime, the measured
normoxic value of 1.97 ml O2/100 cm3min was found to be reasonable and highly reproducible
over many different animals and experiments and thus provided an excellent comparison to VO2
values in altered metabolic states.
As a note to the observed drop in VO2 from the normoxic to the hypoxic range of PISFO2,
a “critical point”, or oxygen tension at which VO2 becomes diffusion-limited at the
mitochondrial level, has been previously reported. For isolated mitochondria, critical PO2 was
determined to be <1 mmHg (Wilson et al. 1979) and for measurements of the resting rat
spinotrapezius preparation, a critical PISFO2 of 2.4 – 2.9 mmHg was quantified (Richmond KN,
et al. 1999). Observations of VO2 with the VO2 Sampling Technique confirmed that there was a
dependence of VO2 on PISFO2, but the point of dependence appeared to occur somewhere
between 22 and 40 mmHg. This order of magnitude difference may be realistic in terms of the
drop in PO2 over the extra- to intracellular oxygen gradient and down to the level of cytochrome
c oxidase, but these mitochondrial PO2 values have yet to be confidently assessed in vivo for rat
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skeletal muscle. However, the measurement of an interstitial critical PO2 of 2.4 to 2.9 mmHg did
appear different from the results using the VO2 Sampling Technique. It is possible that part of
this discrepancy is due to the methodology used to arrest flow, which does not allow for RBC
extrusion from the measurement site, and limited sampling points along the ODC, which was due
to a sampling rate of 0.5 Hz. Another factor may be that they observed single muscle fibers,
whereas the measurement region in this study was 300 μm in diameter and thus covered multiple
fibers. Thus, over the course of many measurements, small pockets of hypoxia may have been
obscured by an otherwise high PISFO2 leading to a depressed reading of VO2. Additionally, our
study does not define a “critical PISFO2” but rather a range where an observed transition from
PISFO2-independence to dependence of VO2 comes into play. Further analysis of the full VO2 vs
PISFO2 curve would be required for a more precise comparison to what has been defined in the
literature as the “critical PO2.” For the purposes of this study, VO2 was related to PISFO2 and
separated into the categories of Normoxia, Intermediate, and Hypoxia to allow for the relevant
comparison of measurements.

VO2 Dynamics of Early Reperfusion Following 1-, 5- and 10-Minute Durations of Ischemia
Presented here are the first in vivo measurements of VO2 dynamics during early
reperfusion following brief periods of ischemia. Durations of 1, 5, and 10 minutes were used to
help assess the consumption of oxygen during periods of ischemia reported to be associated with
preconditioning in skeletal muscle as an indicator of mitochondrial function. VO2 was assessed
at 5, 25, 45, 65 and 85 seconds after onset of reperfusion for all durations of ischemia, and VO2
comparisons were made against baseline (pre-ischemic) measurements made during resting
conditions within the relevant ranges of P0.
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After 1 minute of ischemia, VO2 had risen to 149% of baseline at the 5-second (R5) time
point after reperfusion had begun for normoxic conditions. This initial elevation in VO2 returned
to baseline by the R45 time point and remained there. VO2 measurements taken in the
intermediate range of P0 values showed a similar elevation of 197% of baseline at the R5 time
point that returned to baseline by R45 and persisted there for the remaining measurements. The
hypoxic range of P0 values showed no influence of 1-minute ischemia on VO2 during reperfusion
as compared to baseline (see Figure 25).
Following 5 minutes of ischemia, VO2 measurements first met the conditions of
normoxia at time point R25 and showed an elevation of 218% of baseline. By R45, VO2
remained high, but was now 163% of baseline and then returned to near baseline by R65.
Measurement at the R5 time point was possible in the intermediate range and showed a
substantial elevation in VO2 by 262% of baseline. Then, similar to the normoxic measurements,
VO2 fell progressively over the next few measurements (225% at R25, 196% at R45) until
approximately returning to baseline by R65. As with the 1-minute I/R, the hypoxic range of VO2
measurements showed no change over the reperfusion time course when compared to baseline
(see Figure 26).
Following 10 minutes of ischemia, VO2 measurements first met the conditions of
normoxia at time point R25—similar to the 5-minute duration—and were profoundly elevated to
295% of baseline. Subsequent measurement points showed a progressive reduction to 175% for
R45 and 162% for R65 with no statistical difference from baseline at R85. For the intermediate
range of P0 values, VO2 was found to be 254% of baseline at R5 and showed a progressive return
to baseline by R65 (213% at R25 and 185% at R45). Hypoxic P0 measurements continued to
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show no change during reperfusion as a result of the 10-minute ischemic duration when
compared to baseline (see Figure 27).
Measurements of VO2 made with P0 values < 22 mmHg were grouped together under the
category of Hypoxia. Over the reperfusion timecourses following 1-, 5- and 10-minute durations
of ischemia, there was no apparent change in these VO2 values. This was consistent with the
observation that VO2 is diffusion-limited by the PISFO2 within this range. Realistically, P0 values
had a lower limit of ~7-9 mmHg due to limitations of the R2 probe to accurately report PISFO2
values below 5 mmHg, so these measurements did not include extreme lows in VO2. It is thus
safe to say that for the P0 range of 9 to 22 mmHg, a value of 0.59 ± 0.1 ml O2/100 cm3min (P0 =
13.5 ± 0.4 mmHg) is a physiological Vmax (VO2 cannot increase regardless of demand)for these
conditions measured with the VO2 Sampling Technique.
The intermediate range of P0 values produced similar increases to the normoxic range in
VO2 during reperfusion following 1-and 5-minute durations of ischemia, but exhibited no further
elevation following 10 minutes of ischemia. This could be related to the overlap of PO2dependent and independent VO2 regions within the PISFO2 range of 22 to 40 mmHg. The benefit
of this range appeared in measurements of the R5 time point following 5 minutes of ischemia.
The recovery of PISFO2 was protracted following the longer periods of ischemia due to a
substantial elevation in VO2, and thus failed to rise above 40 mmHg by 5 seconds after the onset
of reperfusion. P0 values did fall within the intermediate range, however, and showed an
increase in VO2 following 5 minutes of ischemia over 1 minute of ischemia for the R5 time
point. There was no apparent rise in VO2 for time point R5 following 10 minutes of ischemia
when compared to 5 minutes of ischemia, but this could be due to a small number of
observations.
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The normoxic range of P0 values allowed for observations of VO2 without limitation by
diffusion. As a result, 1-,5- and 10-minute durations of ischemia resulted in ever increasing rises
in reperfusion VO2 with progressively longer time courses of recovery back to baseline. These
measurements were limited in proximity to reperfusion onset by the amount of time it took for
the recovery of PISFO2 to rise above 40 mmHg due to heightened oxygen demand following the
two longer durations of ischemia.
Quantification of individual contributors to this VO2 enhancement following increasing
durations of ischemia was not possible with this method, but likely has several components.
During ischemic conditions where mitochondrial respiration becomes limited by cytochrome c
oxidase activity, associated rises in NADH have been recorded and linked to a cellular energetic
deficit (Richmond et al. 1999; Clanton 2007). There is also a functional reserve of electron
transport chain activity during normoxic resting conditions that is utilized during conditions of
increased energy demand such as muscle contraction. Measurements of the products of ATP
hydrolysis such as ADP show a 10-fold increase with only a small change in ATP levels during
high intensity exercise compared to rest, indicating that ATP synthesis is able to match this 10fold increase in energy utilization for at least a brief period of time (Sahlin et al. 1998). Based
on this evidence, it appears reasonable to suggest that the majority of the observed rise in VO2
following ischemia is due to enhanced metabolic activity to recover cellular ATP stores. There
may also be some minor component associated with the ROS burst that has been observed
following brief periods of ischemia that is necessary for the induction of protection by preconditioning (Santos et al, 2002; Dost et al, 2008), but to what magnitude this factors into overall
VO2 could not be discerned by the VO2 Sampling Technique in its current form.
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Influence of Cyanide on Resting and Reperfusion VO2
Cyanide was used to demonstrate an association between VO2 as measured by the VO2
Sampling Technique and cytochrome c oxidase activity—the site of inhibition by cyanide. A
pilot dose-response experiment in one animal revealed that a 1 mM topically applied dose was
sufficient to produce a suppression in VO2 during normoxic conditions that was similar to
control VO2 measurements during hypoxic conditions (see Figure 28). This indicated a
substantial, but not total, inhibition of mitochondrial respiration by cyanide. Additional
spinotrapezius muscle preparations were exposed to this 1 mM topically applied dose and
measured in accordance with the defined 1-, 5- and 10-minute I/R protocols.
Resting skeletal muscle VO2 in the normoxic range was found to be reduced by 36% in
cyanide-treated muscles compared to Control. Mean PISFO2 was also considerably higher for
cyanide-treated muscles, which is consistent with an overall decrease in tissue oxygen demand.
The incomplete inhibition of respiration by cyanide is likely due to an incomplete saturation of
the muscle preparation’s mitochondrial volume. Higher doses (10-100 mM) were undesirable
due to potential systemic toxicity, but did show more dramatic reductions in VO2 during a single
pilot experiment (data not shown).
Cyanide-treated tissue was subjected to the 1-, 5- and 10-minute I/R protocols and VO2
was assessed during reperfusion. The R5 time point following 5 and 10 minutes of ischemia
were the only measurements to include hypoxic VO2 values for cyanide. Following 5 minutes of
ischemia, VO2 was found to be significantly higher than the value under control conditions.
Average P0 values were also higher for cyanide by 5 mmHg and, although they still fell within
the hypoxic range, there is a possibility that this difference contributed to the measured elevation
in VO2. Another thought is that prolonged exposure to cyanide resulted in sufficient
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mitochondrial dysfunction to induce a substantial increase in ROS that may have lower kinetic
constraints than cytochrome c oxidase for oxygen utilization, but this hypothesis remains
unsupported by this work.
Treatment with 1 mM cyanide resulted in an overall depression of VO2 during the time
courses of reperfusion for each of the ischemic durations as compared to Control. Over the
course of these measurements, however, it was clear that cyanide’s inhibition of VO2 was
incomplete and thus failed to suppress some of the elevation in VO2 found during reperfusion
following ischemia. The progressive fall in VO2 back to baseline was also similar over the
reperfusion time course. This is likely the result of some cellular populations retaining a mostly
functional mitochondrial capacity for ATP production, which enabled them to pursue a normal
restorative time course following prolonged energy depletion, while other cellular populations
with suppressed respiratory function could not restore the energetic balance—hence the overall
observed reduction in VO2. Additionally, cyanide was observed to have a reduced inhibitory
effect on VO2 as time elapsed following topical application (data not shown). Thus, the
conclusions of this section of the study are simply that mitochondrial respiration is a component
of the observed VO2 and that the concentration of cyanide used in the topical application is
insufficient to produce a maximal inhibition of mitochondrial respiration.

Effect of Nitroglycerin on I/R
Nitric oxide administration has been reported to mimic the ischemic pre-conditioning
effect in skeletal muscle (Ozaki et al, 2002) and, as such, this study sought to measure its effect
on resting and reperfusion VO2 dynamics with the employment of the VO2 Sampling Technique.
NO has proven itself resistant to direct measurement in vivo by both its elusive nature and the
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occurrence of other molecules that can interfere in the chemical and physical detection of NO.
Therefore, instead of attempting to measure the concentration of NO in the microvasculature, the
NO donor nitroglycerin was added to the spinotrapezius muscle, Dose-response changes in VO2
and arteriolar diameter to the topical application of 0.01, 0.1, and 1 mM concentrations of the
NO-donor nitroglycerin (NTG) were measured during resting and I/R conditions in skeletal
muscle. Since we did not possess a reliable method for the detection of NO in vivo, the
vasodilatory response by microvascular arterioles was used to confirm the effective release of
NO into the tissue.
Measurements on four animals showed that 0.1 mM and 1 mM concentrations of NTG
produced similar arteriolar vasodilations to 117% and 120% of baseline, respectively. The 0.01
mM dose caused an apparent elevation in vessel diameter which was not statistically significant.
Considering the low concentrations of NO (~5 nM) that have recently been predicted to be
physiologically relevant (Hall and Garthwaite, 2009), and corresponding findings of NOdependent arteriolar dilations of the same magnitude (Shibata et al. 2006) at both 0.1 and 1 mM
doses of NTG, 0.1 mM was considered sufficient to produce a clear effect on the
microvasculature without delivering needlessly high concentrations of NO to the tissue. The
effectiveness of this dose was confirmed when NTG’s time course of effective influence on
arteriolar diameter when topically applied to the spinotrapezius muscle was recorded. The 0.1
and 1 mM doses both resulted in sustained vasodilatory responses lasting 6 and 7 minutes,
respectively, with a progressive return to baseline by minute 11. This indicated a relatively short
half-life, but still sufficient for measurements of resting VO2 and the ischemic durations of 1 and
5 minutes. Ten-minute I/R measurements were also conducted, but a sustained elevation in NO
could not be confirmed with corresponding measurements of arteriolar diameter. Considering
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the duration of NTG activity as observed by the arteriolar diameter response time course to
topical administration (Figure 32), the 1 minute I/R data most likely contained the highest level
of NO throughout the measurement period.
The dose-response of resting VO2 to 0.01, 0.1 and 1 mM NTG showed a progressive
reduction in normoxic VO2 from baseline with increasing dose. Although the 0.01 and 0.1 mM
doses showed strong trends in reducing VO2, only 1 mM NTG-treated tissue showed a
significant decline of 43% compared to baseline. This suppression of VO2 is consistent with the
description of NO as a reversible, competitive inhibitor of cytochrome c oxidase activity (Brown
2001). The more dramatic decrease in skeletal muscle VO2 by the 1 mM dose than the 0.1 mM
dose indicates that the maximum response of the microvascular arterioles does not necessarily
translate to the maximum response of tissue respiration to NO, but since a measurement of
delivered local NO concentrations was not possible in this study, a minimally effective dose
remains desirable and likely 0.1 mM NTG’s suppression of resting VO2 would have achieved
significance with an increase in sample size.
The dose-response of VO2 during reperfusion for the I/R protocols was measured and
determined to show a uniform reduction at each time point as compared to Control values.
However, only the 0.1 mM dose in the intermediate PISFO2 range had consistently sufficient
number of observations for statistical analysis. Reperfusion following 1 minute of ischemia
showed dramatic reductions in VO2 for all measurement points as compared to Control. P0
values for NTG were significantly lower at the R5 measurement point, but otherwise statistically
the same for other measurements. Following 5 minutes of ischemia, the reperfusion time course
showed a continued depression in VO2 for NTG-treated tissue compared to Control, but
significance was only observed for measurements at R25 and R85. There were no significant
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differences in P0 between NTG-treated tissue and Control. Following 10 minutes of ischemia,
the trend in reduced VO2 readings for NTG-treated tissues continued, but significance was found
only at the R45 measurement point. As indicated by the time course of effective arteriolar
dilation by NTG, it is uncertain by what magnitude the reperfusion time course following 10
minutes of ischemia was influenced by NO compared to the reperfusion periods following 1 and
5 minutes of ischemia (see Figure 35). What is clear is that NO appreciably reduces VO2 during
reperfusion and that this mechanism functions by the competitive inhibition of cytochrome c
oxidase.

Reduction of NO by L-NAME
To reduce the overall levels of NO, enzymatic production was targeted for inhibition with
L-NAME—a non-specific inhibitor of nitric oxide synthase (NOS). To judge the effective
reduction in [NO], arteriolar diameters were measured following treatment with L-NAME and
compared to baseline. Finally, the VO2 Sampling Technique assessed changes in VO2 dynamics
during these periods of reduced [NO] for resting and I/R conditions.
A single animal was used to demonstrate the dose-response of arteriolar diameter and
VO2 to 0.0015, 0.015, 0.15, and 1.5 mM topical applications of L-NAME (see Figures 36 and
37). The 0.15 mM dose appeared to show the greatest amount of vasoconstriction and was not
much different from the 0.015 and 1.5 mM doses for VO2’s measured for resting conditions and
reperfusion following the 1-minute I/R protocol. Contrary to predictions, however, increasing
doses of L-NAME produced a progressive reduction in VO2.
Based on the pilot, a dose of 0.15 mM L-NAME was chosen for topical application to the
spinotrapezius muscle followed by assessment of changes in arteriolar diameter and VO2.
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Arteriolar diameter decreased by 30% following treatment with L-NAME which was consistent
with another finding of a 25% constriction of arterioles in the rat spinotrapezius muscle
following treatment with 0.1 mM L-NAME (Xiang et al. 2008). This level of vasoconstriction
produced significant drops in measured PISFO2, but far from the point where data could no longer
be collected from the normoxic range for measurements of resting and reperfusion VO2.
Treatment with L-NAME produced an apparent decrease in resting VO2 compared to
Control measurements in the range of normoxia, but this difference was not significant (see
Figure 40). PISFO2 values for L-NAME-treated tissues were significantly higher by about 11
mmHg over Control, but whether this would cause a negative trend in VO2 is unclear and
counterintuitive.
To assess the effects of L-NAME on hypoxic respiration where NO has been proposed to
have a greater role in respiratory regulation (Schweizer and Richter, 1994), the R5 measurements
following 5 and 10 minutes of ischemia were chosen, since these time points primarily consisted
of P0 values in the range of hypoxia (see Figure 41). Following 5 minutes of ischemia, VO2 was
elevated for L-NAME-treated tissues at hypoxic time point R5, but this trend was not found to be
significant. Following 10 minutes of ischemia, however, there was a similar, but more
pronounced elevation in VO2 for L-NAME-treated tissues that was found to be significant vs.
Control. These hypoxic measurements at time point R5 following 5 and 10 minutes of ischemia
were the occasions where VO2 was enhanced over baseline while NO production was suppressed
by L-NAME. It is possible, though in need of further study of VO2 during hypoxic conditions,
that suppression of endogenous NO is better visualized under low oxygen conditions due to a
greater involvement of NO in regulating cytochrome c oxidase activity. Thus, VO2 would be
more sensitive to changes in [NO] at lower PO2. PISFO2 values were also slightly, but
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significantly, higher in L-NAME-treated tissues compared to Control and if the “critical PO2” of
cytochrome c oxidase activity had been left-shifted by a reduction in inhibition, then this
difference may be relevant when discussing the observed elevations in hypoxic VO2 for LNAME-treated tissues.
For the reperfusion time courses in 0.15 mM L-NAME-treated spinotrapezius muscle
preparations, VO2 was consistently, but not significantly, lower than under control conditions
(see Figure 42). P0 values were also reduced on average, but did not reach the point of being
significantly lower than Control. It is possible this slight depression in PISFO2 resulted in an
overall reduction in VO2, but the current data suggest there was no significant difference
between Control and L-NAME-treated tissues in terms of VO2 during reperfusion. Additionally,
the VO2 points of elevation and time course of return to baseline were similar to those of the
Control situation. This trend in NOS suppression resulting in a reduction in VO2 has been
reported elsewhere and described as a possible increase in ATP production efficiency due to
reduced cytochrome c oxidase inhibition (Baker et al. 2006), but whether the results from the
VO2 Sampling Technique reflect mitochondrial efficiency or some compensatory mechanism
that regulates oxygen demand when oxygen supply is reduced is unclear and beyond the scope of
this study.

Conclusions
The employment of a new technique to continuously measure the in vivo oxygen
consumption rate of the rat spinotrapezius muscle has yielded results that are consistent with,
more precise than, and unique to similar publications on this subject. Validation of the VO2
Sampling Technique indicated that a sampling rate of 3 measurements per minute was minimally
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invasive and provided a long timecourse of measurements over which muscle metabolism could
be monitored through continuous inspection of changing PISFO2 levels. The robust applicability
of this technique was demonstrated as VO2 was measured during both resting conditions and
following ischemia with minimal effect on the recovery of PISFO2 to baseline and subsequent
measurements of VO2. A correction factor to eliminate the intrinsic methodological contribution
of PQM to VO2 was also established and employed with success to prevent overestimates of
these values. This correction factor and the protocol for calibration of any PQM setup are
presented here and should afford future measurements of PISFO2, with and without the VO2
Sampling Technique, a higher degree of accuracy and an overall strong confidence in the method
itself.
The VO2 Sampling Technique was used experimentally to resolve the VO2 dynamics of
the rat spinotrapezius muscle during the conditions of rest and reperfusion following varying
durations of ischemia. Measurements at rest confirmed PO2 ranges where VO2 is independent of
and dependent on PISFO2. These measurements were grouped into Hypoxic, Intermediate, and
Normoxic categories according to the average PISFO2 immediately prior to tissue compression for
better inter-comparison. Resting skeletal muscle VO2 values were slightly higher than published
values using other methods. This is likely due to the VO2 Sampling Technique’s superior spatial
resolution and direct observation of PISFO2’s that allowed for better selection of regions where
VO2 was independent of oxygen tension over the physiological range. The first direct
measurements of VO2 dynamics during the initial parts of reperfusion following 1-, 5- and 10minute durations of ischemia were made and found to be highly reproducible. These data
confirmed that hypoxic VO2 values were indeed limited by oxygen availability, that the
intermediate PO2 range contained both oxygen-dependent and independent components of VO2,
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and how tissue respiration progressively reacts to compensate for increasing durations of severe
hypoxia. When VO2 was independent of PISFO2, a 3-fold increase was observed at 25 seconds of
reperfusion following 10 minutes of ischemia. This value was presumably higher at earlier time
points, but the current implementation of the VO2 Sampling Technique was unable to
consistently make measurements earlier in reperfusion. The majority of this response was
reasonably associated with an increase in mitochondrial respiration to restore the ATP/ADP
ratio. It was also considered possible that a minor component of this increased VO2 seen during
the reperfusion phases of increasing durations of ischemia was an increase in ROS production as
reported by others in the study of brief ischemic durations in skeletal muscle. A direct
assessment of ROS could not be made with this technique and would require additional methods
to observe the magnitude of change in ROS production and relate it to VO2 values over the same
timecourse.
Cyanide, nitroglycerin, and L-NAME were topically applied to the rat spinotrapezius
muscle and assessed for their influences on VO2 dynamics during rest and conditions of
reperfusion following 1-, 5- and 10-minute durations of ischemia. Cyanide was chosen for its
similar site of action as NO in inhibiting electron transport activity at the level of cytochrome c
oxidase. It attenuated VO2 measurements for all conditions, but was ineffective overall in
completely suppressing mitochondrial function. This was likely due to a combination of
insufficient concentration of cyanide in the topical application to suppress mitochondrial
respiration and a seemingly short duration of functionality (CN at physiological pH exists as a
volatile gas and may have diffused away from the muscle). Its usage did confirm that the
measured VO2 dynamics were the result of mitochondrial activity, but due to a lack of complete
mitochondrial inhibition, it was not possible to use these data to calculate the contributions to
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VO2 of other oxygen consumers. Nitroglycerin (NTG) behaved as expected showing a dosedependent vasodilatory response in microvascular arterioles and in suppressing VO2 during both
resting and reperfusion conditions. Normoxic resting rates of VO2 were suppressed in a dosedependent manner, with the highest dose showing the greatest effect. The influence of NTG on
arteriolar diameter appeared to be maximal for the medium dose, thus indicating that
physiological levels of constitutive NO production were likely surpassed by the highest dose
used. Inhibition of mitochondrial respiration is consistent with the reported action of NO as a
competitive inhibitor of cytochrome c oxidase. How pharmacological application of an NOdonor prior to a brief period of ischemia affects VO2 during early reperfusion had not been
previously reported to our knowledge. For the 0.1 mM dose of NTG in the intermediate range of
PISFO2, there was a clear depression in VO2 following the 1-minute duration ischemic period.
The reperfusion time course following 5 minutes of ischemia also showed a decrease in VO2, but
time points R25 and R45 did not show statistical significance. There was also a graphically clear
depression following 10 minutes of ischemia, but only 1 time point showed significance and
therefore generalization to the entire time course is not warranted. It is also unclear whether
NTG was able to maintain a high level of NO release over the measurement duration of 10
minutes of ischemia with reperfusion. The reduction of NO production by inhibition of NOS
with L-NAME resulted in a clear vasoconstrictive response, but showed no statistically
significant effect on VO2 over the range of normoxic measurements for resting and reperfusion
conditions. There was, however, a trend in hypoxic VO2 elevation over control values for the R5
time point following 5 minutes of ischemia. Following 10 minutes of ischemia, this elevation
persisted and was found to be significant. This may be an indication and confirmation of other
reports that physiological levels of NO have increasing regulatory control over respiration as
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development of hypoxia progresses. Further study over the influence of NO donation and
depletion is necessary for the condition of hypoxia to confirm the role of NO in this process.
NO has been found to mimic the ischemic pre-conditioning effect that confers protection
against subsequent ischemic events. We show here that NO causes a suppression in
mitochondrial respiratory activity during reperfusion following brief periods of ischemia, which
is consistent with findings that a necessary step in the development of protection through
ischemic pre-conditioning is a reduction in the kinetics of the mitochondrial electron transport
chain. If this connection is valid, the VO2 Sampling Technique may be useful in demonstrating
the utility of other drugs in achieving similar profiles of reperfusion as potential mimics of
ischemic pre-conditioning. A reduction in physiological NO levels did not appear to alter
normoxic respiratory rates during conditions of rest and reperfusion, but there was a visible
elevation in VO2 following 10 minutes of ischemia during hypoxia for tissues with suppressed
[NO]. As L-NAME has been found to reverse the effects of pre-conditioning in rabbit hearts
(Horimoto et al. 2000), this finding of enhanced VO2 by a reduction in NO supports the concept
that mitochondrial electron transport chain kinetics are key to the development of ischemic preconditioning protection in skeletal muscle. It is thus that the treatment of oxygen withdrawal, as
occurs during ischemia, may be best performed by tempering the kinetics of VO2 during the
early period of reoxygenation associated with reperfusion.

Future Studies
In principle, the applications of this technique to a wide range of metabolic states and
interventions in different combinations with various thin tissues are abundant. For the near
future, however, improvement of sampling time resolution using shorter tissue compression
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intervals and recovery times should lead to a better delineation of VO2 dynamics during
reperfusion following ischemia and during muscle contraction. Development of a “critical PO2”
value for VO2 with further experimentation and analysis would also greatly support data on the
influence of PISFO2 on respiration so that future studies could be designed to specifically target
certain magnitudes of hypoxia, normoxia, and hyperoxia. Finally, the study of ischemia with
reperfusion requires data on ROS production that correspond to the time points of reperfusion
described by this study. Additional studies that manipulate and measure [NO] during hypoxia
may be able to take advantage of cytochrome c oxidase as a rough quantifier of physiologically
relevant levels of NO that regulate electron transport chain function during rest and conditions of
reperfusion and muscle contraction. Such information would be invaluable to the development
and testing of new therapies for the pharmacological induction of the ischemic pre-conditioning
effect.
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